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Abstract
Stroke is the third most common cause of death in the developed world, and is the
major cause of long term disability in the U.K. Eighty percent of strokes are
ischaemic, or caused by vascular occlusion. Magnetic resonance imaging (MRI)
provides stroke researchers with an invaluable tool to visualise ischaemic processes
non-invasively from very early times after stroke onset. However, despite major
progress, it is still unclear to what degree particular appearances on MRI relate to the
underlying pathophysiological state of the ischaemic lesion, or the clinical outcome
of the stroke patient.
The aim of this thesis is to explore the evolution and issues affecting the analysis of
ischaemic lesions on diffusion- and perfusion-weighted MRI (DWI and PWI) from
acute (< 24 hours) to chronic (90 days) times after stroke onset. This thesis includes
a review of previous human studies of acute DWI and PWI appearance versus final
lesion outcome, a review of the 'DWI/PWI mismatch' model (thought to represent
the ischaemic penumbra, or 'tissue at risk' of infarction), and a systematic review of
previous animal studies of the pathophysiology associated with particular lesion
appearances on DWI.
The methodological problems raised by these reviews are addressed in this thesis
using a large cohort of stroke patients with serial DWI and PWI. The interrater
variability of manual lesion measurements on acute DWI is investigated, and factors
affecting this variability are discussed. The effect of lesion oedema (swelling) on
measurements of ischaemic lesions on MRI is investigated. This thesis also
investigates the tissue state underlying persistent hyperintensity on late DWI, and
whether this is just T2 'shine through', or indicates distinct features in the evolution
v
of the lesion. A novel grid-based analysis method is developed and employed to
track serial DWI and PWI changes more effectively, and the effect of observer
variability on diffusion and perfusion parameters measured by this method is
assessed. Lastly, this thesis discusses the concept of using 'threshold' values to
predict tissue infarction or survival.
Note - The scans reproduced in this thesis arc represented in conventional medical
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The aim of this thesis is to explore the evolution and issues affecting the analysis of
ischaemic lesions on diffusion- and perfusion-weighted magnetic resonance imaging
(DWI and PWI respectively) from acute (< 24 hours) to chronic (90 days) times after
stroke onset using a large group of patients with serial DWI and PWI scanning data.
Scope of thesis
This thesis is organised into 12 chapters:
Chapter 1 provides background information on ischaemic stroke, including clinical
features, causes, pathophysiology, and treatment. The basic principles of magnetic
resonance imaging (MRI) are also reviewed.
Chapter 2 discusses the appearance of ischaemic lesions on DWI and how they are
measured. Problems with measuring lesions on DWI, including ill-defined lesions, T2
'shine through', and tissue swelling are discussed. The use of the 'DWI/PWI
mismatch' and thresholds of DWI and PWI values to identify 'tissue at risk' of
infarction are examined. The issues raised in Chapter 2 form the basis of subsequent
analyses in the thesis.
Chapter 3 comprises of a systematic review of the use of DWI and PWI in animal
models of ischaemic stroke, investigating what particular appearances on DWI mean
in terms of the underlying pathophysiology of ischaemic tissue.
Chapter 4 presents the methods for the recruitment, imaging, and basic lesion
measurement of the large cohort of patients used for the analyses in this thesis.
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Results of basic lesion analysis, including DWI and PWI parameter values from the
visible DWI and PWI abnormalities from baseline (< 24 hours after stroke onset) to
final (90 days after stroke onset) imaging are presented.
Chapter 5 assesses factors that affect lesion volume measurement on DWI by
examining the differences in measured lesion volumes between two observers, and
how the differences relate to lesion morphology and observer experience.
Chapter 6 explores which baseline PWI parameter, if any, identifies 'tissue at risk' of
infarction, and whether the presence of an acute 'DWI/PWI mismatch' as discussed
in Chapter 2 is related to lesion growth.
Chapter 7 investigates ischaemic lesion regions that remain hyperintense on late (>
30 days after stroke onset) DWI, and whether these regions are merely the effect of
T2 'shine through' as discussed in Chapter 2, or if they indicate important underlying
differences in the pathophysiology of the ischaemic tissue.
Chapter 8 consists of the development of a novel grid-based method to investigate
regions of heterogeneity of DWI and PWI parameters within ischaemic lesions. A
manual grid-based analysis method is developed and tested in a small group of
patients to determine if different degrees of abnormality on baseline DWI indicate
different degrees of underlying tissue damage.
Chapter 9 concerns the development of a more efficient grid-based analysis program
for analysis of a larger sample of patients. The effect of observer differences on
lesion volume and extracted DWI and PWI values from lesion analysis with the grid-
based program is assessed.
Chapter 10 investigates the evolution of DWI and PWI parameters in ischaemic
lesions in a large group of patients, including whether differences in lesion
3
appearance on baseline DWI are associated with differences in underlying DWI and
PWI parameter values using the grid-based analysis method as developed and tested
in Chapter 9. Differences in DWI and PWI parameter values at baseline and over
time between patients whose lesions grow, stay the same size, or shrink between
baseline and final imaging are also assessed.
Chapter 11 investigates both general and localised tissue distortion due to swelling
and tissue cavitation after ischaemic stroke. A novel swelling analysis program is
developed and tested to quantify tissue distortion at key stages after onset of
ischaemic stroke.
Chapter 12 is a summary and discussion of the results of this thesis.
Introduction
The rest of this chapter presents background information on ischaemic stroke and the
basic principles ofMRI.
What is 'stroke'?
Stroke is defined as a sudden onset of neurological deficit, often manifested as
hemiparesis or hemianaesthesia, and/or loss of higher cerebral functions such as
• *12
speech or spatial awareness, caused by cerebral haemorrhage or ischaemia ' . A
stroke is further defined as causing symptoms that last longer than 24 hours,
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distinguishing stroke from a transient ischaemic attack (TIA), where stroke-like
symptoms resolve within 24 hours of onset3.
Although the correct mechanism of stroke (as a disorder of the blood vessels) was
not determined until the late 17th century, being variously attributed to causes like a
blow to the head, an imbalance of the 'humours', and fright, the disease itself has
been described since ancient times3'4. Hippocrates (460 - 370 B.C., Figure 1.1)
described apoplexia, literally 'to strike down' in ancient Greek4, as an affliction
characterised by numbness and anaesthesia particularly affecting people between the
ages of 40 - 60 years5. Hippocrates noted that 'to get over a strong attack is
impossible, over a weak one, not easy'4, still poignant today where 1/3 of the annual
15 million stroke sufferers worldwide die, and 1/3 remain dependent on others for
daily care6.
Figure 1.1 Hippocrates (460 - 370 B.C.)
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What is the burden of stroke?
Stroke remains the third most common cause of death in developed countries, and is
the major cause of long term disability in the UK6. Stroke causes 10% of all deaths
worldwide, and carries a heavy economic burden. Approximately 4% of the National
Health Service spending in the UK goes towards stroke services, covering the care
costs for both short and long term follow-up care for stroke patients. Furthermore,
short and long term disability of patients after stroke puts immense pressure on
family members and society6.
How prevalent is stroke?
Epidemiology
The incidence of stroke rises sharply with age, affecting only 0.1 - 0.5 per thousand
o
people under the age of 55, rising to 10-20 per thousand people over the age of 75 .
Men and women are equally affected by stroke; men are slightly more likely to have
a stroke in younger age groups, and women more likely to have a stroke in older age
groups (probably due to the increasing percentage of women in older populations
caused by the younger average age of mortality of men)8. Stroke, unlike other
cardiovascular diseases such as ischaemic heart disease, is prevalent in both
developing and developed countries, but is particularly problematic in developed
countries6'8. In the developed world, regional and ethnic differences in stroke
incidence occur, with areas in Finland, Japan, and Scotland showing high rates of
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incidence, which have been attributed to factors such as cold winters, low economic
status, and a high proportion of people with the known risk factors for stroke8'9.
The diagnosis of 'stroke' currently includes patients presenting with clinical signs of
cerebral ischaemia, intracerebral haemorrhage, and subarachnoid haemorrhage10.
Ischaemic stroke results from vascular occlusion and is the cause of approximately
80% of strokes11'12. Intracerebral haemorrhage, caused by bleeding in the brain
parenchyma, and subarachnoid haemorrhage, caused by bleeding in the sub¬
arachnoid space, cause approximately 15% and 5% of strokes respectively3'11'12. This
study will focus on ischaemic stroke and will not consider strokes caused by
intracerebral and subarachnoid haemorrhages further.
Riskfactors
Previous stroke (or TIA) represents the biggest risk factor for ischaemic stroke, with
10 - 15% of all strokes being recurrent8. High blood pressure is another strong risk
factor; it is estimated that 4/10 deaths caused by stroke could have been prevented
with blood pressure management6. Other common risk factors echo those for other
cardiovascular diseases, including diabetes, high blood cholesterol levels, high salt
intake, obesity, and smoking6'9.
Clinical features of stroke
The presentation of an acute stroke depends on where in the cerebral circulation the
blockage has occurred. Stroke patients present with varying degrees of focal
neurological symptoms: motor symptoms such as weakness and imbalance; speech
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and language disturbances such as slurred speech or difficulty reading; sensory
symptoms such as numbness or visual disturbances; and often general confusion and
forgetfulness2. Because of the functional organisation of the brain, it is possible to
pinpoint the probable location of the arterial blockage2, however due to the
complexity of the brain, infarcts are usually initially classified as syndromes of
symptoms that point to the likely affected arterial territory3'13. For example,
ischaemia of the dominant frontal cortex (associated with speech and language)
usually causes expressive aphasia, leading clinicians to diagnose ischaemia of the
middle cerebral artery which supplies this area of the brain2.
Causes of ischaemic stroke
Cerebral ischaemia, or ischaemic stroke, is caused by occlusion of an intracerebral
artery, usually by thrombosis or an embolism9. Ischaemic stroke has three main
causes, large artery atherothromboembolism, cardiac emboli, and intracranial small
vessel disease3.
Atherothromboembolism
Atherothromboembolism, the cause of approximately 50% of ischaemic strokes,
results from atheroma of large and medium sized intracranial and extracranial
arteries3. Atheroma develops over long periods of time, from the early formation of
fatty streaks through a long term process of injury to the endothelium that ultimately
results in the thickening of the vessel wall (and thus narrowing of the vessel) caused
by fibrolipid plaque formation3. Thrombosis occurs when a plaque grows to occlude
8
the vessel completely, or ruptures, presenting an acutely thrombogenic surface to the
3 • •blood . Embolism occurs when fragments of atheroma or emboli forming at the
plaque surface dislodge from the plaque surface and travel through the circulation to
become lodged in a smaller vessel in the brain3.
Cardiac emboli
Emboli from the heart that travel into the cerebral circulation and occlude a cerebral
vessel account for about 20% of ischaemic stroke cases3. Emboli from the heart vary
greatly in age, size, and composition (e.g. fibrin, calcium, platelets)3. There is some
evidence that cardiac emboli are more likely to cause larger cortical infarcts versus
# T
(vs.) smaller cortical infarcts . Some patients may have cardiac as well as large artery
embolic sources.
Intracranial small vessel disease
Intracranial small vessel disease accounts for approximately 25% of ischaemic stroke
cases3. The cause of intracranial small vessel disease is subject to much debate, but
many attribute it to intrinsic changes and abnormalities of small vessels, which often
cause lacunar ischaemic lesions . Lacunar infarctions are rarely fatal, and may go
undetected clinically3. As this work will focus on large artery stroke, lacunar
infarctions will not be discussed further, although the same principles discussed in
this thesis may apply to the study of lacunar ischaemic lesions.
Other causes
The causes of the last 5% of ischaemic stroke are varied and include cancer,
vasospasm, trauma, snakebites, and complications of pregnancy, but these are rare,
and will not be discussed further3.
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Pathophysiology of ischaemic stroke
Ischaemic stroke causes a decrease or cessation of blood flow to the part of the brain
supplied by the affected artery . Cerebral ischaemia eventually leads to cell death in
the affected area, termed infarction, if the affected part of the brain is not adequately
supplied by collateral blood supply or blood flow is not quickly restored14. The
severity of a stroke depends on the volume, and to some extent the location, of brain
tissue affected. In the past, all tissue in the territory of the affected artery was thought
to die immediately after the onset of ischaemia. However, it is now clear that there
are stages of blood flow decline, and some cells may survive for periods of decreased
blood flow.
Despite comprising only 2% of the body's mass, the brain uses about 20% of the
blood oxygen used by the body9. The brain uses only glucose and oxygen for fuel,
and their consumption is closely coupled to the density of neurons and functional
activity of the tissue. Via the Krebs cycle15, cells use oxygen and glucose to produce
adenosine triphosphate (ATP), the energy source for vital cell processes, and the by¬
products carbon dioxide and water.
Despite the high energy consumption of the brain, glucose reserves in the brain are
only sufficient for about one minute, so continuous delivery of glucose and oxygen
via the cerebral circulation is required to keep the brain functioning normally9.
Although the brain is vulnerable to disturbances in blood flow, there are several
'safety mechanisms' that can protect the brain from damage.
Autoregulation ofcerebral bloodflow
The arteries of the cerebral circulation have an autoregulatory capacity to maintain
the cerebral perfusion pressure when cerebral blood pressure is decreased14.
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Decreases in systemic blood pressure cause cerebral vasodilation in an attempt to
maintain the cerebral blood flow (CBF) and thus delivery of oxygen and glucose to
the tissue. However, the capacity for vasodilation is finite, and when the blood
pressure is decreased below a certain level (systemic pressure of approximately 50
mmHg, Figure 1.2), the CBF becomes pressure-passive and falls with further
reduction in blood pressure, and the brain may not receive enough oxygen and
glucose to operate properly9'14. Maximal vasodilation for a period of time can cause
vasoparalysis, where the autoregulatory capacity of the artery fails and oxygen
extraction is decreased despite increased blood flow (termed 'luxury perfusion', i.e.
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Figure 1.2 Cerebral autoregulation.
Collateral blood supply
Focal disturbances in CBF due to arterial abnormality may be reduced by the
presence of collateral blood supply whereby a neighbouring artery can supply an
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adjacent arterial territory that is under ischaemic stress14. However, collateral
potential varies between individuals, and may not be adequate to supply more than
the periphery of an ischaemic territory so that the tissue at the core of the arterial
territory still becomes infarcted9'14.
Tissue death is no longer considered an instant process after an ischaemic insult. If
autoregulation or collateral blood flow are insufficient to support the tissue
undergoing the ischaemic insult, the cells of the brain can still survive by reverting to




Remarkably, the brain can withstand reductions in blood flow of about 40% of
normal (approximately 20 mL/lOOg/min) before it starts to be adversely affected14.
At this first critical blood flow threshold of approximately 40% of normal (Figure
1.3), ATP can be produced in small quantities anaerobically, but this yields much
less ATP than normal aerobic production so a reduction of energy expenditure is
required .
The affected area of the brain begins to shut down electrical activities such as
spontaneous action potentials (observable by the absence of electroencephalogram
activity) in an attempt to conserve energy for vital cell processes14. The reduced ATP
energy supplies are used to maintain an ion homeostasis that produces the membrane
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potential (meaning the cell is still viable) by powering the ion pumps that actively
pump sodium ions out of the cell and potassium ions into the cell15. At this stage, cell
death is not inevitable; restoration of blood flow will result in a return to normal cell
function9. There is currently some question on how long brain cells can remain
viable in this state of 'suspended animation'; animal studies have shown that even























Figure 1.3 Approximate ischaemic blood flow thresholds. Adapted from Astrup et al.7
Energy failure
Further CBF decreases to < 20% of normal blood flow (approximately 10
mL/lOOg/min) causes energy failure: ATP supplies deplete rapidly, and a massive
increase in extracellular potassium ions indicates failure of the ion pumps and
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subsequent ion homeostasis disruption (Figure 1.3)7. The failure of the ion pumps
causes sodium, calcium, magnesium, and hydrogen ions to accumulate in the cell,
instigating ionic imbalance and acidosis in the cell. Furthermore, anaerobic ATP
production yields lactic acid, which accumulates and causes intracellular and
extracellular acidosis15. The cell's attempts to regulate its lowered intracellular pH,
together with the failure of ion pumps, causes a massive influx of sodium ions into
the cell. There is a subsequent influx of water into the cell via osmosis from the
extracellular space, causing cytotoxic oedema3'9.
Cell death
Failure of the membrane potential for any amount of time begins a cascade that will
result in cell death, whether by necrosis or apoptosis7. The increased intracellular
concentration of calcium ions cause the release of toxic concentrations of excitatory
90 •
neurotransmitters such as glutamate and aspartate , as well as activating proteases
that lyse the structural proteins of the cell membrane and facilitate the release of free
90 • •
radicals that further damage membrane lipids . Increased intracellular calcium ion
concentrations appear to be the key factor in the initiation of necrosis3. In parallel
• • 3with cell death by necrosis, active cell death, or apoptosis, is triggered in some cells .
Lowered intracellular calcium ion and increased zinc ion concentrations appear to
favour apoptotic cell death, but there is a continuum of necrosis and apoptosis in
ischaemic tissue3. If ischaemia continues even longer, the membranes of the blood-
brain barrier (BBB) become compromised and allow plasma constituents to leak into
the extracellular space, causing vasogenic oedema9. Once damage to the BBB has




It is not just the severity of blood flow interruption, but also the length of time that
the blood flow is compromised that determines the fate of the affected tissue. The
'ischaemic penumbra', or area at risk of infarction, captures the notion that brain
tissue may be saved from death if blood flow can be restored in time, either by
spontaneous reperfusion or medical intervention. The concept of the 'ischaemic
91. • .
penumbra' was first postulated by Astrup et al. in 1981, and is defined as a region
of tissue with compromised CBF that is not yet dead surrounding an inner core of
irreversibly damaged tissue (Figure 1.4). Schematically, the 'ischaemic penumbra' is
thought of as a 'shell' of tissue surrounding the 'core' of the infarct (Figure 1.4), but
it is likely these regions are patchy and unevenly distributed in the infarct. It is this
tissue that is the focus of much stroke research: how can we identify this 'tissue at
risk' and salvage it from infarction?
Figure 1.4 Schematic diagram of the ischaemic penumbra. Note the penumbra is not
considered to necessarily be an even 'shell' around an infarct core.
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Treatments for stroke
There are many preventative treatments that reduce the risk of ischaemic stroke, such
as lowering blood pressure and cholesterol and antithrombotic drugs like aspirin,
which remains the cheapest drug available worldwide for stroke prevention22.
Clinicians have a number of available acute treatments for ischaemic stroke,
however, many of these require further clinical trials to confirm benefit and safety.
Ideally, an acute stroke treatment should clearly reduce mortality and long term
• • • • 22
disability and be safe to administer to all stroke patients . No treatment currently
fulfils all these ideals, although aspirin is a well established and widely used
treatment - having modest effects but being safe for most ischaemic stroke patients .
Unproven therapies such as neuroprotective compounds, calcium antagonists, and
haemodilution require further large clinical trials to provide proof of benefit and
safety, although it is likely that these therapies will only be useful and safe in small
subgroups of patients3. Currently the most promising therapy being tested in several
large clinical trials is treatment with thrombolytic or 'clot-busting' agents .
Thrombolytic agents
Intravenous thrombolytic agents, such as recombinant tissue plasminogen activator
9 ^ •
(rtPA), lyse thrombi and improve clinical outcome . However, thrombolytic agents
carry a high risk of intracerebral haemorrhage for some patients, so rtPA
administration must be selective and patients must be rigorously monitored - further
large clinical trials are ongoing to improve patient selection . Currently, licensing
guidelines for rtPA mean that only highly selected suitable patients that arrive at the
hospital within 3 hours of stroke onset may be treated with rtPA, although some trials
are currently testing the benefit of rtPA up to 6 hours after stroke onset24. Newly
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developed plasminogen activators, including desmoteplase (engineered from the
saliva of the vampire bat) are said to be more fibrin specific, dissolving clots locally
without affecting the blood clotting mechanisms, theoretically lowering the risk of
haemorrhage25 - but further clinical trials are needed to determine patient benefit and
safety. The use of these agents might be improved if it was possible to identify
patients with significant amounts of 'ischaemic penumbra', or salvageable 'tissue at
risk' of infarction, quickly and accurately.
Imaging in stroke
With the development of computed tomography (CT) imaging by Cormack and
Hounsfield in the 1970s, clinicians were provided with a means of non-invasively
visualising the brain, leading Cormack and Hounsfield to be awarded the 1979 Nobel
Prize in Physiology or Medicine. CT was, and remains, particularly useful in
distinguishing cerebral infarction from stroke 'mimics' (e.g. intracranial tumours),
and is vital in screening patients for thrombolytic therapy to ensure the absence of
q #
haemorrhage . However, the positive signs of ischaemia on CT are less obvious than
with DWI, especially for small lesions, so most research interest in stroke imaging is
*)ft 97
focused on MRI ' . The development of advanced MRI techniques like DWI has





MRI, in particular DWI and PWI, offers the possibility of determining the underlying
pathophysiological state of ischaemic tissue, and thus might lead to the development
of possible appropriate therapeutic interventions. In fact, MRI has proven so useful
in medicine that Lauterbur and Mansfield, who were foremost in development of
ultrafast magnetic resonance (MR) sequences, shared the 2003 Nobel Prize in
Physiology or Medicine.
Basic MRI
MRI relies on the physical properties of nuclei, in particular hydrogen nuclei
(protons), and their behaviour in the presence of a magnetic field and applied
radiofrequency (RF) pulse. At the atomic level, nuclei can be said to spin about their
• • • on
own axes, generating a tiny magnetic field (Figure 1.5) .
Protons, and other nuclei sharing the spin quantum number lA, align themselves in
• • on
one of two orientations in the presence of a magnetic field (Bo; Figure 1.5) .
Figure 1.5 Nuclei spin about their own axes and produce a small magnetic moment
(left). In the presence of a magnetic field, nuclei align either parallel or antiparallel to
the magnetic field B0 (right).
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One orientation is of slightly less energy than the other, so a few more nuclei align in
this direction, causing a net magnetisation in the direction of the applied magnetic
field (Figure 1.6).
Bo
Figure 1.6 Net magnetisation of nuclei.
Nuclei do not align themselves directly parallel or anti-parallel to Bo; instead they
precess, or follow a circular path about Bo (Figure 1.7) with a characteristic angular
90
frequency, called the Larmor frequency (co) .
Figure 1.7 Precession of nuclei about the magnetic field B0.
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co is proportional to the strength Bo multiplied by a 'gyromagnetic ratio' (y) that is




With the application of a RF pulse of frequency co, the net magnetisation can be tilted
into a different plane, after which the magnetisation will return, or relax, to its
• • 29 • • •
original value . Two important 'relaxation' times can be measured as the tilted
magnetisation both recovers along the original direction of magnetisation (Ti
relaxation time) and decays along the perpendicular direction of magnetisation (T2
relaxation time). Due to magnetic field inhomogeneity, nuclei in different places in
the sample will experience a slightly different magnetic field strength, making them
precess at different frequencies, causing phase differences (T2*). These phase
differences can be 'refocused' using a further 180° RF pulse, which flips the
dephased precessions and focuses them back into a single signal, called a spin echo
(SE) which can then be detected by a receiver coil (Figure 1.8).
Figure 1.8 Refocusing of dephased spins, f = fast, s = slow.
A pulse sequence comprising of a combination of several RF pulses at a particular
repetition time (TR) and time to echo (TE) allows for some amount of control of the
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contrast between tissues. To select a 'slice' through the sample, a magnetic field
gradient can be set up by supplying current to two coils inside the scanner. This
gradient causes one end of the magnet to have a slightly higher field strength than the
other, meaning only a narrow area of the sample aligned longitudinally to Bo will
respond to a particular RF pulse (as co of the nuclei will change with distance from,
and current supplied to, the gradient coil)29.
The use of three orthogonal, in-bore magnetic field imaging gradients allows for
imaging in three dimensions. Once a 'slice' of the sample is selected with one of the
magnetic field imaging gradients, one of the other two gradients is turned on to
spatially encode the slice along one axis. A signal of amplitude vs. time is detected in
the receiver coil: this signal is called a free induction decay (FID), so named because
it decays to zero with a characteristic time constant, T2*. To obtain an interpretable
signal, a series of FIDs are acquired and mathematically manipulated by a method
known as Fourier transformation, which converts the time-dependent FIDs into a
frequency-dependent spectrum2 .
Another 'phase encoding' step must be performed to obtain an image of, for instance,
256 x 256 pixels (two-dimensional picture elements). Repeating the pulse sequence
256 times changing only the 'phase encoding gradient' gives 256 signals of different
frequencies that can be used to assign a signal intensity (SI) to each pixel, from
which a grey-scale image can be created.
SE sequences are used to obtain Tj- and T2-weighted (TjW and T2W respectively)
images. In TjW imaging, tissues with short Ti relaxation times (e.g. fat) appear
bright, while tissues with a long Ti relaxation time (e.g. cerebrospinal fluid [CSF])
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appear dark (Figure 1.9). In T2W imaging (T2WI), the signal intensities are reversed,
with CSF appearing bright (Figure 1.9).
Figure 1.9 Example of T|W and T2W images.
In general, TiW images provide excellent anatomical detail, while T2W images are
frequently used for examination of pathology (Figure 1.9).
Images can be obtained more quickly than standard SE imaging using echo planar
(EP) imaging sequences, at the sacrifice of increased signal-to-noise and more image
artefacts. However, ultrafast imaging techniques are invaluable in diffusion,
perfusion, and functional MRI, as they reduce the influence of motion, can catch
rapid responses, and reduce the time that patients are in the scanner.
Diffusion-weighted MRI
Molecules in a sample experience thermal translational random motion, called
Brownian motion, which can cause signal loss because phases of different spins vary
randomly. This signal loss would seem undesirable, but it can actually be
manipulated to provide diffusion-weighted (DW) images (Figure 1.10).
T2W
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Figure 1.10 Example of a DW image.
In the 1960s, Stejskal and Tanner developed an eponymous sequence to obtain DW
images. As the scale of the movement of a water molecule (approximately 60 pm/s)
is of the order of the size of cells, differences in the diffusion of water in a sample
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can inform on the density, integrity, and pathology of the sampled tissue . DWI is
achieved by adding strong pulsed magnetic field gradients to a standard SE-EP
imaging sequence. These strong pulsed gradients make the images sensitive to small
displacements of water molecules, and the 'weighting', or sensitivity of imaging to
the diffusion of water, is described by a value known as b. The larger the b, the
stronger the diffusion weighting30; T2W images have a b ~ 0 s/mm2 and receive only
a tiny amount (approximately 2%) of signal loss due to diffusion, whereas clinical
DW images typically have a b = 1000 s/mm2. The signal (S) in a voxel (three-
dimensional volume element) in a DW image is calculated using the signal without
diffusion effects (S0) by the Stejskal-Tanner diffusion equation31:
c? c? ADCS = So e
where e is the base of the natural logarithm (Euler's constant), and ADC is the
apparent diffusion coefficient, which measures the movement of a water molecule
due to self-diffusion in a given time, measured in mm2/s. ADC is termed 'apparent'
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as it represents the diffusion of water in biological tissue where water molecules are
restricted by cell membranes and fibre tracts. Typical ADC values in the brain range
from 0.7 x 10~3 mm2/s in the corpus callosum to 3.0 x 10~3 mm2/s in the cerebrospinal
fluid . The restriction of water diffusion in biological tissues such as the brain also
necessitates sampling diffusion images in three orthogonal gradient directions in
order to obtain reproducible, reliable, quantifiable DW images32. White matter tracts
and other restricting membranes in the brain can cause the diffusion to be
anisotropic, or directionally restricted, and the orientation of the pulsed magnetic
field gradient in relation to this anisotropic diffusion can influence the appearance of
the diffusion images. Therefore, DWI is now commonly performed in three
orthogonal directions which are then averaged to obtain an 'isotropic' diffusion
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image with minimal effects from the anisotropy of the tissue . As ADC values are
scalar, they can only describe the magnitude of diffusion. The development of
diffusion tensor (DT) imaging, with sampling in at least six gradient directions,
allows for the measurement of the directionality of diffusion.
As DWI is exquisitely sensitive to the small diffusional motion of water, it is
excellent at visualising some aspects of the pathology of ischaemic stroke, where
fluid balance is compromised in acute stages by cytotoxic oedema and in chronic
stages by vasogenic oedema. Acute DW images generally show a hyperintense
('bright') lesion against a dark background, which is easier to pick out than dark
lesions on a grey background as on ADC images (Figure 1.11). However, there are
several downsides to DWI in comparison to more conventional imaging such as
T2WI and CT. Firstly, because DWI is so sensitive to small diffusional motion, it is
also subject to image artefacts caused by other types of motion, such as pulsatile
24
movement in the heart and lungs (though not a problem in the comparatively 'rigid'
brain) and gross patient movement. Secondly, DWI is subject to T2 'shine through',
where the signal intensity from T2WI can show through on the DW image and make
it unclear how much of the altered signal (e.g. the 'bright' lesion) is due to real
diffusion restrictions30.
DWI ADC
Figure 1.11 DWI and ADC image of a patient with a right hemisphere ischaemic lesion
at 22 hours after stroke onset.
Perfusion-weightedMRI
The perfusion of blood through tissue is commonly measured with MRI in two ways:
arterial spin labelling (ASL) and dynamic susceptibility contrast (DSC) PWI. ASL
PWI involves magnetically 'labelling' the water in blood as it enters the brain with
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pulsed RF energy, and is appealing as it involves no exogenous contract agent .
However, ASL PWI is technically highly demanding, is very susceptible to patient
movement artefacts, has difficulty in measuring long blood transit times (which are
prevalent in stroke patients), and has poor signal-to-noise ratio33. Thus, ASL is a
much less commonly used approach for PWI in acute stroke than DSC PWI, and will
not be discussed further. In DSC PWI, an injection of paramagnetic contrast agent
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(usually gadolinium-based) is traced using classical indicator dilution principles .
After the injection of the bolus of contrast agent, a volume is imaged repeatedly with
*
a T2 -weighted sequence which has a high sensitivity to magnetic susceptibility
effects. The presence of the contrast agent in the sample causes a transient decrease
in SI, and the time course of this change is recorded for all voxels in the volume,
























Figure 1.12 Signal intensity vs. time graph.
The tracer concentration is estimated from the change in T2 SI to obtain a tracer
concentration vs. time curve (Figure 1.13).
Perfusion information obtained from the SI or concentration vs. time curves can be
either 'non-quantitative' (including 'summary' and 'index' measures) or




Figure 1.13 Tracer concentration vs. time graph.
'Non-quantitative' perfusion measures can be used to obtain 'summary' perfusion
parameters, which can be quickly and easily obtained directly from either the SI 01
concentration vs. time curves, and may even be calculated automatically at the time
of examination using software on some MR consoles. 'Summary' PWI parameters,
such as tracer bolus arrival time, time-to-peak (TTP, measured as the time from
tracer bolus arrival to peak concentration), and peak concentration height are
commonly used in MR stroke research33. Though easily obtained and useful for
distinguishing general pathology, 'summary' parameters have no clear relationship to
actual underlying cerebral haemodynamics, so interpretation should be cautious . In
particular, 'summary' parameters do not account for bolus delay and dispersion or
cardiac output - to account for these factors and obtain a more direct measure of
o -2
CBF, complex and technically demanding image processing must be performed .
'Non-quantitative' perfusion measures can also be used to calculate 'index' values of
CBF, cerebral blood volume (CBV), and mean transit time (MTT). These 'index'
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perfusion parameters require complex 'offline' processing, including correction of
the concentration vs. time curves using gamma-variate curve-fitting procedures to
isolate the 'first pass' of the tracer and eliminate the influences of 'subsequent pass'
tracer recirculation. From these corrected concentration vs. time curves, 'index'
perfusion measures of CBV (CBVj), MTT (MTTj), and CBF (CBFj), are calculated.
CBVj is proportional to the area under the concentration vs. time curve, and MTTi is
obtained by calculating the first moment of the concentration vs. time curve. Once
CBVj and MTTj have been calculated, CBFj can be obtained by applying the Central
Volume Principle34'35:
CBF = CBV/MTT
'Index' perfusion parameters are superior to 'summary' perfusion parameters as they
attempt to model only one of the underlying parameters, however, they do not have
either the correct units or the correct scale. For example, CBFj is not quantified in
'absolute' units (e.g. mL/lOOg/min), so an 'absolute' CBFj threshold of tissue
viability cannot be calculated.
It is important to note that 'relative' measures must be calculated in order to analyse
'non-quantitative' perfusion parameters. 'Relative' CBF (CBFr), CBV (CBVr), and
MTT (MTTr) are obtained by normalising the values of a region of interest to a
homologous contralateral region to allow for comparison of values both between
patients and between different scan times within the same patient. Note CBFr, CBVr,
and MTTr have no units. Obtaining quantitative measures of perfusion would
theoretically eliminate these problems33.
'Quantitative', or 'absolute' measures of perfusion require even further complex
processing. An arterial input function (AIF) that records the appearance of the tracer
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bolus as it enters the neurovascular circulation is used in conjunction with the
individual voxel concentration vs. time curves to estimate a property termed the
residue function. The residue function describes the rate at which the contrast leaves
a voxel as if an ideal (instantaneous and infinitely thin) tracer bolus is delivered to
the voxel; i.e. the voxel is instantaneously filled with contrast that then leaves the
voxel over time. The AIF is typically estimated from an intracerebral artery, and is
used to 'deconvolve' the voxel concentration vs. time curve in order to estimate the
residue function - this estimation represents one of the big challenges in obtaining
quantitative PWI . 'Absolute' CBF (CBFa) is assumed to be equal to the maximum
value of the estimated deconvolved residue function36. 'Absolute' CBV (CBVa) is
obtained by dividing the area under the voxel concentration vs. time curve by the
area under the AIF concentration vs. time curve36. 'Absolute' MTT (MTTa) can be
obtained by applying the Central Volume Principle34'35:
MTT = CBV/CBF
Although in theory the perfusion parameters obtained by deconvolution are
quantitative, difficulties in quantifying the contrast concentration in voxels in
different physiological environments in vivo mean these values should be interpreted
with caution37. 'Absolute' parameters have the correct units and will have the same
scaling between serial scans in the same patient, however 'absolute' and 'true' CBF,
CBV, and MTT are almost certainly not equivalent, and are instead related by an
unknown scaling factor33,37.
The complex nature of image processing and the many assumptions made as to the
tracer haemodynamics mean that even 'quantitative' perfusion values are only
approximate37. Furthermore, greatly varying individual haemodynamics in imaging
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subjects mean it is unwise to compare measures between patients - for example,
'baseline' CBF may be lower in a patient with atheroma in the arteries of the head
and neck than in a healthy patient. Thus, it is advisable to calculate and compare
'relative' perfusion parameters even for the current 'quantitative' perfusion
measures.
To MRI, or not to MRI?
MRI is a valuable tool for safely scanning most patients as it does not involve
ionizing radiation. However, there are some contraindications for MRI, for instance
metal implants, pacemakers, and the presence of other magnetic material in the
patient. Furthermore, the narrow cylindrical shape of the bore of the MRI machine
itself (Figure 1.14) means claustrophobic patients often ask to abandon scans early or
refuse imaging to start with, and makes access for patient monitoring difficult.
Figure 1.14 GE Signa 1.5 T MRI scanner in the SHEFC Brain Imaging Research Centre
for Scotland.
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Some acutely ill stroke patients are unable to keep still enough, or have impaired
protection of their airways making it unsafe for them to lay supine for the duration of
the imaging sequences . These contraindications (among others) are not
inconsiderable - up to 20% of acute stroke patients may not be suitable for MRI38'39.
However, MRI does present potential benefits, namely the high sensitivity of
detecting ischaemic lesions even at hyperacute stages26. MRI can provide images of
excellent anatomical detail, as well as information about water diffusion, blood
perfusion, and even functional data, all within one imaging session. Although CT is
conventionally used as the 'gold standard' for detection of haemorrhage in stroke
patients40,41, information that is vital in treatment decision-making42'43, many studies
show that MRI is more accurate at haemorrhage detection, and is more specific in
determining the age of the haemorrhage40'44"48. The high sensitivity ofMRI diffusion
and perfusion imaging to the pathology of ischaemic stroke make it an ideal tool to
further understand the mechanisms and processes involved in ischaemic stroke -
information that could be used to develop more effective treatments for stroke
patients.
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2. Ischaemic stroke lesions on MRI
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Introduction
This chapter will discuss the appearance of ischaemic lesions on DWI, and how they
are measured. Problems with measuring lesions on DWI, including ill-defined
lesions, T2 'shine through', and tissue swelling are also discussed. The use of the
'DWI/PWI mismatch' and thresholds of DWI and PWI values to identify 'tissue at
risk' of infarction are examined.
The appearance of ischaemic stroke lesions on MRI
The sensitivity ofMRI in detecting changes in water diffusion and blood perfusion in
brain tissue means that many studies have investigated the appearances of ischaemic
stroke from acute to chronic stages in an effort to further understand the underlying
pathology of ischaemic tissue and perhaps identify 'tissue at risk' of infarction that
might benefit from treatment.
Early studies in acute stroke demonstrate that ischaemic changes could be detected as
an increased signal on T2WI at approximately 8 hours after stroke onset49'50.
Although Bryan et al.51 reported superiority of T2WI over CT imaging in detecting
ischaemic lesions, others found that T2WI did not perform better than CT imaging in
diagnosing acute ischaemic stroke52. However, the advent of DWI provided stroke
researchers with an ideal tool to investigate early ischaemic changes due to its
excellent sensitivity to changes in the diffusivity ofwater.
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DWI in ischaemic stroke
DWI vs. T2WI and CT imaging
DWI sequences developed in the 1980s enabled visualisation of the self-diffusion of
water in vivo53'54. In early experimental ischaemic stroke research in animals,
ischaemic changes on DWI were seen within minutes, whereas ischaemic changes on
T2WI did not appear until > 2 hours after stroke onset55"57. Early studies in human
acute ischaemic stroke found that DWI detected infarcts at earlier times after
ischaemic stroke than T2WI (Figure 2.1), probably because of the higher signal
contrast between normal and abnormal tissue of DWI compared to T2WI at early
time points58, and could help distinguish old from new ischaemic lesions59"63.
DWI T2WI
Figure 2.1 DWI and T2WI from a patient with a right hemisphere ischaemic lesion at 6
hours after stroke onset. Note the hyperintense DWI lesion, and minimal (if any)
visible T2WI lesion.
Comparative studies show DWI to be more sensitive, have similar specificity, and
higher accuracy for the detection of acute ischaemic lesions compared to T2WI and
CT imaging52'64"67.
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Acute appearance of ischaemic lesions on DWI
New ischaemic lesions appear as a hyperintense ('bright') area relative to
surrounding tissue on DWI within minutes of stroke onset (Figure 2.1). The
underlying ADC images show a hypointense ('dark') lesion reflecting the decrease in
the ADC of ischaemic tissue (Figure 2.2).
13 h 6 d 13 d 32 d 94 d
Figure 2.2 DWI and ADC images from a patient with a left hemisphere ischaemic
lesion from 13 hours (h) to 95 days (d) after stroke onset. Note the compression of the
left lateral ventricle between 13 hours and 13 days and subsequent ex vacuo effect at
94 days after stroke onset.
Evolution of ischaemic lesions on DWI
Ischaemic stroke is a variable condition: some patients have large areas of brain
affected by ischaemia, some small; some patients have early spontaneous resolution
of perfusion deficits, while others may have slower, possibly incomplete, restoration
of blood flow. The range of individual differences in stroke severity and recovery in
ischaemic stroke patients means that studies involving small numbers of patients are
likely skewed by individual differences amongst patients. Furthermore, to establish
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the pattern of ischaemic changes over time, the same patients must be serially
scanned within distinct time points after stroke onset. What does the current literature
say about the evolution of ischaemic lesions on DWI, and do these studies use
adequate numbers of patients and appropriate serial scanning?
The hyperintensity of the DWI lesion persists for variously reported times from 48
hours - 14 days after stroke onset60'62,68"71, and decreases in ADC for 18 hours - 85
cq c i nr\ nn no
days after stroke onset ' ' " . Subacutely, ADC becomes less hypointense,
seeming to return to normal ('pseudonormalisation'60'61), and lesions on DWI
become more isointense. However, this 'pseudonormalisation' does not indicate a
resolution of the lesion; ADC values subsequently become increased relative to
normal, showing as a hypointensity on DWI and a hyperintensity on ADC images at
late times after stroke onset60"62'70 (Figure 2.2).
Typically these studies used groups of approximately 20 patients with acute and
follow-up scanning to assess the time course of DWI changes. Several studies used
larger groups of patients (e.g. number of subjects [n] = 3 079 - 14773), but each patient
had only one scan within a large range of times (e.g. from 2 hours - 417 days after
stroke onset74) that were assembled to create models of lesion evolution on DWI.
Using 'snapshot' images from different patients at a wide range of different times to
form a composite pattern of lesion evolution is problematic due to the small number
of patients at each time point and large degree of variability between patients.
To measure the 'final' lesion appearance and extent, many studies used a scan from <
OA OA
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7 days after stroke onset " . However, as mentioned above, there is clear evidence
that lesion evolution on MRI persists well beyond 7 days after stroke onset.
Furthermore, the lesion can seem to disappear on T2WI (the 'gold standard' for
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measuring chronic ischaemic lesions77'90'91) at < 30 days after stroke onset92'93, a
phenomenon known as 'fogging', which can cause underestimation of lesion volume,
or a false negative for lesion presence77'93. Thus, measurements of lesion extent on
T2WI from < 30 days after stroke onset do not accurately express, and will not be
considered to measure, final infarct extent.
What does lesion appearance on DWI indicate about
tissue state?
Stroke researchers are interested in trying to use acute (< 24 hours after stroke onset)
DWI lesion appearance to determine final infarct extent and clinical outcome.
If acute DWI appearance is to be used to predict the final infarct extent and guide
patient treatment decisions, the pathophysiological state of tissue of a particular
appearance on DWI must be determined.
Experimental models of ischaemic stroke in animals indicate that lesion appearance
on DWI closely correlates with the infarct as determined by histological analysis " ,
and one study in human stroke patients (n = 11) shows that DWI lesions accurately
predict the presence of a pathologically verified lesion on autopsy within 5 days of
DWI94. However, the pathophysiology underlying ischaemic changes on DWI are
still unclear. Hyperacute changes in DWI are not attributed to a change in water
content (as there is no accompanying change on T2WI, which is acutely sensitive to
changes in water content), but rather a change in the distribution of water content61.
The early hyperintensity on DWI (and corresponding hypointensity on ADC) is
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thought to represent cytotoxic oedema, or the influx of water from the extracellular
into the intracellular space55'57. The increase in intracellular water content causes
restriction of the extracellular space, which is thought to cause the decrease in water
diffusion that shows up on acute DWI and ADC images (Figure 2.3)56'57'61.
DWI ADC
Figure 2.3 DWI and ADC images from a patient with a right hemisphere ischaemic
lesion at 6 hours after stroke onset. Note the hyperintense DWI lesion is easily visible,
while the hypointense ADC lesion is less easily distinguished (particularly at the
lesion edges).
The pathophysiology underlying subacute patterns on DWI and ADC is even less
well understood, although processes involved in the evolution of acute ischaemic
damage, including membrane failure (with associated disturbances in ion
homeostasis), cell death, cell lysis, and vasogenic oedema have been postulated as
probable causes61'62'70. Chronic hypointensity on DWI and hyperintensity on ADC
images are thought to represent areas of vasogenic oedema caused by cell death and
resulting tissue cavitation60'69'70'95.
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The pathophysiological correlates of DWI appearance will be explored further in
Chapter 3.
Measuring ischaemic lesions on DWI
Acute DWI lesion volume may predict clinical outcome and could help guide
treatment decisions96"98, but factors influencing DWI lesion measurement have not
been widely assessed. Acute DWI lesions are 'bright' against the 'dark' grey of the
rest of the brain, and are easier to distinguish visually (i.e. greater contrast between
normal and abnormal tissue) than a 'dark' ADC lesion against the slightly lighter
grey of the rest of the brain (Figure 2.3); thus DWI is much more commonly used for
measurement and analysis of ischaemic lesions89,99'100.
However, there is no consensus on the best way to measure lesions on acute DWI.
The most common method of lesion measurement is manual outlining the visible
DWI lesion.
Manual lesion outlining
Manual outlining of the visible DWI lesion has been performed in previous studies
by one observer (often with explicit mention of blinding to clinical and other imaging
details)62'83,84,101"103, or several experienced observers (generally blinded to clinical
and other imaging details), often on more than one occasion, which have been
averaged to obtain a DWI lesion 'region of interest'85,99,100,104"106. Although some
studies report high levels of intraobserver and interobserver reliability for manual
outlining of DWI lesions99,100,104, these studies measured DWI lesions from widely
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variable stages of ischaemic stroke (e.g. from < 7 hours104 - 84 days" after stroke
onset), and used small numbers of patients (e.g. n = 12104 - 28100; Table 2.1).
Table 2.1 Summary of papers measuring reliability of DWI lesion volume
measurement. All studies employed a manual outline method of measuring DWI
lesions, n = number of patients, MR time = time from stroke onset to MRI, r =




n MR time Observers What were the findings?
Baird et al.100 44 28 < 53 h 3 observers, twice
Interobserver reliability: r >
0.95; intraobserver variation: <
5%
Barber et al." 52 18 12 h- 84 d 2 neurologists
Interobserver/intraobserver
variation: < 5%
Rana et al.107 38 15 < 24 h - 14 d medical physicist
and neuroscientist
Interobserver coefficient of
variation: 85 ± 130%
Thijs et al.104 24 12 < 7 h - 7 d 2 observers Interobserver reliability: r >0.95
Others who simply rated the presence or absence of a DWI lesion in the hyperacute
(< 6 hours after stroke onset) stages of ischaemic stroke have demonstrated a lower
degree of interobserver agreement (Table 2.2)64'65'67'107,108. The lesion is likely to be
less hyperintense on DWI in the hyperacute stage of ischaemic stroke59, so manual
lesion measurements would most likely also be less reliable on hyperacute scans.
Furthermore, imaging studies often fail to list details of the observers100'104, for
instance whether they are neurologists or radiologists, or what experience they have
in viewing and assessing DWI scans. Observer experience has been shown to be
important; 'expert' observers have been found to have much higher levels of
interobserver agreement than 'novice' observers65. Factors affecting the variability of
manual lesion measurement on acute DWI will be explored further in Chapter 5.
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Other lesion measurement methods
Other less common lesion measurement methods include: placement of a region of
interest in the visible DWI lesion for extraction of ADC values60'61'69'70,109;
semiautomated thresholding or contouring from a manually placed region or 'seed'
based on local DWI si77'81'88'110"115; and multiparametric iterative 'clustering'
O 1 1 / t 1 o
analysis (with the use of a K-means algorithm) ' " .
Extracting DWI and PWI values from a small region of interest placed within a DWI
lesion is problematic as DWI lesions are heterogeneous, with widely varying degrees
of underlying changes in ADC68'78'119-121 and perfusion113 values - changing the
placement of the region of interest even slightly could greatly change the extracted
ADC122 and PWI values.
Semiautomated lesion segmentation is appealing as it theoretically eliminates
observer variation, however, all studies of these semiautomated lesion segmentation
methods mention the need for some degree of manual observer editing (e.g. for
exclusion of ventricles and delineation of anatomical boundaries), so observer
variability is still an issue. Furthermore, the problems of lesion heterogeneity would
also likely affect semiautomated lesion segmentation - regions of less severe degrees
of abnormality may be missed depending on where the initial contour or 'seed' is
placed.
Multiparametric clustering analysis is a promising method for measurement of
regions of ischaemic tissue as it is observer independent, and using a combination of
MR parameters (T2WI and DWI68 or T2WI, DWI, and PWI116"118) may solve the
issues of individual parameter heterogeneity. Tissue identified as 'at risk' by these
117
multiparametric techniques appears to correlate with clinical outcome , and more
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accurately represent tissue destined for infarction than either DWI or PWI parameters
alone116. However, there are few studies investigating these segmentation algorithms,
and they were developed in small groups of patients (e.g. n = 868 - 14116), so these
methods require much further study and validation to determine their usefulness in
the general population of stroke patients.
Problems with DWI lesion measurement
There is a great variability in changes on DWI and ADC images that often goes
unmentioned, despite increasing evidence that many patients do not follow the
aforementioned 'accepted' patterns of ischaemic changes on MRI. These problems
include: ischaemic lesions that are hazy, ill-defined, and 'patchy' on DWI; the
contribution of T2 'shine through' to DWI lesion appearance; the effect of
oedematous swelling on lesion measurements; and the variability of ADC values due
to age, tissue type, and individual patient differences.
Ill-defined lesions
Although most studies report that lesions on acute DWI are discrete, clearly defined
'bright' regions, the lesion can have regions of subtle, ill-defined hyperintensity
(Figure 2.4). Few have acknowledged the existence of this problem, but it has been
suggested that the areas of the DWI lesion that appear 'hazy' and ill-defined
represent salvageable tissue, i.e. the 'ischaemic penumbra'123'124. However, as
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suggested by Guadagno et al. , lesion regions that are obviously hyperintense on
DWI may not indicate irreversible tissue damage, while regions of more subtle
hyperintensity on DWI may indicate irreversible tissue damage. The presence of
these subtle changes on DWI may be a factor in interobserver variability in lesion
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measurements'26; the effects of acute DWI lesion appearance on lesion measurement
will be explored further in Chapter 5.
Figure 2.4 DWI from a patient with a left hemisphere ischaemic lesion at 4 hours after
stroke onset. Note that the DWI lesion is not uniformly hyperintense, with areas of ill-
defined, subtle hyperintensity.
The appearance of subacute and chronic lesions on DWI also present problems for
lesion measurement. Not only does the ischaemic lesion become less distinct as it
changes from hyperintense to isointense and then hypointense on DWI over time
(Figure 2.2), but the appearance of the ischaemic lesion on DWI is also affected by
T2 'shine through' in the later stages of stroke.
T2 'shine through'
Lesion appearance on DWI has contributions from both the ADC and T2WI signals,
and the relative contribution of each has been shown to change over time70'79.
Specifically, acute hyperintensity on acute DWI is attributed almost solely to the
acute decrease in ADC values, after which hyperintensity on DWI is increasingly
attributed to T2 signal effects until approximately 7 days after stroke onset as ADC
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'pseudonormalises' and has less effect on DWI79. After 7 days from stroke onset, the
effects of increased ADC are cancelled out by an increased T2WI SI; any remaining
hyperintensity on DWI is attributed to this increase in T2WI SI, or T2 'shine
through'76'79. Persistent hyperintensity on DWI has been reported at up to 57 days
after stroke onset74'76, and has been attributed solely to this T2 'shine through'.
However, as previously discussed, ADC values can remain decreased at subacute and
chronic time points (e.g. > 7 days after stroke onset77'78), so it is entirely possible that
persistent hyperintensity on late DWI is still attributable, at least in part, to decreased
ADC. What do persistent decreases in ADC on images from late after stroke onset
indicate? The evolution of diffusion and perfusion parameters in regions of persistent
hyperintensity on late DWI will be explored further in Chapter 7.
Lesion swelling
Another problem affecting lesion volume measurements is oedematous swelling.
Oedema of the ischaemic lesion at subacute times, with apparent maximal effect at 1
- 3 days after stroke onset in humans127, may cause overestimation of the volume of
the ischaemic lesion. Studies in rats have indicated that up to 25% of the volume of
the visible lesion on T2WI at 24 hours after stroke onset may be attributable to
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oedema . Few studies of serial MRI in human ischaemic stroke consider the
possibility that differences in lesion volume over time may be the effect of
oedematous swelling and possible subsequent tissue atrophy as necrotic tissue is
'reabsorbed' and hydrocephalus ex vacuo develops (Figure 2.2). Oedema (whether of
mass effect or less severe localised swelling) in the first few days after ischaemic
stroke is almost universal129: severe oedema causing compression of the lateral
ventricles and lateral shift of midline structures was observed in 13% of patients in
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one study59, and it is likely that lesser degrees of oedema that could nonetheless
affect lesion volume measurements went unnoticed129. Although several studies of
human ischaemic stroke patients acknowledge that a decrease in lesion volume
between early DWI and late T2WI may be attributable to oedema that subsequently
resolves77' 7'100, only one study attempted to eliminate these effects by measuring
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lesion volume over time using anatomical landmarks . The effects of lesion swelling
will be addressed further in Chapter 11.
Tissue composition
Besides the variability in the evolution of ADC changes following the onset of
ischaemia, ADC can also vary with age and tissue type. ADC values in normal white
matter have been shown to be significantly higher in older patients, possibly caused
by mild structural changes inherent in the ageing brain130'131. Furthermore, grey and
white matter exhibit different patterns of changes in both appearance on DWI and
underlying ADC values after ischaemic stroke. In the acute stages after stroke onset,
ischaemic grey matter appears to be more hyperintense on DWI than ischaemic white
matter, suggesting that grey matter is more vulnerable to early ischaemic
damage59' 32. However, the underlying ADC of white matter is significantly more
decreased than in grey matter78'133, so white matter may be more susceptible to
ischaemic damage than previously thought, and the lack of early visible changes on
DWI may cause underestimation of the amount of white matter involved in the
ischaemic lesion132. Grey and white matter also exhibit different patterns of ADC
evolution after stroke onset - the ADC in ischaemic grey matter appears to increase
more quickly than in ischaemic white matter in the subacute stages of ischaemic
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stroke ' . Differences in grey and white matter appearance and evolution on DWI
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and ADC images after ischaemic stroke indicate that lesion composition should be
taken into account when evaluating acute lesions and could have implications for
predicting lesion outcome - these differences will be discussed further in Chapter 7.
Despite the problems affecting lesion measurement, what does the current literature
say about the ability of acute DWI to predict tissue destined for infarction?
Acute DWI appearance as a predictor of tissue
infarction
Acute DWI lesion volume has been shown to be both a good90'91'99'112'134 and a
poor135'136 clinical outcome predictor. Several studies suggest that a large (e.g. > 1496
- 2297 mL) acute DWI lesion indicates a poor clinical outcome96'97, but others have
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found no correlation of DWI lesion volume and clinical outcome ' - there is
always the danger that a large lesion may be in a relatively clinically 'silent' area of
brain, and a small lesion in particular areas of brain (e.g. the internal capsule) could
1
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cause severe deficit . However, the volume of abnormality on acute (< 24 hours
after stroke onset) DWI correlates well (e.g. Pearson's product moment correlation
coefficient r = 0.72106 - 0.92138) with final infarct volume as measured on
T2WI64'90'97'99*101'106'138'139. The concept that the acute DWI lesion represents the
'core' of tissue destined for infarction is in increasing dispute105'113; although the
acute DWI lesion and final T2WI lesion correlate well, that does not mean they are
equal (i.e. the acute DWI lesion could consistently underestimate or overestimate
final lesion extent). Several studies measuring lesion volume on DWI in the
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hyperacute (< 6 hours after stroke onset) stages of stroke, when the appearance of the
lesion on DWI is likely still evolving, have found that early DWI volume tends to
underestimate final infarct extent100'109. One study found that DWI lesions from > 6
hours after stroke onset more closely matched the final infarct extent compared to
DWI lesions from < 6 hours after stroke onset100, so consideration of time of imaging
is vital, as already discussed in relation to lesion oedema. Animal16'19'14 '141 and
human studies105'125'142 have shown that even regions of severe hyperintensity on
DWI and decreased ADC have been shown to recover, and tissue appearing normal
on DWI or with mild/no acute decrease in ADC have proceeded to infarction. This
poor correlation of appearance on DWI and ADC images with recovery or infarction
is likely related to the presence or absence and timing of reperfusion, as well as the
time of imaging. Does adding information about the haemodynamic state of the
lesion help to identify tissue at risk of infarction?
Measuring the 'ischaemic penumbra' on MRI
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Currently the most widely studied method to identify the 'ischaemic penumbra' , or
tissue that is viable but at risk of infarction, is by assessing acute 'DWI/PWI
mismatch'.
'DWI/PWImismatch'
Because of the apparent ability of DWI to predict final infarct extent, the 'DWI/PWI
mismatch' model suggests that the acute DWI lesion represents the dead 'core' of an
infarct, and, if a larger lesion on PWI is present, the region of 'mismatch' represents
the 'ischaemic penumbra', or 'tissue at risk' of infarction that remains salvageable
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(Figure 2.5). Several studies have shown that the presence of a 'DWI/PWI mismatch'
predicts that the lesion on final T2WI will be larger than the lesion on baseline DWI
(i.e. the lesion will grow)99"101'138-143-144
DWI CBFi MTTi
Figure 2.5 DWI, CBF|, and MTT; images from a patient with a right hemisphere
ischaemic lesion at 13 hours after stroke onset. Note the 'DWI/PWI mismatch', i.e. the
hyperintense lesion on DWI appears smaller than the visible lesion on the CBF| and
MTTi images.
However, as previously mentioned, there is some question as to whether the acute
DWI lesion accurately identifies the ischaemic 'core', and whether the 'DWI/PWI
mismatch' accurately identifies the 'tissue at risk' of infarction113'145'146. Furthermore,
there is a great disparity in how PWI is measured (as discussed in Chapter 1). Of 10
studies found to investigate acute 'DWI/PWI mismatch' and final (> 30 days after
stroke onset) lesion extent, 1/10 used a 'summary' measure of perfusion (TTP)101,
2/10 used 'index' measures of perfusion (MTTi and CBVj)91'102, 5/10 used 'absolute'
measures of perfusion (CBFa, CBVa, and MTTa)106'138'143'144'147, and 2/10 did not
adequately describe their methods of perfusion measures (although they probably
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measured 'summary' XTP)99'100. The great variability of perfusion parameters
measured, including TTP, CBVj, MTT;, CBFa, CBVa, and MTTa, make it unclear as
14R
to what perfusion parameter best represents the ischaemic penumbra , although
MTT (both MTTj and MTTa) appears to overestimate the 'tissue at risk' of
infarction91102>106>144> I47_
Various methods of measurement of the 'DWI/PWI mismatch' and final lesion
extent on T2WI were used, including: manual outline of the visible abnormality on
DWI, PWI, and T2WI91'99"101'106; use of an MTTa threshold143; thresholds of
percentages of contralateral PWI values147; lesion edge autosegmentation with
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manual correction ' ; and statistical voxel-by-voxel analysis of ipsilateral vs.
contralateral parameter values144.
The quantification of threshold DWI and PWI values that quickly and reliably
identify the 'ischaemic penumbra' would allow clinicians to base treatment decisions
on the presence and extent of 'tissue at risk' of infarction.
Thresholds of ischaemic tissue viability
Numerous attempts have been made at obtaining diffusion and perfusion thresholds
for identifying tissue destined for infarction, however many of these measure
'outcome' lesion extent on scans from insufficient times after stroke onset (e.g. < 7
days after stroke onset85'89'104'142), so do not actually measure final lesion extent. Of
six studies found with lesion outcome measures from > 30 days after stroke onset,
two suggested a 'relative' (normalised to a normal homologous contralateral region)
ADC (ADCr) threshold11 '123 and four suggest perfusion thresholds that predict tissue
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infarction144'147'149,150. Bykowski et al.119 and Desmond et al.123 propose ADCr
thresholds of 0.53 and 0.85 respectively, but both warn that there is a large overlap of
ADC values between tissue that does and does not proceed to infarction, and that a
single MR parameter 'threshold' is unlikely to sufficiently capture the complex
ischaemic pathology to allow for clinical decision making.
'Relative' perfusion thresholds for prediction of infarction suggested include: CBFr
= 0.59, CBVr = 0.85, and MTTr - 1.63 by Rohl et al.150, and CBFr = 0.70 (or CBFa
= 33.9 ± 9.7 mL/lOOg/min) and CBVr = 1.20 (or CBVa = 4.2 ± 1.9 mL/lOOg) by
Rose et al.144. However, both Rohl et al.150 and Rose et al.144 caution that a CBV
threshold may not be clinically useful due its bimodal behaviour in response to
changes in cerebral perfusion pressure, and that the suggested thresholds would need
testing on a larger sample of patients. Butcher et al.149 report a mean MTTa delay of
8.3 s relative to normal in tissue that proceeds to infarction, but caution that MTTa
and CBFa values overlap significantly, and that CBVa values are not significantly
different between infarcted and 'salvaged' tissue to distinguish 'tissue at risk' of
infarction. Furthermore, Parsons et al.147 warn against using a single perfusion
parameter threshold, as different perfusion parameters provide complementary
information about the complex physiology of ischaemic tissue.
The use of a single threshold to predict what tissue will proceed to infarction is
clearly problematic; there is a large overlap of ADC and perfusion values in tissue
that eventually does and does not become infarcted, and underlying ischaemic
physiological processes are complex and variable. Furthermore, the patient sample
sizes used in the studies (e.g. n = 1 1150 - 35149) to identify these ischaemic thresholds
have been small and would require testing in much larger patient groups.
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Studies using multiparametric predictive models incorporating T2WI, DWI, and PWI
information appear promising, but as aforementioned, have been developed in small
samples of patients (e.g. n = 10117 - 26l31) and require further investigation and
validation to determine their value in predicting what tissue will proceed to
infarction116-118'144'151.
What questions remain unanswered?
Although there have been many studies ofDWI and PWI in human ischaemic stroke,
it is still unclear what appearance on the different MRI sequences means in terms of
the underlying pathology of the ischaemic stroke, and if the acute appearance on
MRI informs on the recoverability of the tissue. There is great variability between
patients in changes of DWI SI, ADC values, and PWI parameters over time that
often goes unmentioned. Thus, to summarise, problems with imaging studies that
limit what their results mean and how they can be applied include:
• small numbers of patients studied
• unclear clinical characteristics of patients
• wide range of times of imaging
• wide range ofPWI parameters used
• unclear lesion measurement techniques, including lack of observer details and
intraobserver and interobserver reliability data
• how to manage the effects of tissue distortion due to oedema
• not accounting for heterogeneity within lesions on DWI and PWI
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This thesis will aim to explore these issues in order to help clarify what ischaemic
changes on MRI mean in terms of the viability of the underlying tissue and thus
perhaps help guide clinical decision making.
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Systematic review of DWI and PWI
animal models of ischaemic stroke
Introduction
This chapter comprises of a systematic review of the use DWI and PWI in animal
models of ischaemic stroke, investigating what particular appearances on DWI mean
in terms of the underlying pathophysiology of ischaemic tissue.
What do animal studies tell us about the underlying
pathophysiology of ischaemic stroke lesions?
DWI and PWI may distinguish transiently from permanently damaged brain, and
lesion appearance on MRI might be a surrogate marker for the effectiveness of new
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treatments . Although DWI has been available for a decade, the relationship
between DWI lesion characteristics and tissue viability remains unclear.
The precise point in the ischaemic cascade where lesions become visible on DWI,
and the point of no recoverability, is not known. The 'DWI/PWI mismatch' may
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represent the 'ischaemic penumbra', or 'tissue at risk' that remains salvageable .
Animal studies of focal ischaemia (as a model of human ischaemic stroke) provide
an opportunity to investigate the pathological changes underlying lesion appearance
on MRI154. We aimed to identify information available about the pathophysiological
state underlying DWI and/or PWI lesion appearance in animal models of ischaemic
stroke, to inform on the interpretation of DWI and PWI lesion appearance and
potential for salvage of 'tissue at risk' of infarction in stroke patients.
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We therefore performed a systematic review of all experimental studies of DWI and
PWI in animal models of focal ischaemic stroke to assess all the available
information on the histological correlates of DWI and PWI lesion appearances, and
the likelihood of permanent tissue damage or recovery in the presence of particular
DWI and/or PWI lesion appearances. Excerpts from this chapter have recently been
published in Cerebrovascular Diseases155 (Appendix 2); permission to reproduce the
material within this thesis has been obtained by the publisher (S. Karger AG, Basel,
Switzerland) and the co-author (JMW).
Systematic review methods
The methodology of this systematic review was adapted from that used in the
Cochrane Database of Systematic Reviews156. Although developed for systematic
reviews of randomised controlled trials, the same principles apply to, and have been
successful in, systematic reviews of observational and diagnostic studies.
Search strategy
We searched for published articles of DWI, PWI, or a combination of the two in
animal models of ischaemic stroke in the English and non-English language literature
on MEDLINE (US National Library of Medicine, National Institutes of Health,
Bethesda, MD, USA) and EMBASE (Elsevier Group, Amsterdam, Netherlands)
from 1966 - December 31, 2002 (for a complete list of search terms see Appendix 2).
To validate the search strategy (in accordance with established systematic review
methodology156), we also hand searched the last five years (January 1998 - December
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2002) of the three journals that contributed the most papers from the literature search
{Brain Research, Journal ofCerebral Blood Flow and Metabolism, and Stroke), and
reference lists in all included articles.
Inclusion criteria
We included studies published in full of DWI, PWI, or a combination of the two, in
mammalian models of focal ischaemic stroke, with histological analysis performed
within a maximum of 24 hours of the last MRI session. One reviewer (the author)
identified the abstracts and excluded articles not relevant to this review. Papers were
reviewed by the second reviewer (JMW) and final decisions made by discussion.
Exclusion criteria
Studies without DWI or PWI, non-mammalian animal models, non-focal models of
stroke, global models of ischaemic insult, non-ischaemic models of brain injury, no
histological analysis performed, and histological analysis performed > 24 hours after
the last MRI session were excluded (the dynamic nature of ischaemic stroke would
prevent histological results being related to imaging appearance after a long time
lapse between imaging and histological analysis). Reviews, conference papers, and
studies only appearing in abstract form were excluded. Publications which appeared
to include data previously published elsewhere were excluded. Where the inclusion
of a paper was in question, a consensus was reached between the two reviewers.
Methodological quality scoring
A methodological scoring system was devised to reflect different aspects of animal
imaging methodology (Table 3.1). Aspects of the animal model, imaging method,
histological procedures and analysis, and blinding of analyses were assessed for all
papers. These criteria were drawn up in advance of evaluating the identified papers
57
as part of the primary methodology of the review in accordance with Cochrane
methods156.
Table 3.1 Methodological quality scoring system.
Question Issue 1/2 mark













reproducible? species, strain, sex
source, average weight, housing
and feeding details
3 MRI reproducible?
make, model and strength
of
MR scanner, b value
DWI performed in 3 orthogonal






fixatives and stains listed
without specific values
and concentration
concentration of fixatives and stains,
size/location brain slices; method of
analysis clearly described
5 Histological time
< 24 hours from last
imaging session
< 6 hours from last imaging session




specifically mentioned blinding in
text








'correlated well' on visual
exam
in-depth investigation with methods
clearly described
9 Subregion analysis
done on either imaging or
histology
if performed on both imaging and
histological results
10 Aim
clear hypothesis with discussion of
how results relate
Data extraction
One reviewer (the author) extracted information on: the study year; number and type
of animals used (species, strain, and sex); ischaemia model (method and duration of
occlusion, whether transient or permanent); MRI protocol (make, model, strength of
scanner, scanning protocol); anaesthetic and animal life support in the MR scanner;
time from imaging to histology; histological protocol (details of fixation and analysis
of histological slices, including how the histological slices were matched to the MR
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slices for analysis), MR image analysis (lesion volume, ADC values, blinding of
image and histological analysis and what MRI appearance corresponded to what
macroscopic or histological state). Data extraction was verified by the second
reviewer (JMW).
Studies explicitly stating that the analysis of the histological lesion was blind to the
DWI lesion and vice versa, and/or studies achieving a quality score > 6 were
examined further to extract specific information about the relationship between DWI
appearance and histological damage. We aimed to undertake analyses of how
particular DWI and/or PWI appearances were associated with histological features if
such information was available.
Results of systematic review
The search yielded 1420 articles on MEDLINE and 1243 article on EMBASE,
totalling 2663 papers, 943 of which were repeats, leaving an initial database of 1720
articles. 1579 papers were excluded (reasons given in Table 3.2), mostly because the
ischaemia model was not relevant to human ischaemic stroke (e.g. global not focal).





Not a stroke model 649 41%
Not an animal study 99 6%
Global ischaemia 162 10%
Inappropriate models (e.g. head trauma or aneurysm) 136 9%
Reviews, letters, abstracts 153 10%
No DWI 297 19%
No histology (includes 11 with histology > 24 hours from last MRI) 83 5%
TOTAL 1579 100%
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The remaining 141 studies, concerning the use of DWI and/or PWI were included.
The total number of animals in these papers was over 2817 (2/141 studies did not
• 1S7 1S8 • •
report animal numbers ' ), with a mean n = 21 animals per paper (median n = 18).
General details of included studies
Of the 141 included papers, 108/141 (77%, n = 2255, 80% of animals) used rats,
19/141 (14%, n = 315, 11% of animals) used cats, 8/141 (6%, n = 178, 6% of
animals) used mice, 3/141 (2%, n = 31, 1% of animals) used pigs, 2/141 (1%, n = 36,
1% of animals) used rabbits, and 1/141 (1%, n = 2, 0.1% of animals) used monkeys
(Figure 3.1).
100 i
rats cats mice rabbits pigs monkeys
Figure 3.1 Percentage of total animals by species in studies in review, n = number of
animal subjects in the studies in the review (mean n = 21, median n = 18, total n >
2500).
A middle cerebral artery occlusion (MCAO) model was used in 130/141 (92%; n =
2641) of the included papers, an internal carotid artery occlusion (ICAO) model in
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4/141 (3%; n = 63) papers, a common carotid artery occlusion (CCAO) model in
3/141 (2%; n = 48) papers, the Rose-Bengal cortex lesion model in 3/141 (2%; n =









MCAO ICAO R-B CCAO CCAO & MCAO
Figure 3.2 Percentage of lesion models in studies in review. R-B = Rose-Bengal cortex
lesion.
Methodological quality scores
In general, methods were not reported in detail (Table 3.3, Figure 3.3). The mean
total methodological quality score was 5.73/10 (Table 3.3).
Only 13/141 (9%) papers adequately described their animal subjects. Basic
differences in animal strain and sex can make a large difference in results (e.g. the
apparently neuroprotective effects of oestrogen in a MCAO model of ischaemia in
female rats159). Only 34/141 (24%) papers adequately described the MR procedures
well enough that they might be reproduced. Many papers did not mention
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measurement ofDWI in three orthogonal directions (necessary to obtain reliable and
reproducible quantification ofADC values32).






1 0.92 119 84%
2 0.47 13 9%
3 0.61 34 24%
4 0.85 102 72%
5 0.85 98 70%
6 0.25 9 6%
7 0.09 9 6%
8 0.51 31 22%
9 0.17 18 13%
10 0.88 124 88%




Figure 3.3 Percentage of papers scoring 1/1 on the methodological quality scoring
points. See Table 3.1 for the methodological quality scoring criteria.
Few studies mentioned blinding of the image and histological analysis to each other.
Failure to employ blinding and randomisation in animal studies of drug effects is
known to increase the likelihood of a positive result160. Half (71/141, 50%) of the
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studies did not mention blinding of any of the analyses at all. Only 3/141 (2%)
studies, including 51/2817 (2%) of the total animals used in all included studies,
explicitly stated that histological analysis was blind to DWI analysis and vice
versa16'161'162, so we can only be sure that data from 2% of the animals was analysed
completely free of bias. The way in which the MR images and analyses were
compared to histological data generally lacked detail, with only 31/141 (22%) studies
comparing DWI and histological slices any further than simply saying they
'correlated well'. However, the precise meaning of a 'good correlation' was not
given, and explicit mention of how the histological slices were matched to MR slices
for analysis was either lacking, or described only as being 'eyeballed' for a best fit.
Only 18/141 (13%) studies examined any subregions of the DWI lesion or
histological abnormality.
Perfusion values were obtained and reported in some papers, but in such different
ways that it was not possible to extract the information as to the relationship between
perfusion parameters, DWI and histological data in ways that allowed data synthesis.
We have therefore concentrated on the correlation ofDWI and histological data.
Data extracted on DWI and histopathological lesion appearances
Although all 141 papers were examined, papers with a quality score < 6 consistently
failed to provide data on the relationship ofDWI appearance and histological data, so
we focused on papers with a quality score > 6, and papers with explicit mention of
blinding of histological and imaging analyses. 51/141 (36%) papers achieved a
quality score of > 6, yet only 13/141 (9%) contained information on the relationship
of DWI lesion appearance to histological data (Table 3.4), including 3/13 (23%)
papers that explicitly mentioned blinding of image to histological analysis16'161'162.
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Only 1/13 (8%) of the papers that compared DWI lesion appearance to histological
data explicitly described the method of aligning histological slices to MR slices for
analysis161; the other 12/13 (92%) papers either did not mention how histological
slices were matched to MR slices, or simply used 'eyeballing' to match up the DWI
and histological slices. Of the 13 papers that compared DWI lesion appearance to
histological data, only 3/13 (23%) papers explicitly mentioned blinding of DWI
analysis to histological analysis and vice versa16'161'162. As these three papers provide
the least biased comparison ofDWI to histological data, we focused on their results
first.
Three papers with explicit blinding ofhistological to DWI analysis
and vice versa
Jacobs et al.161 used a permanent MCAO model in rats, with an unsupervised,
automated tissue segmentation technique (ISODATA) to outline the lesion from a
composite of T2WI and ADC data. The regions obtained with the ISODATA
technique were coregistered and compared to manually outlined haematoxylin and
eosin (H&E) stained histological slices at acute (4-8 hours), subacute (16 - 24
hours), and chronic (48 - 168 hours) times after onset of occlusion. Histological
damage, including swollen and shrunken neurons, was seen beyond the edges of the
'bright' DWI lesion at 4 hours after occlusion onset, showing that at acute stages
DWI underestimated cortical ischaemia. The ADC image was poorer than the DWI
image at assessing the extent of tissue damage in the acute stage, but was better at the
subacute and chronic stages after onset of occlusion.
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Neumann-Haefelin et al.16 compared 30 minutes, 1 hour, or 2.5 hours of transient
MCAO in rats with histological analysis at 7 days after onset of occlusion. DWI and
ADC abnormalities reversed after 30 minutes and 1 hour (but not after 2.5 hours) of
occlusion, but reappeared at 24 hours in all groups. At 24 hours after occlusion onset,
the DWI lesion in the 30 minutes and 1 hour occlusion groups was not as extensive
as in the 2.5 hours occlusion group. An infarct was seen histologically at 7 days with
all three durations of occlusion, and was not significantly different in area between
the groups, even in those with complete disappearance of the DWI lesion after
reperfusion.
Ringer et al.162 used a transient 30 minute MCAO model with DWI during, at 3 - 5
hours, 1 day, and 7 days after occlusion onset, and neuronal (microtubule associated
protein 2 [MAP-2]), astrocytic (glial fibrillary acidic protein [GFAP]), heat shock
protein 72 (hsp72), and cresyl violet stained histological analysis at 5 hours and 7
days after occlusion onset. The DWI abnormalities visible at 30 minutes reversed at
3-5 hours, but recurred at 24 hours after reperfusion. When the DWI was normal at
5 hours, there was a significant decrease in MAP-2 immunoreactivity in 30% of the
initial DWI lesion, GFAP was normal, hsp72 staining was extensive and, together
with cresyl violet staining extent, corresponded to the initial DWI lesion extent.
Hence, the 'normalisation' of the DWI abnormality did not indicate that the
underlying tissue was normal, as the neurons (MAP-2) showed signs of structural
damage and stress. The normal GFAP staining suggested that non-neuronal cell
components may be more capable of recovery thereby partially compensating for
altered fluid balances and contributing to the apparently 'normal' DWI appearance.
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Remaining ten papers with a methodological quality score >6
Although blinding was not explicitly mentioned in the remaining 10/13 papers that
achieved a methodological quality score of > 6, they did achieve high quality scores
reflecting good methodological descriptions in other domains. We therefore
examined them in detail also. Of these 10 papers, all except one (of cats168) used rats.
The intraluminal suture method of MCAO was used in 8/10 papers; the remaining
two studies by Detre et al.163 and Sutherland et al.168 used fibrin-rich emboli to
occlude the middle cerebral artery (MCA) and a microaneurysm clip to occlude the
MCA respectively. All studies killed the animals immediately after the final MRI
except one (who killed animals 2 hours after the start of the final MRI session168).
The 13 papers that compared DWI lesion appearance with histological data (Table
3.4) also indicated that histological neuronal damage persisted or progressed despite
the apparent waxing and waning of the DWI lesion16,162,164. They further support the
observation that the resolution of the early DWI lesion after reperfusion, and its
reappearance after 24 hours of reperfusion, may be more due to changes in astrocytes
and glial cells than a decrease in neuronal damage. A consistent comment in several
papers was that astrocytes swelled (presumably restricting the extracellular space and
water movement, and thus affecting DWI), while neurons shrank. Neuronal damage
appeared to persist once initiated, while astrocytes swelled or shrank, which may
explain the apparent 'normalisation' of the DWI lesion17,162,166. This suggests that
DWI recovery and 'secondary' DWI decline are perhaps not caused by 'secondary
injury' to neurons, but occur due to the progression of primary damage of astrocytes
(astrocytes swelled and shrank over time)17,18,162,166. The DWI lesion signal intensity
('brightness') seemed to reflect the amount of neuronal damage - after 90 minutes of
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occlusion and 24 hours of reperfusion, the more intense the DWI signal within the
initial DWI lesion, the greater the proportion of dead neurons164. Acute ADC values
may not be a good determinant for recoverability, one study found that despite great
variability in acute ADC values in groups of animals undergoing 30, 60, and 150
minutes of occlusion, all groups showed a similar degree of histological tissue
damage at 7 days after occlusion onset16. The reduction in ADC at the end of 30
minute occlusion was also similar in areas which, following 24 hours of reperfusion,
had only 10% of dead neurons as those which had 50% of dead neurons18. However,
in another study, the ADC value at the end of vessel occlusion did correspond to the
amount of neuronal damage, as larger decreases in the ADC occurring after 90
minutes of occlusion correlated with increasing levels of neuronal damage after 24
hours of reperfusion164. It was also clear that even short periods (e.g. 30 minutes) of
transient ischaemia in rats caused permanent damage to neurons16"19. Differing
degrees of damage were also seen in different parts of the brain for a given duration
of occlusion - damage to the striatum (particularly the caudoputamen) was worse
than damage to the cortex as seen on both DWI and histology17"1 ' 5.
Discussion
DWI and PWI are frequently used in studies of ischaemic stroke, and are generally
thought of as displaying 'neuronal' damage. However, the exact degree of ischaemic
damage at the cellular level demonstrated by DWI and PWI, and the likelihood of
recovery, has yet to be determined1 9. Although the proportion of studies that we
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were able to examine in detail was disappointing (due to missing information), a
consistent suggestion emerged - that glial cell ischaemic changes are the main
contributors to the both the initial appearance and evolution of the ischaemic lesion
on DWI. Thus 'neuroprotection' strategies may not be best monitored with DWI,
unless it is likely that the drug in question has actions on non-neuronal cell types. If
glial cells are responsible for much of the DWI lesion evolution, then new
approaches to avoid adverse events (such as massive infarct swelling) should
consider interventions in the glial cell 'ischaemic cascade'.
This review has identified several important correlations between DWI and
histological data, but many papers were not informative. It is possible that some
studies were not set up specifically to examine the relationship between DWI and
histological data, however, the limited description of the animals used, MRI
procedures, and histological analysis, combined with absence of blinding of image
and histological analyses, uncertainties about how the image data were compared to
the histological data, and few subregional analyses, means that there are still many
unanswered questions about the relationship ofDWI and PWI lesion appearance and
the underlying pathophysiological state of the brain tissue. Blinding of image and
histological interpretation is vital if biases are to be avoided160.
We examined all papers, but found that papers scoring < 6 on our quality scoring
system did not inform on the relationship between DWI and histological tissue state -
frustratingly only 13/51 (26%) of papers scoring >6/10 had information on the
relationship ofDWI and histological data.
Amongst the studies scoring > 6 on our quality scoring system (Table 3.4), several
potentially important methodological issues became apparent which might explain
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some of the differing results. Firstly, several of the studies used repeated or very
prolonged periods of anaesthesia with isoflurane18'19 - either might contribute to
cerebral damage in areas of vulnerable ischaemic brain, tipping potentially
vulnerable tissue towards permanent damage and making cell damage appear worse
for a given ischaemic insult. Secondly, only one study mentioned taking care to
perfuse and fix the tissue for histological analysis in a way that should eliminate
artefactual 'dark, shrunken' neurons166. How much of the neuronal damage seen on
histological examination in other studies could be due, even in part, to fixation
effects? Perhaps damage inflicted by tissue fixation could account for some of the
inconsistency of results, as for example seen in Muller et al.153 and Muller et al.167,
where the lesion on DWI was larger than the histological lesion in the former, and
smaller than the histological lesion in the latter despite using seemingly identical
methods in the same research laboratory. When comparing histological slices to MRI
slices, it is important to ensure that the same areas of the brain are being compared. It
was not clear in the majority of the papers whether, and how, this 'matching' of
histological and MR slices was performed, although 'eyeballing' seemed to be the
most frequently used method. Thus, it is difficult to be sure that the histological slice
represented the same tissue as that of the 'matched' MR image.
Despite this, several consistent patterns emerged (Table 3.4) with implications for
studies in human ischaemic stroke patients. Histological damage persists and
progresses despite the DWI lesion waxing and waning, i.e. referring to reappearance
of the DWI lesion after a period of normalisation as 'secondary injury' in human
studies is probably not correct in pathophysiological terms. Acute ADC values are
not good predictors of tissue recovery as similar values were obtained from tissue
70
that subsequently mostly recovered as from other areas which were permanently and
severely damaged. However, the intensity ('brightness') of the DWI signal does
seem to relate to the proportion of damaged neurons - the more abnormal ('brighter')
the DWI signal, the greater the proportion of damaged neurons. The intensity of the
DWI signal is the most rapidly and easily interpreted information from DWI in the
clinical situation - the observer can assess the lesion 'brightness' immediately, so
this is probably one of the more clinically useful results of this work. Changes in
astrocytes, rather than neurons, probably account for much of the DWI lesion waxing
and waning - the neurons are said to shrink, while the astrocytes are reported to
swell. IfDWI signal change is at least in part the result of restricted water movement
in the extracellular space, then swollen astrocytes rather than shrunken neurons
(assuming the 'shrinkage' is not a fixation artefact) could be the major contributor to
this appearance. In rats, even 30 minutes of ischaemia is lethal to some neurons, and
damage to the caudoputamen (both on DWI and histological slices) was worse for a
given degree of ischaemia than damage in the cortex.
Where next? Experimental methodology could be more clearly and consistently
described; occlusion methods, animals, and MRI methods should be described in a
reproducible way, and blinded methods of image and histological analyses are
essential to reduce bias. More information is required on how DWI abnormalities
relate to cellular changes - at what degree of 'brightness' on DWI does the tissue
pass the point of no recovery, and how does this change with increasing time after
stroke onset? The Stroke Therapy Academic Industry Roundtable discussion
concluded that little animal research done to date 'has translated into effective
treatment modalities for stroke in humans'170. Perhaps the focus on neurons, both
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experimentally and in imaging studies, has deflected attention from the contribution
of other important cell types to the total damage and likelihood of recovery in
ischaemic lesions as a whole. Experimental studies may help with translational
research to clarify and determine mechanisms for important relationships between
MRI appearances found in clinical studies and histopathology. However the
methodology should be clearly described, the model should be relevant to stroke
patients, and important differences in proportions of cerebral cells (e.g. neurons and
glial cells) between animals and humans and their contributions to the ischaemic
process should be considered.
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This chapter presents the methods for the recruitment, imaging, and basic lesion
measurement of the large cohort of patients used for the analyses in this thesis.
Results of basic manual lesion analysis, including DWI and PWI parameter values
from the visible DWI and PWI abnormalities from baseline (< 24 hours after stroke
onset) to final outcome (90 days after stroke onset) imaging are presented.
Methods
Patient Recruitment
Patients were recruited prospectively (between June 2000 and June 2004) from the
hospital stroke service at Western General Hospital, Edinburgh by stroke physicians.
Patients with symptoms of ischaemic stroke of all severities who could be imaged
within a maximum of 24 hours of stroke onset (baseline) were eligible for this study.
Local ethics approval was obtained from the Lothian Local Research Ethics
Committee. All patients were examined by a trained stroke physician on admission
and diagnosed as having probable or definite stroke. Baseline clinical assessment and
stroke scoring were performed immediately using the National Institutes of Health
Stroke Scale (NIHSS)171 and Oxfordshire Community Stroke Project (OCSP)
classifications13. Imaging was repeated at approximately 5, 14, 30, and 90 days after
stroke onset. Patients were followed up at 90 days after stroke onset to determine
their functional status using the modified Rankin Scale (mRS)172'173. A final
diagnosis (stroke, TIA, or non-stroke) was reached by a panel of experts in stroke
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neurology and imaging using all available clinical and imaging information for each
patient after the patient was discharged.
Imaging
All MRI data were obtained using a GE Signa LX 1.5 T (General Electric,
Milwaukee, WI, USA) clinical scanner (located in the Scottish Higher Education
Funding Council [SHEFC] Brain Imaging Research Centre for Scotland [SBIRCS] in
the Division of Clinical Neurosciences, Western General Hospital, Edinburgh),
equipped with a self-shielding gradient set (22 mT/m maximum gradient strength and
120 T/m/s slew rate) and manufacturer-supplied 'birdcage' quadrature head coil. The
MRI examination consisted of standard sequences for stroke diagnosis including a
fast SE-T2W sequence, a gradient echo TjW sequence, and DWI and PWI as detailed
below. The total duration of the MRI examination from the patient entering to
leaving the MRI suite was 20 - 40 minutes.
Imaging was repeated where possible at 5, 14, 30, and 90 days after stroke onset. To
ensure that the slice locations used in the follow-up scans corresponded as closely as
possible to those in the first, the subject's head position and tilt in the first scan were
recorded and the patient was repositioned as close as possible to this position in the
follow-up scans.
DWI
Diffusion MRI data were acquired using a DT-MRI protocol based on SE-EP
imaging. In this protocol, sets of axial DW-EP images (b = 0 and 1000 s/mm ) were
collected with diffusion gradients applied sequentially along six non-collinear
directions174. Five acquisitions consisting of a baseline T2W-EP image and 6 DW-EP
images (a total of 35 images) were collected per slice position. The acquisition
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parameters for the DW-EP imaging sequence were: 15 axial slices of 5 mm thickness
and 1 mm slice gap, a field-of-view (FOV) of 240 x 240 mm, an acquisition matrix
of 128 x 128 (zero filled to 256 x 256), a TR of 10 s and a TE of 98.8 ms. In a small
number of patients who were very ill and judged unlikely to tolerate the entire DT-
MRI protocol, a shorter DW-MRI sequence was used. This sequence shared the same
acquisition parameters as the DT-MRI protocol, except that only two averages were
collected and the diffusion gradients were applied sequentially in three orthogonal
directions. Other than not containing diffusion anisotropy data, the DWI maps and
underlying ADC values were the same in patients receiving the shorter sequence so
for the purposes of this thesis data from these shorter DW-MRI sequences will be
considered the same as data from the full DT-MRI sequences.
PWI
Perfusion MRI data were acquired by imaging the dynamic signal change following
a bolus injection of a gadolinium-based contrast agent (gadopentetate dimeglumine).
Patients were injected with either 1.0 mmol Gadovist® (10 mL @ 5 mL/s; Schering
AG, Germany) or 0.5 mmol Omniscan™ (20 mL @ 5 mL/s; Amersham Health AS,
Norway) in the antecubital vein. Thirty-four volumes of 15 axial slices of 5 mm
thickness and 1 mm slice gap were acquired over a period of 82.5 s using a single-
shot T2*-weighted GRE-EP imaging sequence with a FOV of 240 x 240 mm, an
acquisition matrix of 128 x 128 (zero filled to 256 x 256), a TR of 2.5 s and a TE of
30 ms. Four baseline volumes were collected before contrast administration.
Image Processing
The DICOM (Digital Imaging and Communications in Medicine, National Electrical
Manufacturers Association, Rosslyn, VA, USA) standard format images were
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transferred from the scanner to a Sun Ultra Sparc Station 10 (Sun Microsystems,
Mountain View, CA, USA) and converted into Analyze™ (Mayo Foundation,
Rochester, MN, USA) format using in house software written in the C programming
environment.
Computational image realignment techniques were used to realign the diffusion and
perfusion imaging data from the baseline and all subsequent scans to the T2WI
volume from the baseline DT-MRI scan. This realignment minimises any small
remaining positioning errors and removes bulk patient motion and eddy current
induced artefacts175.
The set of five component DW-EP images for each gradient direction were averaged
to obtain seven high signal-to-noise ratio images for each brain slice. From the signal
intensities measured from the DW-EP images, the six elements of the apparent
diffusion tensor of water (D) and T2WI SI from each voxel were estimated by
• • • 17f\ • • • •
multivariate linear regression . After diagonalisation of D to yield the magnitude
sorted eigenvalues (ki, X2, X3), maps of the T2WI SI and average ADC, calculated
as :
ADC = (Trace D) / 3 = (h + h + h) / 3
were generated on a voxel-by-voxel basis.
For the perfusion data, tracer concentration vs. time curves were produced voxel-by-
voxel from the SI vs. time data, and gamma-variate fitting procedures were applied
to remove the effects of tracer recirculation177. 'Index' perfusion measures were
calculated; CBVj as the area under the voxel concentration vs. time curves, MTTj as




All perfusion data presented in this thesis (CBF, CBV, and MTT) are 'index'
parameters as described in Chapter 1 (and thus can be assumed to be CBFj, CBVj,
and MTTj). Note, since 'index' perfusion data is not quantitative, extracted perfusion
values are in arbitrary units (AU). Colour perfusion maps were produced by
windowing the grey-scale perfusion maps to the MATLAB® (The MathWorks,
Natick, MA, USA) 'jet' colour scale (Figure 4.1), which ranges from blue
(minimum) to red (maximum).
max
min
Figure 4.1 Example of a MTT colour map (centre, in a patient with a right hemisphere
ischaemic lesion at 13 hours after stroke onset), calculated by windowing the grey-
scale signal intensities (left) to the MATLAB® 'jet' colour scale (right).
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Basic region of interest analysis
All lesion volume measurements were performed on a Sun Ultra Sparc Station 10
using Analyze™. For each patient, for all scans performed at each MRI time point,
the visible abnormalities (if present) on DWI, CBF, and MTT images were
measured. DWI SI and colour CBF and MTT maps were printed on paper and a
board-certified neuroradiologist with 10 years of DWI lesion interpretation (JMW),
blind to clinical and other imaging data, outlined the visible lesion on the paper copy.
The author (who had 12 months experience of viewing and measuring acute stroke
lesions on DWI at the beginning of the study), blind to baseline clinical and outcome
data, used these outlines to trace around the lesions on the Sun workstation, and
outlined a homologous contralateral region of interest for each lesion region. Image
brightness and contrast were adjusted for maximum contrast between hyperintense
tissue and normal appearing brain. ADC, CBF, and MTT values were extracted for
the DWI, CBF, and MTT lesion and contralateral regions. Relative ADC, CBF, and
MTT (ADCr, CBFr, and MTTr) values were calculated for each patient by dividing
the lesion values by the contralateral values to allow for comparison of data between
patients and over multiple scan times. Total lesion volumes were obtained by
sampling the number of outlined voxels on each slice on which the lesion was visible
and multiplying by the slice thickness.
Statistical analyses
General patient demographic data were obtained and compared, including the sex,
age (mean and range), initial NIHSS score (mean, median, and range), OCSP
classifications, and mRS at 90 days after stroke onset (mean, median, and number of
patients dependent [mRS = 3-5] and dead [mRS = 6] at 90 days after stroke onset).
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Mean (± standard deviation [SD]) time from stroke onset to baseline and subsequent
MR scanning are reported.
Mean (± SD) ADCr, CBFr, and MTTr values are reported and compared for all
available patient scans at each time point. Baseline ADCr, CBFr, and MTTr were
compared to normal (test value = 1, as they are relative values) using standard t-tests.
Changes in ADCr, CBFr, and MTTr values over time (from baseline to 90 days after
stroke onset) were analysed using general linear model (GLM) repeated measures
regression analysis (dependent variables = ADCr, CBFr, and MTTr values). MR
parameters were fit to a linear model, except for CBF, which was fit to a quadratic
model as the evolution of CBF in ischaemic tissue over time exhibits significant
quadratic effects.
All statistical analyses in this thesis were performed in SPSS® 11.0 (SPSS Inc.,
Chicago, IL, USA). Differences were considered significant at the observed
significance level (p) of 0.05 throughout this thesis.
Results
Patient details
A total of 161 patients were recruited, 27 of which were excluded from this analysis
for the following reasons: 14 patients had unusable, incomplete scanning (e.g. could
not tolerate scanning procedure due to claustrophobia), 11 patients had a
haemorrhage, and two patients had a intracerebral tumour.
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Of the 134 patients included in the general image analysis, 72/134 (54%) were male,
the mean age was 64 (range: 35 - 99 years), and the mean NIHSS score on admission
was 9 (median 7, range: 0 - 29). OCSP classifications: 31/134 (23%) patients had a
total anterior circulation infarct (TACI), 62/134 (46%) patients had a partial anterior
circulation infarct (PACI), 27/134 (20%) patients had a lacunar infarct (LACI),
10/134 (8%) patients had a posterior circulation infarct (POCI), and 4/134 (3%)
patients had an uncertain OCSP classification. All patients were treated with aspirin,
but none received thrombolysis or any investigational neuroprotective drugs. Mean
mRS score at 90 days after stroke onset was 3 (median 2); 46/134 (34%) patients
were dependent (mRS = 3-5) and 20/134 (15%) patients were dead (mRS = 6).
Final diagnoses by expert panel after patient discharge were: 127/134 (95%) patients
had a stroke, 5/134 (4%) patients had a TIA, and 3/134 (2%) patients were classified
as non-stroke patients. All patients were included in the general analysis in this
chapter, as they represented a typical population of patients presenting with stroke¬
like symptoms, but patients diagnosed as only having had a TIA and non-stroke
patients were excluded from further in-depth analyses presented later in this thesis.




Mean (± SD) time from stroke onset to baseline MRI was 14 ± 11 hours, with 42/134
(31%) patients imaged within 6 hours, 29/134 (22%) patients between 6 and 12
hours, and 63/134 (47%) patients between 12 and 24 hours after stroke onset (Table
4.1). 60/134 (45%) patients had a scan at 5 days, performed at a mean of 5.4 ± 1.0
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days; 52/134 (39%) patients had a scan at 14 days, performed at a mean of 12 ± 2
days; 43/134 (32%) patients had a scan at 30 days, performed at a mean of 31 ±3
days; 40/134 (30%) patients had a scan at 90 days, performed at a mean of 96 ± 7
days after stroke onset (Table 4.1). Whether PWI was performed (some patients were
unable to complete PWI, or had unusable images due to movement artefacts), and the
number of patients with visible lesions on DWI, CBF, and MTT images for each
scan time can be found in Table 4.1. Six patients had non-sequential multiple
scanning: one patient had the baseline and 14 day scans only; two patients had the
baseline and 90 day scans only; one patient had the baseline, 5 day, and 90 day scans
only; one patient had the baseline, 30 day, and 90 day scans only; and one patient
had all but the 14 day scan.
Table 4.1 Mean (± SD) scan times, number of patients (n), whether PWI was performed,

















n % n % n % n %
14 ± 11 h 134 123 92% 111 83% 61 50% 66 54%
5 ± 1 d 60 58 97% 58 97% 32 55% 34 59%
12 ± 2 d 52 48 92% 45 87% 21 44% 25 52%
31 ± 3 d 43 42 98% 39 91% 24 57% 23 55%
96 ± 7 d 40 23 58% 28 70% 16 70% 13 57%
MRI characteristics ofthe regions of interest
All three patients with a final diagnosis of 'non-stroke' had a baseline scan only, on
which there were no visible lesions on DWI or PWI.
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Figure 4.2 Mean A) ADCr, B) CBFr, and C) MTTr values from baseline to 90 days after
stroke onset for all patients with any number of scans. See Table 4.2 for patient
numbers at each scan time. Values were obtained from the manually-outlined visible
abnormality as seen on DWI (for ADCr), CBF, and MTT images at each scan time. Error
bars represent ± 1 SD of the mean.
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Table 4.2 lists the number of patients with DWI and PWI data at each scanning time
point, mean (± SD) ADCr, CBFr, MTTr values, and lesion volumes for the visible
abnormality on each scan. Figure 4.2 shows graphs of ADCr, CBFr, and MTTr
values from baseline to 90 days after stroke onset.
Baseline ADCr in the lesion was significantly decreased compared to normal (ADCr
= 0.815 ± 0.162, n = 134, t-test p < 0.01), and increased significantly over time
(GLM regression p < 0.01; Figure 4.2). ADC appeared to reach a nadir at
approximately 5 days after stroke onset (ADCr = 0.799 ± 0.152, n = 60), and
appeared to 'pseudonormalise' by approximately 20 days after stroke onset (Table
4.2, Figure 4.2).
Baseline CBFr in the lesion was significantly decreased relative to normal (CBFr =
0.865 ± 0.194, n = 123, t-test p < 0.01), and changed significantly over time;
appearing to increase to a peak at approximately 14 days after stroke onset and
subsequently decrease (GLM regression p = 0.01; Table 4.2, Figure 4.2). Baseline
MTTr in the lesion was significantly prolonged relative to normal (MTTr = 1.170 ±
0.217, n = 123, t-test p < 0.01), and decreased significantly over time (GLM
regression p < 0.05), appearing to reach a nadir at approximately 14 days after stroke




This study represents one of the largest cohorts of ischaemic stroke patients with
serial DWI and PWI to date, with all acute and subsequent clinical and imaging
assessments and analyses performed blindly and independently of each other. Final
diagnosis was determined after patient discharge by a panel of experts using all
available clinical and imaging details - this represents the 'gold standard' for stroke
diagnosis, but is not often employed. Without this final diagnosis, there is a danger of
including patients with TIA and patients that have not had a stroke, which would
possibly underestimate or bias the assessment of the usefulness ofMRI in stroke, and
affect the diffusion and perfusion parameters extracted.
Diffusion andperfusion parameters
Previous studies have reported initial ADCr values of 0.53 - 0.81 sampling regions
manually drawn around the acute (< 24 hours after stroke onset) DWI
abnormality7 '7 '77' 7'178 ; the initial ADCr decrease found in this study is at the 'least-
decreased' end of this spectrum. However, these previous studies have been in
smaller numbers of patients (mean n = 43), and have mainly included only patients
with more severe strokes. Other studies report even more severely decreased baseline
ADC values (e.g. ADCr = 0.36 - 0.68)61'72'73,119. However these studies measured
ADC values only from a small region of interest placed in the centre of the visible
DWI abnormality. As discussed in Chapter 2, sampling ADC in a small region within
a lesion is problematic due to the heterogeneity of ADC values within lesions.
In this study, ADCr values were still decreased relative to normal at 14 days after
stroke onset, i.e. ADC values had not yet 'pseudonormalised'. As mentioned in
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Chapter 2, previous studies report 'pseudonormalisation' of ADC values within a
wide variety of times, from 18 hours - 85 days after stroke onset, with the majority
within 4-10 days after stroke onset, earlier than found in this study. Again, the small
patient numbers (typically n = 20 - 30) and inclusion of only more severe stroke
patients in previous studies, compared to the large number of patients and inclusion
of patients with all severities of stroke in this study, may explain the differences in
the evolution of ADC values reported. Furthermore, this study had serial scanning in
a large number of patients at specific time points - the values are not individual
'snapshots' of different patients at widely varying imaging times that were 'stitched'
together in an attempt to determine patterns of ADC change. This study also utilised
relative ADC values, with each patient acting as their own 'control', thus eliminating
the effects of any individual differences in ADC (e.g. differences in age-related ADC
changes which were not always accounted for in previous studies).
Few studies have reported the actual perfusion values in the acute visible PWI lesion
- most studies of acute PWI have investigated only how the acute PWI lesion
volume, or how the presence and degree of 'DWI/PWI mismatch', relates to the final
infarct volume. One study measuring acute CBFa and MTTa values within the visible
acute DWI lesion found both more severely prolonged MTT and lower CBF than in
the present study179. However, as acute PWI lesions are generally larger than the
acute DWI lesions, measuring CBF and MTT values from only the acute DWI lesion
will likely represent only the most severely affected tissue - in this study, CBF and
MTT values were extracted from the entire visible abnormality on CBF and MTT
images, thus likely incorporating regions of less severe deficit (i.e. 'oligaemic' tissue,
especially for MTT).
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Several studies have attempted to define a MTTr or CBFr 'threshold' that predicts
tissue infarction. Suggested MTTr (e.g. 1.28149 - 1.6315°) and CBFr (e.g. 0.59150 -
0.70144) thresholds indicate more prolonged MTT and decreased CBF than found in
this study, but again it is likely that the initial PWI lesion as measured in this study
includes oligaemic tissue that will not infarct. Furthermore, it is still unclear which
perfusion measure (e.g. 'index' vs. 'absolute') and parameter (e.g. CBF vs. MTT)
most closely identifies 'tissue at risk' of infarction145. Extracting baseline CBF and
MTT values from a region comprising of tissue that is part of the final (e.g. > 30 days
after stroke onset) infarct on T2WI would be more appropriate for development of a
baseline perfusion threshold. The relationship of baseline PWI parameters and the
'DWI/PWI mismatch' to final infarct extent will be explored further in Chapter 6.
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5. Factors affecting lesion
measurement on acute DWI
Introduction
This chapter assesses factors that affect lesion volume measurement on DWI by
examining the differences in measured lesion volumes between two observers, and
how the differences relate to lesion morphology and observer experience.
Factors affecting lesion measurement on acute DWI
Acute (< 24 hours after stroke onset) DWI lesion volume may predict clinical
outcome96"98, and patient management and clinical trial design are increasingly
influenced by information obtained from DWI6 ' °. However, factors influencing
DWI lesion measurement have not been widely assessed. Studies which simply
assessed observer reliability in detecting the presence and subjective extent (e.g.
whether the lesion occupied less than or greater than 1/3 of the MCA territory) of an
acute DWI lesion without objectively measuring lesion volume were not considered
directly relevant to factors influencing lesion volume measurement (Table
2.2)64'65'67'108. Problems with lesion measurement highlighted in Chapter 2 included
measurement of DWI lesion volumes at widely varying stages after ischaemic stroke
(e.g. from < 7 hours104 - 84 days99 after stroke onset), and small numbers of patients
(e.g. n = 12104 - 28100; Table 2.1). Some discrepancies between these studies could be
due to different methods used to measure ischaemic lesion volumes on DWI, or
possibly to inherent features of the lesions which might influence volume
measurement. For instance, during the hyperacute (< 6 hours after stroke onset)
stages of ischaemic stroke, the lesion on DWI is likely less hyperintense and the
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edges less well defined than at later times59, so acute lesion volume measurements
could be less reliable than these studies suggest. Also, previous studies have not
explored factors that might affect DWI lesion volume measurement.
Therefore we tested the effect of baseline (< 24 hours after stroke onset) DWI
ischaemic lesion appearance on the difference in baseline DWI lesion volume
obtained by two typical measurement approaches. To test if the use of an automated
ADC threshold (which would reduce observer differences as discussed in Chapter 2)
was feasible, we also applied two appropriate ADC thresholds in four exemplar
patients.
Methods
The first 83 patients recruited as part of the larger cohort of patients as described in
Chapter 4 were included in the present analysis.
Lesion measurement
In addition to the measurement method as described in Chapter 4 (method A,
neuroradiologist-guided manual outlining of the visible DWI abnormality), a second
method of lesion measurement was employed. This second method (method B) was
the same as method A, with the exception that the neuroscientist (the author), blind
to baseline clinical and outcome data, independently traced around the hyperintense
lesion on the baseline DWI without guidance from the neuroradiologist. Total lesion
volumes were obtained by summing the number of outlined voxels on each slice on
which the lesion was visible and multiplying by the slice thickness.
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Lesion morphology categorisation
Each lesion was scored by the neuroradiologist, blind to all clinical and other
imaging data, according to whether it appeared: a) solitary or multi-focal; and b) had




Figure 5.1 Examples of ischaemic lesions on DWI at < 24 hours after stroke onset
showing the four lesion appearance morphologies. Note the right and left images are
from different patients.
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We defined a 'solitary' lesion as a single, solitary hyperintense lesion on DWI, and a
'multi-focal' lesion as two or more separate hyperintense lesions on DWI of similar
age and within the same arterial territory. We defined a lesion as 'well-defined' if its
edges were clear and sharp, and 'ill-defined' if its edges were subtle, not easily
distinguished, with less signal intensity difference between the lesion and normal
brain.
Lesion measurement by ADC thresholding
To assess the effect of thresholding on an ADC value on lesion volume, we chose
four exemplar patients, one from each lesion category (single and well-defined,
single and ill-defined, multi-focal and well-defined, and multi-focal and ill-defined),
and applied two ADC thresholds commonly mentioned in previous studies and
thought to indicate thresholds for ischaemic but viable vs. non-viable brain (0.55 and
0 65 X 10"3 mm2/S)61'70'74'79'80'88> 117,120,123,132,178,181-185
Statistical analyses
General patient demographic data were obtained and compared as previously
described (Chapter 4).
The DWI lesion volumes measured by methods A and B were not normally-
distributed (Kolmogorov-Smirnov test p < 0.01), so the range and median lesion
volumes are reported, and median lesion volumes were compared using Wilcoxon
signed rank sum tests. We calculated the absolute difference of lesion volumes
between methods A and B.
To determine if the degree of difference between the two measurement methods was
related to the time from stroke onset to MRI, absolute lesion volume difference for
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MRI data from < 6 hours, 6-12 hours, and > 12 hours after stroke onset were
compared with a Kruskal-Wallis test.
To assess any association of degree of difference between the two measurement
methods with lesion appearance, absolute lesion volume difference between the
different lesion morphologies (solitary and well-defined, solitary and ill-defined,
multi-focal and well-defined, and multi-focal and ill-defined) were compared with a
Kruskal-Wallis test.
To assess any association of time from stroke onset to MRI and lesion clarity, time
from stroke onset to MRI (< 6 hours, 6-12 hours, or > 12 hours after stroke onset)
• i • • • • 2and lesion clarity (ill-defined or well-defined) were compared with a Chi-Square (x )
test.
To determine if lesion volume was associated with the degree of difference between
the two measurement methods, we plotted the difference (method B - method A) vs.
the mean of the lesion volume measurements between lesion measurement methods
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A and B (Bland Altman plots ). We also assessed whether larger lesions had a
greater degree of observer difference by comparing the absolute lesion volume
difference between the two measurement methods and whether the mean lesion
volume was < 5000 mm or not using a Mann-Whitney U-test.
In the four exemplar patients we used to test ADC thresholds, we compared the
lesion volumes obtained by applying the two ADC thresholds and the two manual




In total, 83 patients were recruited, but 20/83 (24%) patients had no visible lesion on
DWI so were excluded from the present analysis. Of the remaining 63 patients: 34/63
(54%) were male, the mean age was 73 years (range: 39 - 95 years), and the mean
NIHSS score on admission was 8 (median 6, range: 0 - 28). OCSP classifications:
10/63 (16%) patients had a TACI, 29/63 (46%) patients had a PACI, 20/63 (32%)
patients had a LACI, and 4/63 (6%) patients had a POCI. Mean mRS score at 90
days after stroke onset was 3 (median 2); 22/63 (35%) patients were dependent (mRS
= 3-5) and 8/63 (13%) patients were dead (mRS = 6).
Generalpatient scan characteristics
Mean (± SD) time from stroke onset was 15 ± 14 hours, with 21/63 (33%) patients
imaged within 6 hours, 12/63 (19%) patients between 6 and 12 hours, and 30/63
(48%) patients between 12 and 24 hours after stroke onset.
Lesion volume differences
The lesions as measured by method B (neuroscientist alone, median volume = 3498.1
mm3, range: 74.7 - 269731.9 mm3; Table 5.1) were significantly smaller than those
measured by method A (neuroradiologist-guided, median volume = 4293.5 mm ,
range: 96.7 - 334472.2 mm3, Wilcoxon test p < 0.01; Table 5.1). 51/63 (81%) of the
lesion volumes measured were smaller with method B compared to method A. The
median absolute volume difference between the two measurement methods was
1516.1 mm3 (range: 0 - 64740.2 mm3; Table 5.1).
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Differences in lesion volumes between the two measurement methods were
significantly associated with time from stroke onset to MRI (Kruskal-Wallis test p <
0.04): lesion volume differences were greatest for lesions from < 6 hours after stroke
onset (median difference = 4363.8 mm3), intermediate for lesions from 6-12 hours
after stroke onset (median difference = 1340.3 mm3), and smallest for lesions from >
12 hours after stroke onset (median difference = 670.2 mm3).
Influence of lesion morphology
Of the 63 patients in the present analysis, 18/63 (29%) patients had solitary and well-
defined lesions, 29/63 (46%) patients had solitary and ill-defined lesions, 2/63 (3%)
patients had multi-focal and well-defined lesions, and 14/63 (22%) had multi-focal
and ill-defined lesions (Table 5.1).
Absolute volume differences were significantly different between the different lesion
morphologies (Kruskal-Wallis test p < 0.01): the greatest degree of difference
between the two measurement methods was in multi-focal and ill-defined lesions
(median difference = 5466.8 mm ; Figure 5.2, Table 5.1), followed by solitary and
ill-defined lesions (median difference = 1520.5 mm ; Figure 5.2, Table 5.1),
followed by multi-focal and well-defined lesions (median difference = 395.5 mm3;
Figure 5.2, Table 5.1), and lastly, with the least degree of observer difference,
•3
solitary and well-defined lesions (median difference = 162.6 mm ; Figure 5.2, Table
5.1).
• • • • • 2Lesion clarity was significantly associated with time from stroke onset to MRI (x
test p < 0.01): lesions from < 6 hours after stroke onset were more likely to be ill-
defined (observed 20 vs. expected 14) and lesions from >12 hours after stroke onset
were more likely to be well-defined (observed 15 vs. expected 10).
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Figure 5.2 Median absolute difference in baseline DWI lesion volume (between lesion
measurement methods A and B) by lesion morphology.
Influence of lesion volume
Plots of the difference (method B - A) vs. the mean of the lesion volumes between
the two lesion measurement methods are shown in Figure 5.3 (mean ± SD difference
■J
#
= -5373.9 ± 13544.8 mm ). These plots suggests that larger lesions have greater
observer variability than smaller lesions; the difference between methods A and B is
nearly zero for lesions less than approximately 5000 mm in volume, but thereafter
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Lesion size was significantly related to the degree of lesion volume difference
between the two measurement methods (Mann-Whitney U-test p < 0.01): lesions
with a mean volume > 5000 mm3 had larger absolute differences between the two
lesion measurement methods (median difference = 7224.6 mm3) than lesions with a
"3 O
mean volume of < 5000 mm (median difference = 254.9 mm ).
The influence of lesion volume on the degree of lesion volume difference between
the two measurement methods may be confounded by the fact that more larger (>
•J "7
5000 mm ) lesions than smaller (< 5000 mm ) lesions were ill-defined (84% vs. 53%
respectively).
Lesion volume measurement by ADC thresholding
3 2
In the four exemplar cases, thresholding at an ADC of 0.55 x 10" mm /s tended to
identify a larger volume of tissue than that obtained by the two manual methods of
lesion measurement on DWI because of inclusion of tissue apparently normal on
DWI remote from the ischaemic region, but also failed to include parts of the actual
ischaemic lesion which appeared abnormal on DWI and ADC (Table 5.2, Figure
5.4).
Table 5.2 Volumes (mm3) of abnormal tissue found for each of the four lesion




















Well-defined Solitary 288738.3 260916.5 358715.0 395866.4
Well-defined Multi-focal 584.5 413.1 3053.3 14396.5
Ill-defined Solitary 76280.3 24903.8 47687.7 104319.1
Ill-defined Multi-focal 12484.9 6222.7 9703.1 39941.0
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An ADC threshold of 0.65 x 10" mm /s identified an even larger volume of normal
tissue remote from the infarct, both in the ipsilateral and contralateral hemispheres,
but still did not include all parts of the visible lesion on DWI and ADC (Figure 5.4).
In the four exemplar cases, lesion volumes obtained from the four lesion
measurement methods were significantly different (Friedman test p < 0.01): lesion
volumes were smallest using measurement method B (median volume = 15563.3
mm3; Table 5.2), followed by lesion volumes obtained using an ADC threshold of
0.55 x 10"3 mm2/s (median volume = 28965.4 mm3; Table 5.2), followed by lesion
volumes obtained using measurement method A (median volume = 44382.6 mm3;
Table 5.2), and lastly, measured lesion volumes were largest using an ADC threshold
of0.65x 10"3mm2/s (median volume = 72130.1 mm3; Table 5.2).
Discussion
The appearance of the acute ischaemic lesion on DWI strongly influences lesion
volume measurement. Our patients reflected a range of stroke severity, lesion sizes
and appearances typical of many acute stroke patients admitted to hospital and
imaged within 24 hours of stroke onset.
DWI lesions that were multi-focal or ill-defined produced the largest differences
between all the measurement methods. Hyperacute lesions (i.e. from < 6 hours after
stroke onset) were more likely to be ill-defined, and had a greater degree of observer
difference than lesions from > 6 hours after stroke onset. Lesion volume was also
important; lesions less than approximately 5000 mm3 in volume produced little
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difference between observers, but larger lesions produced substantial differences,
possibly because larger lesions tended to be ill-defined.
The less experienced neuroscientist underestimated lesion extent compared with the
neuroradiologist. Visual underestimation of DWI lesion extent by less experienced
observers was also found by Fiebach et al.65, who found higher agreement for
'experts' compared to 'novices' in detecting the presence and visually assessing the
extent of ischaemic lesions on DWI. Thus, not surprisingly, observer experience is
important and should be considered in the study design - despite this many studies
do not list observer details100'104.
Measurement variation for whatever reason may reduce the power of a study, and
necessitate an increase in the sample size187'188. Having one rater perform all lesion
volume measurements, as suggested by Coutts et al.12 , would eliminate
interobserver measurement variability, but may not account for differences due to
lesion characteristics, is expensive, and is difficult to implement routinely.
• • 119 123 178
ADC thresholds may identify infarcted tissue or 'tissue at risk' of infarction ' ' ,
but we found difficulties with the ADC thresholds because in the four exemplars
chosen, neither threshold identified the full extent of the DWI lesion and both
detected areas of apparently abnormal tissue quite remote from the infarct that
appeared normal on DWI and ADC images. Thus, at the very least, thresholding
would require an observer to choose the hemisphere of interest, possibly even the
general lesion location, and exclude any tissue erroneously included in the volume,
defeating the purpose of applying a threshold to eliminate observer error.
Furthermore, white matter ADC values increase with age130'131, so different
thresholds would be needed for patients of different ages, or indeed for patients of
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the same chronological ages who might have different levels of age-related
background white matter changes189. Multiparametric tissue characterisation
incorporating ADC values, T2WI, PWI, or other MRI data116"118 may avoid this
problem, but require further investigation.
DWI is being used increasingly in observational studies and as a 'surrogate outcome
predictor' to reduce sample size in clinical trials190. It is therefore important that
factors which influence lesion volume measurement on DWI are recognised and
quantified, and that methods are found to reduce variation. This particularly applies
to hyperacute stroke where early lesions are most likely to be ill-defined rather
sharply defined. Therefore, studies using DWI in acute stroke should account for the
potential factors influencing lesion measurement in sample size calculations, and
clearly define their measurement methods.
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6. Acute PWI parameters and final
infarct extent
Introduction
This chapter explores which baseline PWI parameter, if any, identifies 'tissue at risk'
of infarction, and whether the presence of an acute 'DWI/PWI mismatch' as
discussed in Chapter 2 is related to lesion growth.
PWI and 'tissue at risk' of infarction
In patients with acute ischaemic stroke, the 'mismatch' between the acute lesion on
9 1
DWI and PWI may represent the 'ischaemic penumbra' and may provide a target of
salvageable tissue both within, and possibly beyond, 6 hours after stroke onset24. In
several studies, the presence of an acute PWI lesion larger than the DWI lesion at
baseline predicted ischaemic lesion growth on final (> 30 days after stroke onset)
T2WI99'101,102'104'147'191. Some studies also examined ischaemic lesion growth at
earlier time points (<30 days after stroke onset), however the lesion may still be
evolving61, 'fogging' may cause underestimation93, and oedema may cause
overestimation77'101 of T2WI infarct extent at these earlier time points. Hence 30 days
after stroke onset is the minimum time at which final infarct extent should be
assessed.
As discussed in Chapter 1, there are several ways of obtaining perfusion information




'Summary' estimates of perfusion (e.g. TTP) are easily obtained, and may be a good
• 109 • • •
estimate of MTT , but cannot be compared between imaging episodes, and are
functions of at least two of the underlying perfusion parameters33. 'Index' measures
of CBF, CBV, and MTT (CBFj, CBVj, and MTTj) are superior to 'summary'
measures as they attempt to model only one of the underlying perfusion parameters,
but as discussed in Chapter 1 they are not 'quantitative'.
'Quantitative'perfusion measures
'Quantitative', or 'absolute', perfusion measures require deconvolution of the
concentration vs. time curve with an arterial input function . As discussed in
Chapter 1, although 'quantitative' perfusion parameters (CBFa, CBVa, and MTTa)
have the correct units, they are currently only approximate measures of the true
underlying haemodynamics and must be interpreted with caution.
Which perfusion parameter identifiesfinal infarct extent?
CBV is not considered a good predictor of 'tissue at risk' due to its bimodal nature
and insensitivity to bolus delay and dispersion37'150. Thus, parameters reflecting CBF
and MTT have emerged as the most likely candidates for predicting final infarct
extent.
Previous studies comparing acute (< 24 hours after stroke onset) PWI data with final
lesion extent on T2WI > 30 days after stroke (Table 6.1) produced rather confusing
results. Of the 13 papers found, 2/13 (15%) tested 'summary' measures of perfusion
(TTP, total n = 39)"'101, 2/13 (15%) tested MTT, (total n = 36)91'105, 6/13 (46%)
tested MTTa (total n = 146y38,i43,i44,i49,i93,i94; and 3/13 (23%) tested CBFa and MTTa
(total n = 53; Table 6.1)106'147'150. None directly compared CBFj and MTTj.
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TTP correlated strongly with final infarct volume99'101, MTTj91'105 and
MTTa138,143'144'149'193'194 overestimated final infarct volume, and in the three direct
comparisons of CBFa and MTTa106'147'150, twQ poun(j CBFa106'150 and one that
MTTa 147 related best to final infarct volume (Table 6.1). Some patients also received
thrombolysis and/or putative neuroprotective agents, with only 4/13 (31%) studies
only including patients treated conservatively105'144'147'150, and 2/13 (15%) studies
were restricted to patients with a 'DWI/PWI mismatch'147'150, possibly biasing any
relationship between baseline PWI and final infarct extent. The small sample sizes
(and possible inclusion of the same patients in separate publications), use of different
methods for measuring PWI lesions, probable use of inappropriate statistical tests
(parametric rather than non-parametric), few comparisons of CBF and MTT, and
total absence of data comparing CBF, and MTTj (more rapidly calculated in the acute
situation than CBFa and MTTa), mean that it is unclear which PWI lesion most
accurately delineates 'tissue at risk' of infarction.
We aimed to determine whether 'index' CBFj or MTTj on baseline (< 24 hours after
stroke onset) DSC PWI most closely identified the final (> 30 days after stroke
onset) infarct extent on T2WI. We also determined the relationship between
'DWI/PWI mismatch' and 'lesion growth', i.e. how best to identify 'tissue at risk' of
infarction in the acute phase of stroke.
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Patients (as described in Chapter 4) with MRI data at baseline and at > 30 days after
stroke onset were included in the present analysis.
Baseline PWI andDWI andfinal T2WI lesion volume analysis
A neuroradiologist (JMW), blind to all clinical and other imaging data, guided
tracing around the visible lesions on DWI, CBFj and MTTj maps as described in
Chapter 4. The neuroradiologist also traced around the final T2WI lesion on the later
of the 30 or 90 day scans, (using the same manual outline method as described in
Chapter 4). Total lesion volumes were obtained by summing the number of outlined
voxels on each slice on which the lesion was visible and multiplying by the slice
thickness.
Statistical analyses
General patient demographic data were obtained and compared as previously
described (Chapter 4).
The baseline DWI, CBFj, MTTj, and final T2WI volumes were not normally-
distributed (Kolmogorov-Smirnov test p < 0.01), so median lesion volumes were
compared using Wilcoxon signed rank sum tests, and correlations between baseline
DWI, CBFj, and MTTj volumes with final T2WI lesion volume were assessed with
Spearman's rank correlation coefficients (p). We also calculated mean (± SD)
volumes for comparison with previous studies which reported mean volumes, and
Pearson's product moment correlation coefficients (r, appropriate for normally-
distributed data) to compare baseline DWI, CBFj, and MTTj with final T2WI lesion
volume, to determine whether use of Pearson's r might account for some differences
between previous studies.
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'Lesion growth' was defined as final T2WI lesion volume > baseline DWI lesion
volume, and 'DWI/PWI mismatch' as baseline PWI lesion volume > baseline DWI
lesion volume. Chi-square (%2) tests were used to test whether the presence of a
DWI/CBFj or DWI/MTTj 'mismatch' was related to 'lesion growth'.
Results
Patient details
Forty-six patients were included in the present analysis: 28/46 (61%) were male, the
mean age was 72 years (range: 37 - 94 years), and the mean NIFISS score on
admission was 8 (median 8, range: 0 - 25). OCSP classifications: 12/46 (26%)
patients had a TACI, 29/46 (63%) patients had a PACI, 4/46 (9%) patients had a
LACI, and 1/46 (2%) patients had a POCI. Mean mRS score at 90 days after stroke
onset was 2 (median 2); 13/46 (28%) patients were dependent (mRS = 3-5) and
2/46 (4%) patients were dead (mRS = 6).
Generalpatient scan characteristics
Mean (± SD) time from stroke onset to baseline MRI was 10 ± 7 hours; 18/46 (39%)
patients were imaged within 6 hours, 11/46 (24%) patients between 6 and 12 hours,
and 17/46 (37%) patients between 12 and 24 hours after stroke onset. Final T2WI
was performed at 30 days after stroke onset (mean 32 ± 4 days) in 6/46 (13%)
patients, and at 90 days after stroke onset (mean 96 ± 7 days) in 40/46 (87%)
patients.
Ill
Baseline PWI and DWI andfinal T2WI lesion volumes
Baseline PWI lesion volumes
Baseline median CBFj and MTTj lesion volumes were 23737.1 mm3 and 50603.0
mm3 respectively (Table 6.2). Baseline CBFj volumes were significantly smaller than
baseline MTT; volumes (Wilcoxon test p < 0.01). There were 11/46 (24%) patients
with no visible lesion on baseline CBFj, and 10/46 (22%) patients with no visible
lesion on baseline MTTj; 6/46 (13%) of these patients had no visible lesion on either
baseline CBFj or MTTj.
Baseline DWI lesion volumes
All patients had a visible lesion on baseline DWI. The median baseline DWI lesion
volume was 13278.1 mm3 (Table 6.2). Baseline DWI lesion volumes were
significantly smaller than baseline CBFj (Wilcoxon test p = 0.01) and MTTj volumes
(Wilcoxon test p < 0.01); baseline CBFj and MTTj volumes were larger than baseline
DWI volumes in 25/46 (54%) and 33/46 (72%) patients respectively.
Final T2WI lesion volumes
The median final T2WI lesion volume was 18472.4 mm3 (Table 6.2). All patients had
a visible lesion on final T2WI corresponding with the lesion indicated on baseline
DWI.
Baseline PWI vs. final T2WI lesion volumes
Baseline CBFj lesion volumes were not significantly different to final T2WI volumes
(Wilcoxon test p = not significant [NS]; Table 6.2). Baseline MTTj volumes were
significantly larger than final T2WI volumes (Wilcoxon test p < 0.01; Table 6.2).
Baseline DWI lesion volumes were not significantly different from final T2WI lesion
volumes (Wilcoxon test p = NS; Table 6.2).
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Figure 6.1 Scatter plots of final T2WI volumes vs. baseline A) DWI, B) CBF, and C) MTT
lesion volumes, p = Spearman's rank correlation coefficient.
114
Correlation between baseline DWI, PWI, andfinal T2WI lesion
volumes
Final T2WI infarct volume most strongly correlated with baseline DWI lesion
volume (Spearman's p = 0.68, p < 0.01), followed by baseline CBFj lesion volume
(Spearman's p = 0.55, p < 0.01), and baseline MTTj lesion volume (Spearman's p =
0.49, p < 0.01; Figure 6.1, Table 6.2). Using Pearson's r (calculated to see whether
use of this less appropriate statistic in previous studies might explain some of the
differences in results), final T2WI lesion volume was most strongly correlated with
baseline MTTj lesion volume (Pearson's r = 0.66, p < 0.01), followed by baseline
DWI lesion volume (Pearson's r = 0.53, p < 0.01), and baseline CBFj lesion volume
(Pearson's r = 0.41, p < 0.01; Table 6.2).
'DWI/PWImismatch' and 'lesion growth'
There was no significant association between 'lesion growth' (final T2WI lesion
volume > baseline DWI lesion volume) and the presence or absence of a 'DWI/PWI
mismatch' (baseline CBFj or MTTj lesion volume > baseline DWI lesion volume)
(Table 6.3). On baseline CBFj, 15/25 (60%) patients with 'mismatch' had 'lesion
growth' and 10/25 (40%) patients did not; 11/21 (52%) without 'mismatch' had
'lesion growth' and 10/21 (48%) did not {fi test p = NS; Table 6.3). On baseline
MTTj, 21/33 (64%) with 'mismatch' had 'lesion growth' and 12/33 (36%) did not;
5/13 (38%) without 'mismatch' had 'lesion growth' and 8/13 (62%) did not (%2test p
= NS; Table 6.3). Thus 'DWI/PWI mismatch' was equally common amongst patients
whose lesions grew as amongst those whose lesions did not grow between baseline
DWI and final T2WI (Figure 6.2).
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Some previous studies found a stronger correlation between acute MTT and final
infarct volumes than we did (e.g. Spearman's p = 0.77 - o.90106'138'144'147), but these
studies measured volumes on MTTa images, were small (mean n = 21, Table 6.1),
tested some very restricted perfusion thresholds (e.g. highest 70% of MTT signal
intensities147), and employed various lesion measurement methods. Furthermore, it is
important to distinguish between 'correlation' and 'size equivalence' - a good
correlation between baseline MTT volume and final T2WI lesion volume is
compatible with MTT significantly overestimating final infarct volume. Previous
studies also support the conclusion that acute MTT (both MTT; and MTTa) lesions
overestimate final lesion extent91'105'106'138-143'144-147-149'193-194.
'DWI/PWI mismatch' and 'lesion growth'
We found no significant association between DWI/CBFj or DWI/MTTj 'mismatch'
and 'lesion growth' (Table 6.3) contrary to some previous studies99'106'138'143,144'147'150.
By including both patients with and without 'DWI/PWI mismatch' we were able to
demonstrate that 'lesion growth' was equally common between patients with and
without 'DWI/PWI mismatch'. Half of the patients without 'DWI/PWI mismatch'
had 'lesion growth', implying that patients without a 'DWI/PWI mismatch' might
benefit from acute stroke treatments and should not be denied this possibility by
being excluded from acute stroke treatment trials.
The presence of an acute 'DWI/PWI mismatch' is now being used as a selection
criterion for patient inclusion in trials of stroke treatments. Two recent studies used
the 'DWI/PWI mismatch' as an inclusion criterion in trials of thrombolysis195'196, one
of which reported a failure to show an association between the volume of 'DWI/PWI
mismatch' and lesion expansion195 (the other did not mention any association of
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'DWI/PWI mismatch' with lesion expansion). However, both studies found that
reperfusion was inversely associated with 'lesion growth'195'196. Many previous
studies have shown that reperfusion (whether spontaneous or pharmacologically
enhanced) is associated with better clinical outcome87'101'193,197"199 which has been
overlooked in the focus on 'DWI/PWI mismatch' during the last few years.
Should 'index' or 'absolute'perfusion parameters be used?
The superiority of 'absolute' over 'index' measures of perfusion is not yet proven.
'Absolute' measures are still only estimates of the 'true' underlying
haemodynamics37 and require considerably more complex image processing than
'index' measures, so are less appropriate to the acute stroke setting. Newer perfusion
measures including flow heterogeneity194 and bolus-delay corrected maps106 appear
promising in the small groups of patients studied so far (n = 19106 - 23194), but further
validation is required to determine their usefulness in the general population of
stroke patients.
Limitations and strengths
The strengths of this analysis include the large sample size (although still small
considering the heterogeneity of ischaemic stroke), inclusion of patients with and
without 'DWI/PWI mismatch', careful clinical characterisation, blinded image
analysis and outcome assessment, and careful use of statistics. A possible limitation
is our use of manual rather than 'threshold' lesion measurement methods. However,
the manual lesion measurement method is currently the most rapid method to apply
in the clinical setting. Thresholds might reduce observer variation but problems with
'threshold' lesion measurement (as discussed in Chapters 2 and 5) include: complex
and variable haemodynamics underlying ischaemic stroke; great overlap of baseline
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perfusion values between tissue that does and does not infarct147'149; and the time-
dependency of PWI parameter thresholds (i.e. a threshold for ischaemic but viable
brain at 3 hours after stroke onset may be very different to that at 6 hours after stroke
onset) - to date no studies have been large enough to assess these effects. None of
our patients received thrombolysis or any investigational neuroprotective drugs,
therefore this series represents a measure of the presence or absence of spontaneous
lesion expansion and could be used to estimate sample sizes for future acute stroke
treatment trials using acute DWI and PWI features to predict outcome.
In conclusion, acute DWI, CBFj, and MTTj lesion volumes all correlated well with
final T2WI lesion volume, but acute MTTj lesion volume significantly overestimated
final infarct volume. Of the two 'index' PWI measures, the acute CBFj lesion most
closely identifies the final T2WI lesion. There was no clear association between the
presence of a 'DWI/PWI mismatch' and lesion expansion - the commonly quoted
concept that the 'DWI/PWI mismatch' represents 'tissue at risk' of infarction may be
incorrect. About half of all patients without 'DWI/PWI mismatch' have 'lesion
growth' so may benefit from acute stroke treatments, and certainly should not be
excluded from clinical trials.
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7. Persistent hyperintensity on DWI
late after ischaemic stroke
Introduction
This chapter investigates ischaemic lesion regions that remain hyperintense on late (>
30 days after stroke onset) DWI, and whether these regions are merely the effect of
T2 'shine through' as discussed in Chapter 2, or if they indicate important underlying
differences in the pathophysiology of the ischaemic tissue.
Persistent hyperintensity on DWI late after ischaemic
stroke
Identifying effective treatments for acute ischaemic stroke requires improved
understanding of the mechanisms of development and evolution of the ischaemic
lesion. The extreme sensitivity ofDWI and PWI to early cerebral ischaemic changes
has focused attention on their use as early diagnostic tools to distinguish permanently
from transiently damaged brain, and as a surrogate marker for effectiveness of new
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treatments . However, the evolution of DWI and PWI lesion appearances at later
stages after stroke, and the relationship to underlying tissue state, has been less
intensively studied.
As discussed in Chapter 2, DWI appearance is influenced by the underlying ADC
values and the T2 relaxation time of the tissue. The ischaemic lesion becomes
hyperintense on DWI relative to normal tissue within minutes of injury in animal
models of ischaemic stroke57, and within hours of stroke onset in ischaemic stroke
patients66'69 (Figure 7.1). In the acute stages of ischaemic stroke, hyperintensity on
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Figure 7.1 DWI, ADC, and T2WI of a patient with a right hemisphere ischaemic lesion
from baseline to 31 days after stroke onset. Note the lesion on DWI is hyperintense
compared to normal tissue at 6 hours, and decreases to become isointense or
hypointense compared to normal tissue by 13 days after stroke onset.
In the subacute stages of ischaemic stroke, ADC gradually increases to
approximately normal values ('pseudonormalisation') at approximately 14 days after
70
stroke onset, after which it becomes increased relative to normal . Thereafter,
hyperintensity on DWI has been solely attributed to increases in the T2 relaxation
time of the tissue (T2 'shine through')79, thought to reflect increased tissue water
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content from vasogenic oedema61. The time taken for any hyperintensity on DWI
(whether due to ADC or T2 effects) to become isointense or hypointense relative to
normal tissue (Figure 7.1) is reported to occur within 15-72 days after stroke
onset ''71'74'76 . any persistent DWI hyperintensity at these late times has been
attributed to the T2 'shine through' effect58'74'79.
We observed that in some patients, parts of some infarcts remained hyperintense at >
30 days after stroke onset (Figure 7.2), whereas other parts did not, and in some
patients all hyperintensity had resolved by 30 days after stroke onset. If persistent
hyperintensity at late time points is a T2 'shine through' effect, why are only some
patients affected, and in these patients, why is only part of the infarct hyperintense on
DWI?
We hypothesized that regions of infarcts remaining hyperintense late after stroke
might have distinct underlying pathophysiology, such as different blood flow
patterns, than the infarcts (or parts of infarcts) not remaining hyperintense. Perhaps
these regions of late hyperintensity on DWI represent parts of lesions that either: a)
became abnormal later than the rest of the infarct but were still following the
'conventional' ischaemic pattern of evolution; b) were progressing through the
ischaemic cascade more slowly than the rest of the infarct and thus might represent
tissue that remained viable for a longer period; or c) or experienced some other sort
of delayed repair process.
We therefore examined the DWI and PWI of a large cohort of patients all imaged
from acute (< 24 hours) to late (> 30 days) stages after stroke onset to determine if
the patterns of DWI and PWI changes were indeed different in the infarct regions
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remaining hyperintense compared with those that had become isointense on DWI late
after stroke.
3 h 7 d 14 d 26 d
Figure 7.2 DWI, ADC, and T2WI of a patient with a right hemisphere ischaemic lesion
from baseline to 26 days after stroke onset. Note the lesion on DWI has a region of
persistent hyperintensity at 26 days after stroke onset, corresponding with a region of
hypointensity on the ADC image.
Methods
Patients (as described in Chapter 4) with MRI data at all four MR scanning time
points up to 30 days after stroke onset were included in the current analysis. The
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visibly abnormal acute lesion on the baseline DWI was manually outlined as
described in Chapter 4 (Figure 7.3).
A) B) C)
Figure 7.3 A) DWI of a patient with a right hemisphere ischaemic lesion at 26 days
after stroke onset, B) with lesion and homologous contralateral region outlined in
white, C) with 'still hyperintense' regions outlined in black.
Measurement of regions still hyperintense' on late DWI
The DWI scans from 30 days after stroke onset were assessed for 'still hyperintense'
regions, defined as areas of persistent hyperintensity compared to the rest of the
visible lesion, by a neuroradiologist (JMW) blind to clinical and other imaging
details. Patients with persistent hyperintensity on 30 day DWI were defined as 'still
hyperintense', and patients with isointense or hypointense lesions on 30 day DWI
were defined as 'isointense'. In patients with still hyperintense infarct regions at 30
days after stroke onset, there were also other areas of the original infarct that were
not still hyperintense (i.e. were isointense) - these isointense regions were referred to
as 'not still hyperintense'. Areas of persistent hyperintensity on 30 day DWI were
separately outlined using the same method as previously described for the acute DWI
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lesions (Figure 7.3). Baseline DWI infarct regions and regions appearing 'still
hyperintense' on 30 day DWI were applied to the coregistered scans from 5, 14, and
30 days after stroke onset. Patients with no persistent hyperintensity on 30 day DWI
had only baseline scan infarct regions applied to the coregistered scans from 5, 14,
and 30 days after stroke onset.
ADC, CBF, and MTT values for each scan time were extracted for all areas traced,
and relative values (ADCr, CBFr, and MTTr) were calculated as previously
described.
All lesions on subsequent scans were checked to ensure they were original lesions
and not the result of new ischaemic events.
Lesion composition analysis
A neuroradiologist (JMW), blind to all clinical and other imaging data, scored the
lesion on baseline DWI as comprising of grey matter, white matter, or both grey and
white matter. If present, the 'still hyperintense' region on the 30 day DWI was also
scored as comprising of grey matter, white matter, or both. The scans from 30 days
after stroke onset were reviewed blind to the baseline scans. Finally, the 30 day scans
were compared with the baseline scan to determine whether the hyperintensity on 30
day DWI had been within the original boundary of the ischaemic lesion at baseline,
or whether the hyperintensity at 30 days after stroke onset represented a subsequently
developing new area of infarction.
Statistical analyses
General patient demographic data were obtained and compared as previously
described (Chapter 4).
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Clinical details of 'isointense' and 'still hyperintense' patients were compared: age
and time from stroke onset to baseline and subsequent MRI with standard t-tests;
baseline NIHSS with a Mann-Whitney U-test; and sex, OCSP classifications, and
whether the patients were dead or dependent (mRS = 3 - 6) at 90 days after stroke
onset or not with Chi-Square (x2) tests.
Mean (± SD) ADCr, CBFr, and MTTr values are reported and compared. To test if
persistent hyperintensity reflected an initial difference or prolonged ADC
abnormality, standard t-tests (paired for comparing regions within 'still hyperintense'
patients, unpaired for the two region types in 'still hyperintense' patients vs.
'isointense' patients) were performed for ADCr values from baseline and 30 days
after stroke onset. CBFr and MTTr at baseline and 5 days after stroke onset, and peak
CBFr and nadir MTTr values and their timing200 were also compared with standard t-
tests (paired and unpaired as described above for ADCr values) to identify early
perfusion differences in tissue destined to be 'isointense' vs. 'still hyperintense'.
GLM repeated measures regression analysis was performed to compare changes in
ADCr, CBFr, and MTTr values over time (from baseline to 30 days after stroke
onset, dependent variables = ADCr, CBFr, and MTTr values; ADCr and MTTr fit to
a linear model, CBFr fit to a quadratic model): between patients with 'isointense'
infarcts at 30 days after stroke onset and patients with 'still hyperintense' infarcts,
both in areas that remained hyperintense and those that became isointense (between
subjects factor = 'isointense' vs. 'still hyperintense' and 'isointense' vs. 'not still
hyperintense'). As data from lesion areas that remained 'still hyperintense' and 'not
still hyperintense' in patients with remaining hyperintensity is paired data, the
difference in ADCr, CBFr, and MTTr between the two lesion areas was calculated
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and GLM repeated measures regression analysis was performed to analyse any
differences between the two areas over time (from baseline to 30 days after stroke
onset, dependent variables = difference in ADCr, CBFr, and MTTr values).
Results
Patient details
Forty-two patients with MRI data at all four scanning time points up to 30 days after
stroke onset were included in the present analysis: 23/42 (55%) were male, the mean
age was 71 years (range: 36 - 93 years), and the mean NIHSS score on admission
was 9 (median 8, range: 0 - 25). OCSP classifications: 13/42 (31%) patients had a
TACI, 25/42 (60%) patients had a PACI, 3/42 (7%) patients had a LACI, and 1/42
(2%) patients had a POCI. Mean mRS score at 90 days after stroke onset was 2
(median 2); 12/42 (29%) patients were dependent (mRS = 3-5) and 2/42 (5%)
patients were dead (mRS = 6).
Generalpatient scan characteristics
Mean (± SD) time from stroke onset to baseline MRI was 10 + 7 hours, with 16/42
(38%) patients imaged within 6 hours, 11/42 (26%) patients between 6 and 12 hours,
and 15/42 (37%) patients between 12 and 24 hours after stroke onset. The 5 day
scans were performed at a mean of 5 ± 1 days, the 14 day scans at a mean of 12 ± 2
days, and the 30 day scans at a mean of 31 ±3 days after stroke onset.
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MRI characteristics
Table 7.1 lists, and Figure 7.4 shows graphs of the mean (± SD) ADCr, CBFr, and
MTTr values for each infarct region from baseline to 30 days after stroke onset.
'Still hyperintense' vs. 'isointense'patients
On 30 day DWI, 27/42 (64%) patients had 'still hyperintense' infarct regions. All
regions remaining hyperintense on 30 day DWI were within the baseline lesion (i.e.
were not the result of a subsequent ischaemic event).
Patient details
Sex and age did not significantly differ between 'isointense' and 'still hyperintense'
patients. Clinically, 'still hyperintense' patients had a higher NIHSS score on
admission (mean 10 vs. 6, median 9 vs. 4, Mann-Whitney U-test p < 0.01) and were
more likely to be dead or dependent (mRS = 3 - 6, x2 test p < 0.05) compared to
'isointense' patients. It appeared that 'still hyperintense' patients were more likely to
have had a TACI than 'isointense' patients (41% vs. 13% respectively), but this was
• • 2
not statistically significant (% test p = NS).
Generalpatient scan characteristics
'Still hyperintense' patients had their initial MRI scan later after stroke onset than
'isointense' patients (mean 12 hours vs. 7 hours after stroke onset, t-test p < 0.03).
However, there were no significant differences in the times from stroke onset to
subsequent MRI scans between 'still hyperintense' and 'isointense' patients (t-tests
all p = NS).
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Figure 7.4 Mean A) ADCr, B) CBFr, and C) MTTr values for all patients studied. See
Table 7.1 for patient numbers at each scan time. SH = tissue remaining 'still
hyperintense' and NSH = rest of the baseline DWI lesion in 'still hyperintense'
patients; ISO = tissue from the baseline DWI lesion in 'isointense' patients, followed
through subsequent coregistered scans. Error bars represent ± 1 SD of the mean.
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ADCr at baseline and 30 days after stroke onset
ADCr at baseline was significantly lower in 'still hyperintense' (ADCr = 0.760 ±
0.122) and 'not still hyperintense' (ADCr = 0.734 ± 0.110) regions in 'still
hyperintense' patients compared to the infarct region in 'isointense' patients (ADCr
= 0.850 ± 0.123, t-tests p < 0.05 and p < 0.01 respectively; Table 7.1) suggesting
more pronounced ischaemic damage in lesions that would be 'still hyperintense' at
30 days after stroke onset. ADCr values at 30 days after stroke onset were
significantly lower in 'still hyperintense' regions (ADCr = 1.012 ± 0.206) compared
with both 'not still hyperintense' regions in 'still hyperintense' patients (ADCr =
1.289 ± 0.229, paired t-test p < 0.01) and the infarct region in 'isointense' patients
(ADCr = 1.209 ± 0.157, t-test p < 0.01; Table 7.1).
ADCr evolution
'Still hyperintense' lesion areas had a lower baseline ADCr which remained lower
over time compared to lesion areas in 'isointense' patients (GLM regression p <
0.01; Figure 7.4). Within patients with 'still hyperintense' lesion areas, ADCr in
areas 'not still hyperintense' increased more rapidly than in 'still hyperintense' tissue
from 14 days after stroke onset onwards, reaching higher values by 30 days after
stroke onset (GLM regression p < 0.01; Figure 7.4).
CBFr andMTTr at baseline and 5 days after stroke onset
There was no difference in CBFr or MTTr at baseline between the three groups (t-
tests all p = NS). Although the CBFr appeared to be higher in 'isointense' lesions
(CBFr = 1.231 ± 0.252) compared with 'still hyperintense' lesions (CBFr = 1.130 ±
0.575) at 5 days after stroke onset, the difference was not statistically significant (t-
test p = NS; Table 7.1, Figure 7.4). MTT at 5 days after stroke onset was
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significantly prolonged relative to normal in the 'still hyperintense' regions (MTTr =
1.251 ± 0.470) compared with 'isointense' patients (MTTr = 1.035 ± 0.074, t-test p <
0.05; Table 7.1, Figure 7.4).
Peak CBFr and nadir MTTr values and their timing
Also, although the peak CBFr and the nadir of the MTTr appeared to occur earlier in
'isointense' than in 'still hyperintense' tissue (mean 6 days vs. 8 days after stroke
onset) the difference was not statistically significant. The peak CBFr ('still
hyperintense' CBFr = 1.285 ± 0.481 vs. 'isointense' CBFr = 1.319 ± 0.205) and
nadir MTTr ('still hyperintense' MTTr = 0.992 ± 0.166 vs. 'isointense' MTTr =
0.991 ± 0.054) values were also not significantly different between 'still
hyperintense' and 'isointense' tissue (t-tests all p = NS).
CBFr andMTTr evolution
The evolution of CBFr from baseline to 30 days after stroke onset differed only
between 'still hyperintense' and 'not still hyperintense' lesion areas, where the
difference in CBF between the two decreased over time (GLM regression p < 0.05;
Figure 7.4). There was no statistically significant difference in the pattern of change
in CBFr over time between 'isointense' and 'still hyperintense' tissue (GLM
regression p = NS), despite the CBF in 'isointense' tissue appearing to increase to a
higher peak level more quickly within the first 5 days after stroke onset compared to
'still hyperintense' tissue.
Apart from the difference at 5 days after stroke onset mentioned above, there was no
significant difference in the pattern of change on MTTr between the three tissue
types (GLM regression all p = NS; Figure 7.4).
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Lesion composition
Table 7.2 lists the lesion compositions of the different lesion regions. Lesions on the
baseline DWI scan were comprised of grey matter in 4/42 (10%) patients, white
matter in 5/42 (12%) patients, and both grey and white matter in 33/42 (79%)
patients (Table 7.2). Grey matter lesions were all in 'isointense' patients (4/4, 100%),
whereas most of the white matter lesions were in 'still hyperintense' patients (4/5,
80%; Table 7.2). Of lesions comprised of both grey and white matter, 23/33 (70%)
were in 'still hyperintense' patients (Table 7.2). In 'still hyperintense' patients, the
regions of hyperintensity on 30 day DWI were almost exclusively in white matter
(25/27, 92%); only 1/27 (4%) were composed of grey matter, and 1/27 (4%) of both
grey and white matter (Table 7.2).
Table 7.2 Lesion composition of the baseline DWI lesion and lesion regions 'still
hyperintense' on DWI at > 30 days after stroke onset (SH region). Values for
'isointense' patients (ISO), 'still hyperintense' patients (SH), and all patients are
reported.
Tissue composition
Scan time Patient/lesion type Grey matter White matter Both
n % n % n %
Baseline ISO n = 15 4 27% 1 7% 10 67%
Baseline SH n = 27 0 0% 4 15% 23 85%
Baseline all patients n = 42 4 10% 5 12% 33 79%
> 30 d SH region n = 27 1 4% 25 92% 1 4%
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Discussion
Persistent hyperintensity on DWI at 30 days after stroke onset has been attributed to
T2 'shine through', but we have found that 'still hyperintense' areas on DWI have
significantly different ADCr values than isointense areas, and are therefore not
simply caused by T2 'shine through'. This, combined with the different pattern of
perfusion changes observed in 'still hyperintense' areas on late DWI compared with
the rest of the infarct, and with infarcts with no areas of persistent hyperintensity,
suggest important differences in lesion evolution. 'Still hyperintense' patients were
also different in that they had more severe strokes and worse functional outcome at
90 days after stroke onset than 'isointense' patients.
What do these differences in infarct evolution mean? Significantly lower baseline
ADCr values in the 'still hyperintense' patients suggest that the tissue was initially
more abnormal than in 'isointense' patients. ADCr values recovered less quickly in
areas of persistent hyperintensity, perhaps indicating prolonged intracellular oedema
or other slower repair processes following the ischaemic insult. Perfusion also
recovered more slowly in 'still hyperintense' tissue - MTTr remained prolonged for
longer and, although only reaching significance between areas remaining and not
remaining hyperintense in patients with 'still hyperintense' lesions, CBFr appeared to
recover more slowly. Thus 'still hyperintense' tissue has a slower pattern of recovery
of ADC and perfusion parameters. Perhaps 'still hyperintense' tissue experiences a
poor reflow phenomenon, or some other factor (e.g. delayed lysis of the thrombus in
the major artery supplying the affected area) that contributes to slower recovery of
blood flow, possibly prolonging ischaemia and lesion evolution.
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We found previously that ADC values evolved differently in grey and white matter
from baseline to 14 days after stroke onset133. In the current study, the hyperintense
regions on 30 day DWI were almost exclusively located in white matter, further
supporting evidence for differential evolution of ischaemic damage between grey and
white matter.
Several other studies suggest that persistent DWI hyperintensity occurs in patients
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with specific types and localities of lesions. Geijer et al. suggest that small cortical
and lacunar infarcts may remain hyperintense on DWI for longer periods (e.g. 54 -
144 days after stroke onset) than larger infarcts. Schulz et al.202 found that late (mean
of 21 days after stroke onset) DWI hyperintensity was correlated with higher age and
acute NIHSS in a group of patients with mild strokes. Both these studies merely drew
attention to the existence of late DWI hyperintensity but did not determine the
pattern of early infarct evolution.
The possible limitations of the present study include the subjective method of
deciding which tissue was 'still hyperintense' on 30 day DWI; a judgement made by
visually examining the relative signal hyperintensity of the DWI lesion - if areas
clearly stood out from the background by being hyperintense relative to the rest of
the infarct or to normal brain, then they were classed as 'still hyperintense'. We did
not use a threshold of DWI signal intensity or ADC value specifically to avoid the
problem of masking any important tissue differences which might have occurred by
imposing a fixed arbitrary parameter value as discussed in Chapters 2 and 5. We used
'index' perfusion parameters which may have masked some subtle between patient
differences, however, we calculated and compared relative parameters to limit the
impact of any differences between patients and scan times. Although this study is
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large compared to other serial studies of DWI and PWI parameters in ischaemic
stroke patients, the number of 'isointense' (n = 15) and 'still hyperintense' (n = 27)
patients are small. The standard deviations of PWI data are very wide with the
current methods of obtaining perfusion information, meaning important differences
between patient groups may be missed. There are also several serious statistical
issues that impose limitations on the analysis of serial DWI and PWI data. The
commonly used conventional statistical models for analysis of repeated measures
data, such as GLM regression analysis, require fitting to a linear (or cubic or
quadratic) model. However, the complex and variable nature of changes in DWI and
PWI parameters after ischaemic stroke make it unclear which fit model is most
appropriate. The use of'summary measures' of serial data200, such as peak CBFr and
nadir MTTr values and their timing as used in this analysis, may eliminate some of
the problems related to analysis of repeated measures data, such as complex changes
over time that do not fit any existing statistical model and missing data. However, we
did not find any significant differences in the 'summary measures' we calculated and
compared between lesion types, possibly because of small patient numbers.
Matthews et al.200 also suggest the calculation and comparison of the 'area under the
curve' for non-linear (e.g. peaked) repeated measures data, however we did not use
this analysis here as the patient groups were small. We do calculate and compare
'area under the curve' data in Chapter 10 with a larger patient group. With use of a
larger sample size, improvements in PWI, and development of more appropriate
statistical models for serial data the differences in DWI and PWI evolution seen in
this analysis would likely be significant.
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If persistent DWI hyperintensity indicates slower evolution of ischaemic tissue, then
the opportunity might exist to intervene in some way, even late after stroke. Reasons
for delayed reperfusion, or the 'poor reflow' phenomenon, are not well understood;
perhaps the areas have different inflammatory responses, so treatments such as anti¬
inflammatory agents or some other method of gentle encouragement of better blood
flow (e.g. careful systemic blood pressure regulation) might influence tissue repair at
subacute stages after stroke onset.
In summary, tissue remaining hyperintense on late DWI should not just be dismissed
as areas of T2 'shine through'. Further study is required to determine what these 'still
hyperintense' lesion areas mean in terms of clinical recovery, and whether any later
intervention could improve outcome.
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8. Grid-based analysis of ischaemic
stroke lesions on baseline DWI
Introduction
This chapter consists of the development of a novel grid-based method to investigate
regions of heterogeneity of DWI and PWI parameters within ischaemic lesions. A
manual grid-based analysis method is developed and tested in a small group of
patients to determine if different degrees of abnormality on baseline DWI indicate
different degrees of underlying tissue damage.
Examining lesion heterogeneity with grid-based
analysis methods
There is increasing evidence that ischaemic lesions are heterogeneous, with regions
of varying appearance on DWI and underlying ADC and perfusion
abnormalities68'78'113'119'120. However, what these regional differences mean in terms
of underlying tissue pathophysiology and viability has not been widely assessed. The
most commonly used methods of lesion measurement such as manual tracing or the
use of a single parameter 'threshold' as discussed in Chapter 2 do not take account of
these underlying subregions of varying abnormality.
To be able to more easily track and analyse the evolution of DWI and PWI
parameters in subregions of ischaemic lesions, we developed and tested a grid-based
analysis approach. Grid-based analysis allows for classification tissue according to
differences in appearance on DWI. We implemented a manual grid-based analysis
method in a series of patients to assess if differences in lesion appearance on baseline
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DWI indicated differences in the underlying tissue abnormality as determined by
ADC values, and how this related to any differences in PWI parameters.
Manual grid analysis
Methods
Eight patients with a representative range of ischaemic lesion appearance on baseline
DWI were selected from the larger patient cohort (as described in Chapter 4) for
initial development of the grid-based analysis method: 5/8 (62.5%) patients had
'solitary' DWI lesions, 3/8 (37.5%) patients had 'multi-focal' DWI lesions; 2/8
(25%) patients had 'well-defined' DWI lesions, and 6/8 (75%) patients had 'ill-
defined' DWI lesions as described in Chapter 5.
For each patient, the axial slice that passed through the centre of the visible
ischaemic lesion on baseline DWI was chosen for analysis. A 5 x 5 voxel grid (voxel
= 4.39 mm , grid box = 109.86 mm ) was applied over the chosen DWI slice in
Analyze™ (Figure 8.1). A 10 x 10 voxel grid (grid box = 439.45 mm3) was also
tested in the development of the manual grid-based analysis, however the 10 x 10
voxel grid was too large to allow for sufficient discrimination between areas of
different degrees of abnormality on DWI so the smaller 5x5 voxel grid was used.
Image brightness and contrast were adjusted for maximum distinction between
hyperintense tissue and normal appearing brain.
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Figure 8.1 Manual grid analysis example image (Patient A, left hemisphere ischaemic
lesion on DWI at 4 hours after stroke onset). Each grid box is 4.69 x 4.69 mm.
The images were printed out onto paper, and a neuroradiologist (JMW), blind to
clinical and other imaging details, scored each grid box according to the appearance
of the tissue inside the grid box on baseline DWI (Figure 8.1). A grid box was
excluded from analysis if > 25% of the box was comprised of 'background' (outside
of brain) or CSF to avoid skewing results with partial volume effects.
Tissue classification
Grid boxes were scored as follows: 'definitely abnormal', if the whole grid box
contained clearly hyperintense tissue; 'possibly abnormal', if > 50% of the box
appeared hyperintense relative to normal tissue, or if the hyperintensity was only
subtle; 'ipsilateral normal', if the tissue in the grid box appeared normal and was in
the hemisphere ipsilateral to the ischaemic lesion; or 'contralateral normal' if the
tissue in the grid box appeared normal and was in the hemisphere contralateral to the
ischaemic lesion (Figure 8.2).
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Figure 8.2 Examples of the tissue classifications scored according to baseline DWI
appearance as used in the grid-based analysis method (Patient A, left hemisphere
ischaemic lesion on DWI at 4 hours after stroke onset).
The grid box classifications from the baseline scan were applied to the subsequent
coregistered scans from 5, 14, and 30 days after stroke onset. DWI SI, ADC, CBF,
and MTT values for each grid box and mean values for each tissue classification at
each scan time were extracted. Relative values (DWIr, ADCr, CBFr, and MTTr)
were calculated and compared by dividing the 'definitely abnormal', 'possibly
abnormal', and 'ipsilateral normal' values by the 'contralateral normal' values.
Statistical analyses
General patient demographic data were obtained and compared as previously
described (Chapter 4).
Mean (± SD) DWIr, ADCr, CBFr, and MTTr values are reported and compared.
Baseline DWIr, ADCr, CBFr, and MTTr values for 'definitely abnormal', 'possibly
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abnormal', and 'ipsilateral normal' tissue were compared to normal (test value = 1,
as they are relative values) using standard t-tests. Baseline ADCr, CBFr, and MTTr
in 'definitely abnormal' and 'possibly abnormal' tissues were compared using
standard paired t-tests to determine if differences in baseline DWI appearance were
indicative of the degree of underlying baseline ADC, CBF, and MTT abnormality.
ADCr at 30 days after stroke onset in 'definitely abnormal' and 'possibly abnormal'
tissues were also compared using standard paired t-tests to determine if differences in
baseline DWI appearance were indicative of the degree of underlying damage as
suggested by ADC abnormality at outcome. Changes in ADCr, CBFr, and MTTr
values over time (from baseline to 30 days after stroke onset) were analysed using
GLM repeated measures regression analysis (dependent variables = ADCr, CBFr,




Eight patients were included in the present analysis: 7/8 (88%) were male, the mean
age was 66 years (range 39 - 80 years), and the mean NIHSS score on admission was
10 (median 8, range: 4 - 25). OCSP classifications: 3/8 (38.5%) patients had a TACI,
and 5/8 (62.5%) patients had a PACI. Mean mRS score at 90 days after stroke onset
was 3 (median 2); 2/8 (25%) patients were dependent (mRS = 3-5) and 1/8 (12.5%)
patients were dead (mRS = 6). Individual patient details are listed in Table 8.1.
145
Table 8.1 Demographics, clinical details, and MR scan times for the patients analysed









Time from onset to MRI
1 (h) 2(d) 3(d) 4(d)
A M 78 4 PACI 2 4 4 9 31
B M 80 7 PACI 1 14 7 13 33
C M 39 8 TACI 0 5 4 11 27
D M 78 8 PACI 6 3 6 13 30
E M 70 25 TACI 5 4 7 13 30
F F 52 20 TACI 5 5 6 13 31
G M 67 5 PACI 0 7 6 13 27
H M 68 6 PACI 1 5 6 10
Mean 66 10 3 6 h 6 d 12 d 30 d
Median 8 2
Generalpatient scan characteristics
Mean (± SD) time from stroke onset to baseline imaging was 6 ± 4 hours, with 6/8
(75%) patients imaged within 6 hours, 1/8 (12.5%) patients between 6 and 12 hours,
and 1/8 (12.5%) patients between 12 and 24 hours after stroke onset. The 5 day scans
were performed at a mean of 6 ± 1 days, the 14 day scans at a mean of 12 ± 2 days,
and the 30 day scans at a mean of 30 ± 2 days after stroke onset (Table 8.2).
Individual patient scan times are listed in Table 8.1. Note one patient (Patient H) did
not have imaging at 30 days after stroke onset.
MRI characteristics
Table 8.2 lists and Figure 8.3 shows graphs of the mean (± SD) DWIr, ADCr, CBFr,
and MTTr values for each tissue classification (scored according to baseline DWI
appearance and applied to subsequent scans) from baseline to 30 days after stroke
onset.
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Table 8.2 Mean (± SD) scan times and DWIr, ADCr, CBFr, and MTTr values for the three
tissue classifications at each scan time for the patients analysed with the manual grid-
based analysis methods (n = 8). Tissue classifications were scored according to




DWIr ADCr CBFr MTTr
6 ± 4 h
Definitely
abnormal
1.634 ±0.171 0.712 ±0.151 0.765 ± 0.484 1.429 ±0.365
Possibly
abnormal
1.277 ±0.137 0.817 ±0.098 0.870 ± 0.442 1.290 ±0.214
Ipsilateral
normal




2.070 ±0.635 0.668 ±0.183 1.324 ±0.310 0.992 ±0.091
Possibly
abnormal
1.611 ± 0.453 0.748 ±0.145 1.194 ±0.256 1.009 ±0.072
Ipsilateral
normal
1.073 ±0.120 0.972 ±0.055 1.065 ±0.105 1.047 ±0.084
12 ± 2 d
Definitely
abnormal
1.415 ±0.491 0.912 ± 0.255 1.359 ± 0.429 1.104 ± 0.177
Possibly
abnormal
1.235 ±0.256 0.879 ±0.129 1.117 ± 0.298 1.118 ± 0.128
Ipsilateral
normal




1.208 ±0.124 1.124 ± 0.198 0.776 ± 0.220 1.158 ±0.209
Possibly
abnormal
1.150 ± 0.133 1.009 ±0.088 0.795 ±0.132 1.114 ± 0.094
Ipsilateral
normal
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Figure 8.3 Mean A) DWIr, B) ADCr, C) CBFr, and D) MTTr for the patients analysed with
the manual grid-based analysis method (n = 8). Tissue classifications were scored
according to baseline DWI appearance, which were applied to subsequent
coregistered scans. Error bars represent ± 1 SD of the mean.
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Tissue classified as 'possibly abnormal' and 'definitely abnormal' had significantly
increased baseline DWIr compared to normal ('possibly abnormal' DWIr = 1.634 ±
0.171, 'definitely abnormal' DWIr = 1.277 ± 0.137, t-tests both p < 0.01; Table 8.2);
'definitely abnormal' tissue had significantly higher DWI SI at baseline than
'possibly abnormal' tissue (paired t-test p < 0.01). The DWIr in both 'definitely
abnormal' and 'possibly abnormal' tissue changed significantly over time (GLM
regression both p < 0.01), with a peak at approximately 5 days after stroke onset,
after which it declined to approximately normal at 30 days after stroke onset (Figure
8.3). There were no significant differences in DWIr at baseline or over time in tissue
classified as 'ipsilateral normal' (t-tests p = NS, GLM regression p = NS; Figure
8.3).
In terms of underlying ADCr values, both 'possibly abnormal' and 'definitely
abnormal' tissue had significantly decreased ADC relative to normal at baseline
('possibly abnormal' ADCr = 0.712 ± 0.151, 'definitely abnormal' ADCr = 0.817 ±
0.098, t-tests both p < 0.01; Table 8.2); 'definitely abnormal' tissue had a
significantly lower ADC than 'possibly abnormal' tissue (t-test p = 0.03). The ADC
in both 'definitely abnormal' and 'possibly abnormal' tissue increased significantly
over time (GLM regression both p < 0.01), appearing to reach a nadir at
approximately 5 days after stroke onset, after which it 'pseudonormalised', and
became slightly increased relative to normal at approximately 30 days after stroke
onset (Figure 8.3). There were no significant differences in ADCr in 'ipsilateral
normal' tissue at baseline or over time (t-test p = NS, GLM regression p = NS;
Figure 8.3). There was no significant difference in ADC at 30 days after stroke onset
between 'definitely abnormal' and 'possibly abnormal' tissue (paired t-test = NS).
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Baseline CBF was significantly decreased relative to normal only in 'definitely
abnormal' tissue (CBFr = 0.765 ± 0.484, t-test p < 0.01; Table 8.2); baseline CBF in
'definitely abnormal' tissue was significantly lower than in 'possibly abnormal'
tissue (paired t-test p < 0.05). CBF in 'definitely abnormal' tissue also changed
significantly over time (GLM regression p = 0.01), appearing to increase from an
initially decreased relative to normal value between approximately 5-14 days after
stroke onset, and subsequently appeared to decrease to a below-normal level by 30
days after stroke onset (Figure 8.3). There were no significant changes in CBF over
time in 'possibly abnormal' or 'ipsilateral normal' tissue (GLM regression both p =
NS), although CBF in 'possibly abnormal' tissue appeared to follow a similar pattern
to CBF in 'definitely abnormal' tissue, i.e. increase from an initially decreased
relative to normal value between approximately 5-14 days after stroke onset, and
subsequently appeared to decrease to a below-normal level by 30 days after stroke
onset (Figure 8.3).
Baseline MTT was significantly prolonged relative to normal in 'definitely
abnormal' (MTTr = 1.429 ± 0.365, t-test p = 0.01), 'possibly abnormal' (MTTr =
1.290 ± 0.214, t-test p < 0.01), and 'ipsilateral normal' (MTTr = 1.139 ± 0.142, t-test
p = 0.03) tissues (Table 8.2). There was no significant difference between the
baseline MTT in 'definitely abnormal' and 'possibly abnormal' tissue (paired t-test p
= NS). Although MTT appeared to decrease over time in all tissue classifications,
reaching a nadir at approximately 5 days after stroke onset, these trends were not
statistically significant (GLM regression all p = NS; Figure 8.3).
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Differences in the evolution of 'possibly abnormal'
tissue
When the individual patient data were examined, two patterns of DWIr and ADCr
evolution in 'possibly abnormal' tissue emerged. In 4/8 (50%) patients (Patients C, F,
G & H), the 'possibly abnormal' tissue appeared to be initially similar, and follow a
similar evolution to, 'ipsilateral normal' tissue; in the other 4/8 (50%) patients
(Patients A, B, D & E), the 'possibly abnormal' tissue appeared to be initially
similar, and follow a similar evolution to, 'definitely abnormal' tissue in terms of
DWIr and ADCr values (Figure 8.4).
Methods
Patients were grouped into 'possibly abnormal' like 'normal' tissue (Group 1) and
'possibly abnormal' like 'definitely abnormal' tissue (Group 2).
Statistical analyses
Clinical details of Group 1 and Group 2 patients were compared: age and time from
stroke onset to baseline and subsequent MRI with standard t-tests; baseline NIHSS
with a Mann-Whitney U-test; and sex, OCSP classifications, and whether the patients
were dead or dependent (mRS = 3 - 6) at 90 days after stroke onset or not with Chi-
Square (% ) tests.
Mean (± SD) DWIr, ADCr, CBFr, and MTTr values are reported and compared.
Baseline DWIr, ADCr, CBFr, and MTTr values between Group 1 and Group 2 were
compared with standard t-tests. GLM repeated measures regression analysis was
performed to compare changes in DWIr, ADCr, CBFr, and MTTr values over time
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Figure 8.4 Individual mean A) DWIr and B) ADCr values from baseline to 30 days after
stroke onset for the patients analysed with the manual grid-based analysis method (n
= 8). Note that the 'possibly abnormal' values in the patients in Group 1 (left) appear to
follow 'normal' tissue patterns, while in Group 2 (right) they follow 'definitely
abnormal' tissue patterns. Tissue classifications were scored according to baseline
DWI appearance, which were applied to subsequent coregistered scans. Error bars
represent ± 1 SD of the mean.
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(dependent variables = DWIr, ADCr, CBFr, and MTTr values; between subjects




There were no significant differences in the sex, baseline NIHSS, OCSP
classifications, or likelihood of being dead or dependent at 90 days after stroke onset
between the patients in Groups 1 and 2. However, the patients in Group 2 ('possibly
abnormal' like 'definitely abnormal' tissue) were significantly older than the patients
in Group 1 ('possibly abnormal' like 'normal' tissue); mean age 76 years vs. 57
years, t-test p < 0.05).
Generalpatient scan characteristics
There were no significant differences in time from stroke onset to baseline or any
subsequent MRI between the patients in Groups 1 and 2 (t-tests all p = NS).
MRJ characteristics ofGroup 1 vs. Group 2
Table 8.3 lists and Figure 8.5 shows graphs of the mean (± SD) DWIr, ADCr, CBFr,
and MTTr values for each tissue classification (scored according to baseline DWI
appearance and applied to subsequent scans) for Group 1 and Group 2 from baseline
to 30 days after stroke onset.
DWI SI in 'possibly abnormal' tissue was initially significantly more increased
relative to normal in Group 2 compared to Group 1 (Group 2 DWIr = 1.383 ± 0.064
vs. Group 1 DWIr = 1.171 ± 0.098, t-test p = 0.01; Table 8.3), and remained more
increased relative to normal over time (GLM regression p = 0.02; Figure 8.5).
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Figure 8.5 Mean A) DWIr, B) ADCr, C) CBFr, and D) MTTr for Group 1 ('possibly
abnormal' like 'normal' tissue, n = 4) and Group 2 ('possibly abnormal' like 'definitely
abnormal' tissue, n = 4) patients. Error bars represent ± 1 SD of the mean.
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Although not significantly different at baseline (t-test p = NS), the DWI SI in
'definitely abnormal' tissue was more increased relative to normal in Group 2
compared with Group 1 over time (GLM regression p = 0.04; Figure 8.5).
Baseline ADC in 'possibly abnormal' tissue was significantly more decreased
relative to normal in Group 2 vs. Group 1 (Group 2 ADCr = 0.752 ± 0.074 vs. Group
1 ADCr = 0.881 ± 0.075, t-test p = 0.05; Table 8.3), and although not statistically
significant, appeared to remain decreased relative to normal for longer in Group 2 vs.
Group 1 (GLM regression p = NS; Figure 8.5). Although not statistically significant,
the ADC in 'definitely abnormal' tissue in Group 2 appeared to be more decreased
relative to normal at baseline (t-test p = NS), and remain decreased relative to normal
for longer than in Group 1 (GLM regression p = NS; Figure 8.5).
Although the baseline CBF of 'possibly abnormal' tissue appeared to be lower in
Group 2 compared to Group 1 (Group 2 CBFr = 0.617 ± 0.315 vs. Group 1 CBFr =
1.123 ± 0.431), there was no statistically significant difference between groups (t-test
p = NS; Table 8.3). However, there was a significant difference between the
evolution of CBF in 'possibly abnormal' tissue between Groups 1 and 2 (GLM
regression p < 0.01); CBF increased more rapidly between baseline and 5 days after
stroke onset, and the peak CBF occurred later in Group 2 than in Group 1
(approximately 12 days vs. 5 days after stroke onset; Figure 8.5). Although the
baseline CBF of 'definitely abnormal' tissue appeared to be lower in Group 2
compared to Group 1 (Group 2 CBFr = 0.456 ± 0.248 vs. Group 1 CBFr = 1.074 ±
0.481), there was no statistically significant difference between groups (t-test p = NS;
Table 8.3). However, the evolution of CBF in 'definitely abnormal' tissue was
significantly different between Groups 1 and 2 (GLM regression p = 0.03); CBF
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increased more rapidly between baseline and 5 days after stroke onset, and the peak
CBF occurred later in Group 2 than in Group 1 (approximately 12 days vs. 5 days
after stroke onset; Figure 8.5).
Baseline MTT of 'possibly abnormal' tissue was not significantly different between
Group 1 and Group 2 (t-test p = NS; Table 8.3). Although it appeared that the MTT
in 'possibly abnormal' tissue in Group 2 decreased more rapidly between baseline
and 5 days after stroke onset relative to Group 1, this pattern was not statistically
significant (GLM regression p = NS; Figure 8.5). There were no significant
differences in MTT between Groups 1 and 2 in 'definitely abnormal' tissue either at
baseline or over time (t-test p = NS, GLM regression p = NS).
There were no significant differences in DWI SI, ADC, CBF, or MTT between
Group 1 and Group 2 in 'ipsilateral normal' tissue either at baseline or over time (t-
tests all p = NS, GLM regression all p = NS; Table 8.3, Figure 8.5).
Discussion
The manual grid method demonstrated that the subregions of abnormality (degrees of
'brightness') on DWI probably reflect the underlying degree of tissue damage as
measured by ADC abnormality. Tissue that appears 'possibly abnormal' on DWI is
initially significantly less abnormal in terms of ADC values than tissue that appears
'definitely abnormal'. The fate of the 'possibly abnormal' tissue appears to be related
to baseline CBF and MTT values, and the pattern of changes in CBF and MTT from
baseline to approximately 5 days after stroke onset. The age of the patient might also
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be important - patients whose 'possibly abnormal' tissue became less abnormal were
significantly younger than patients whose 'possibly abnormal' tissue became more
abnormal, although the small sample size means that this analysis is only
exploratory. However, analysis of a larger sample of patients with the manual grid-
based analysis is impractical as it is extremely labour intensive and liable to observer
error; each grid box must be individually identified, the 'place' in the grid must be
manually calculated, and extracted DWI and PWI parameters must be manually
assigned to the appropriate tissue classification category.
Exploring these issues in a larger group of patients with a more automated approach
would help to elucidate how early diffusion and perfusion changes affect outcome;
thus we developed a grid-based program to reduce analysis time and observer error.
The development and testing of observer variation of this grid-based program will be
discussed in the following chapter.
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9. Development and observer




This chapter concerns the development of a more efficient grid-based analysis
program for analysis of a larger sample of patients. The effect of observer differences
on lesion volume and extracted DWI and PWI values from lesion analysis with the
grid-based program is assessed.
SGAT grid analysis
After the initial testing of the manual grid-based analysis in Chapter 8, an internally-
developed grid-based program, SBIRCS Grid Analysis Tool (SGAT), was developed
in MATLAB® by Dr. Paul Armitage to provide a more efficient method of grid-
based analysis in a larger group of patients.
Methods
For each patient, the axial slice that passed through the centre of the visible
ischaemic lesion on baseline DWI was chosen for analysis. The SGAT program
displays an observer-selected image from the DWI sequence, windowed to a
standard signal intensity, with a 5 x 5 voxel grid (voxel = 4.39 mm3, grid box =
109.86 mm3) laid over the image (Figure 9.1). Grid boxes containing only
?0"7
background or CSF are automatically segmented using FSL software BET and
FAST204 (FMRIB Analysis Group, Oxford, UK) and marked by the program
(although these can still be edited by the observer if necessary). The observer first
marks a line of voxels separating the right and left hemispheres, and indicates which
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hemisphere is ipsilateral to the ischaemic lesion by clicking on it with the mouse.
The observer can then classify each grid box (as 'definitely abnormal' or 'possibly
abnormal') according to its appearance on baseline DWI by selecting it with the
mouse. A coloured 'x' appears in each box as it is classified, the colour
corresponding to the classification. Once all the 'definitely abnormal' and 'possibly
abnormal' tissue is classified, large numbers of grid boxes containing 'normal' tissue
can be classified by clicking on the 'fill' option, which scores all unclassified boxes
as either 'ipsilateral normal' or 'contralateral normal' in relation to the hemisphere
selection as described above. This grid-based analysis is much faster to perform than
the manual grid-based analysis and overcomes observer error issues, such as losing
one's 'place' in the grid.
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Figure 9.1 The SGAT grid analysis program user interface (Patient A, left hemisphere




Tissue classifications ('definitely abnormal', 'possibly abnormal', 'ipsilateral
normal', and 'contralateral normal') and scoring criteria were the same as previously
described in Chapter 8 for the manual grid analysis (Figure 8.2).
Observer variation in SGAT grid analysis
Methods
A group of 50 patients with visible lesions on baseline DWI from the larger cohort of
patients as described in Chapter 4 were included in the present analysis. Two
observers scored the baseline DWI scans to evaluate the effect of observer
differences on the volume of tissue selected as each tissue classification and the
effect on measured DWI and PWI parameters between two observers using the
SGAT grid-based analysis program. The evolution of diffusion and perfusion
parameters in the different tissue classifications will be presented in Chapter 9.
Tissue classification
Grid-scoring was performed by the author (Observer A), and a neuroradiologist
(JMW, Observer B), blindly and independently of one another and clinical and other
imaging details.
Statistical analyses
General patient demographic data was obtained and compared as previously
described (Chapter 4).
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We combined 'possibly abnormal' and 'definitely abnormal' tissue (weighted mean
of the two) to compare all 'abnormal' tissue as some patients did not have any tissue
that was rated as 'definitely abnormal' by one or both of the observers. DWI SI,
T2WI SI, ADC, CBF, CBV, and MTT values for each grid box and mean values for
each tissue classification for each observer were extracted. Note that DWI SI, T2WI
SI, CBF, CBV, and MTT values are not quantitative, so are in arbitrary units (AU).
We compared the volume of tissue scored as each tissue classification by each
observer. The volume of tissue scored as each tissue classification by each observer
was calculated by multiplying the number of boxes scored as each tissue
classification by the volume of a grid box (109.86 mm ). The volume data was not
normally-distributed (Kolmogorov-Smirnov test p < 0.01), so median volumes of
each classification of tissue were compared using Wilcoxon signed rank sum tests
and correlations between the volume of tissue scored as each tissue classification by
the two observers were assessed with Spearman's rank correlation coefficients (p).
Plots of the difference (Observer A - Observer B) vs. the mean DWI SI, T2WI SI,
ADC, CBF, CBV, and MTT values (Bland Altman plots186) for each tissue
classification between Observers A and B were compared to assess differences in
MR parameters when two observers score lesions according to baseline DWI
appearance using the SGAT grid analysis program.
In order to compare the magnitude of 'between observer differences' directly across
different MR parameters, which have different mean values and ranges of values, we
also expressed the 95% limits of agreement (mean difference ± 2 SD) of the
'observer difference' as a percentage of the mean DWI SI, T2WI SI, ADC, CBF,
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CBV, and MTT values between observers (95% limits of agreement between
observers divided by the mean between observers, expressed as a percentage).
Results
Patient details
Fifty patients with visible lesions on baseline DWI were included in the present
analysis: 31/50 (62%) were male, the mean age was 73 years (range: 37 - 94 years),
and the mean NIHSS score on admission was 10 (median 8, range: 0 - 27). OCSP
classifications: 16/50 (32%) patients had a TACI, 29/50 (58%) patients had a PACI,
4/50 (8%) patients had a LACI, and 1/50 (2%) patients had a POCI. Mean mRS score
at 90 days after stroke onset was 3 (median 2); 14/50 (28%) patients were dependent
(mRS = 3-5) and 7/50 (14%) patients were dead (mRS = 6).
Generalpatient scan details
Mean (± SD) time from stroke onset to baseline imaging was 9 ± 6 hours, with 25/50
(50%) patients imaged within 6 hours, 10/50 (20%) patients between 6 and 12 hours,
and 15/50 (30%) patients between 12 and 24 hours after stroke onset.
Tissue classification
In all 50 patients, both observers scored at least one grid box as 'possibly abnormal'.
In 3/50 (6%) patients, neither observer scored any tissue as 'definitely abnormal',
and in 7/50 (14%) patients, the less experienced observer (the author) did not score




The volume of tissue scored as 'abnormal' (combined 'definitely abnormal' and
'possibly abnormal') by Observer A was significantly smaller than the volume of
tissue scored as 'abnormal' by Observer B (median volume Observer A = 3021.24
mm3 vs. Observer B = 4174.80 mm3, Wilcoxon test p < 0.01; Table 9.1). There were
no significant differences in the volumes of tissue scored as 'ipsilateral normal'
(median volume Observer A = 19006.35 mm3 vs. Observer B = 18072.51 mm3,
Wilcoxon test p = NS) or 'contralateral normal' (median volume Observer A =
21588.14 mm3 vs. Observer B = 21643.07 mm3, Wilcoxon test p = NS; Table 9.1).
The volume of tissue scored as 'abnormal', 'ipsilateral normal', and 'contralateral
normal' by each observers correlated very highly (Spearman's p = 0.95, p = 0.94,
and p = 0.79 respectively, all p < 0.01; Table 9.1).
Table 9.1 Median volume of tissue scored as each tissue classification for each
observer using the SGAT grid analysis program, Wilcoxon signed rank sum tests and
Spearman's rank correlation coefficients (p) between observers.
Tissue
classification
Median volume (mm3) Wilcoxon
test
Spearman's
PObserver A Observer B
Abnormal 3021.24 4174.80 p < 0.01 0.95
Ipsilateral normal 19006.35 18072.51 NS 0.94
Contralateral
normal
21588.14 21643.07 NS 0.79
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Table 9.2 Mean DWI SI, T2WI SI, ADC, CBF, and MTT values for each tissue
classification for each observer using the SGAT grid analysis program.





A 440.19 ±77.54 293.71 ± 22.74 288.46 ± 24.32
B 415.56 ±73.22 286.86 ±23.68 285.56 ±25.12
T2W SI (AU)
A 944.66 ± 134.35 788.58 ± 105.56 783.91 ±96.96
B 945.09 ± 136.42 775.48 ± 93.95 770.64 ±91.22
ADC (10~6
mm2/s)
A 760.62 + 157.89 963.37 ± 92.06 974.53 ± 89.47
B 817.77 ± 175.88 971.64 ±83.63 971.44 ±89.84
CBF (AU)
A 974.56 ±451.61 1146.96 ±347.40 1180.47 ± 350.30
B 1027.60 ±438.64 1151.97 ± 340.57 1166.88 ±340.97
CBV (AU)
A 1138.60 ±451.55 1191.78 ±469.03 1132.25 ±425.90
B 1187.83 ±453.11 1192.08 ±467.48 1127.86 ±423.51
MTT (AU)
A 1323.97 ±522.92 1072.63 ± 378.16 977.54 ±315.30
B 1295.99 ± 508.89 1058.88 ± 371.74 980.34 ± 316.26
MR1 characteristics
Table 9.2 lists the mean (± SD) DWI SI, T2WI SI, ADC, CBF, CBV, and MTT
values for each tissue classification for Observers A and B. Plots of the difference
(Observer A - Observer B) vs. the mean DWI SI, T2WI SI, ADC, CBF, CBV, and
MTT values between the two observers for are shown in Figure 9.2 for 'abnormal'
tissue, Figure 9.3 for 'ipsilateral normal' tissue, and Figure 9.4 for 'contralateral
normal' tissue. Figures 9.2 - 9.4 also include the mean between observers and 95%
limits of agreement (mean difference ± 2 SD) for each MR parameter.
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Figure 9.2 Bland Altman plots of A) DWI SI, B) T2WI SI, C) ADC, D) CBF, E) CBV, and F)
MTT values from tissue rated 'abnormal' (combined 'definitely abnormal' and
'possibly abnormal' tissue) by two observers. The black dashed line represents the
mean difference, and the grey dashed lines represent ± 2 SD of the mean (95% limits
of agreement).
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Figure 9.3 Bland Altman plots of A) DWI SI, B) T2WI SI, C) ADC, D) CBF, E) CBV, and F)
WITT values from tissue rated 'ipsilateral normal' by two observers. The black dashed
line represents the mean difference, and the grey dashed lines represent ± 2 SD of the
mean (95% limits of agreement).
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mean difference 2.91
limits of agreement -8.36 to 14.19
D)
CSF Contralateral normal tissue
mean difference 14.72



















T, Contralateral normal tissue
mean difference 13.69
limits of agreement -42.52 to 69.90
E)
Mean (AU)
CBV Contralateral normal tissue
mean difference 5.36
imits of agreement -68.47 to 79.19
Mean (SI)
ADC Contralateral normal tissue
mean difference 3.45







MTT Contralateral normal tissue
mean difference -2.76











Mean (* 10"* mmJ/s)
- % e 4***+
1000 2000
Mean (AU)
Figure 9.4 Bland Altman plots of A) DWI SI, B) T2WI SI, C) ADC, D) CBF, E) CBV, and F)
MTT values from tissue rated 'contralateral normal' by two observers. The black
dashed line represents the mean difference, and the grey dashed lines represent ± 2
SD of the mean (95% limits of agreement).
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DWI and observer differences
The mean DWI SI value for 'abnormal' tissue was more abnormal (i.e. 'brighter') for
Observer A compared to Observer B (440.19 ± 77.54 vs. 415.56 ± 73.22 AU; mean
difference Observer A - Observer B = 24.63 AU; Figure 9.2, Table 9.2). Observer
A's more abnormal DWI SI values for 'abnormal' tissue, together with the
significantly smaller volume of tissue scored as 'abnormal' by Observer A compared
to Observer B, means that Observer A was less perceptive in scoring tissue as
appearing 'possibly abnormal' or 'definitely abnormal' on baseline DWI. The 95%
limits of agreement for 'abnormal' tissue DWI SI values are narrow (-8.64 - 57.90
AU; Figure 9.2).
There was little difference between Observers A and B in terms of DWI SI values in
tissue classified as 'ipsilateral normal' (mean difference Observer A - Observer B =
6.86 AU) and 'contralateral normal' (mean difference Observer A - Observer B =
2.91 AU) tissue classifications (Figure 9.3, Figure 9.4). The 95% limits of agreement
for DWI SI values between Observers A and B are narrow for DWI values for
'ipsilateral normal' (-6.26 - 20.00 AU; Figure 9.3) or 'contralateral normal' (-8.36 -
14.19 AU; Figure 9.4) tissue.
ADC and observer differences
When tissue was classified according to baseline DWI appearance, the mean ADC
value for 'abnormal' tissue was more abnormal (i.e. lower) for Observer A compared
to Observer B (mean ADC Observer A = 760.62 ± 157.89 vs. Observer B = 817.77 ±
f\ 9 f\
175.55 x 10" mm /s; mean difference Observer A - Observer B = -57.14 x 10"
mm2/s; Figure 9.2, Table 9.2). These ADC values agree with the volume and DWI SI
value results that suggest Observer A was more conservative in scoring tissue as
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appearing 'abnormal' on baseline DWI. The 95% limits of agreement for 'abnormal'
tissue ADC values are much wider than for DWI values (-193.75 - 79.47 x 10"6
mm /s; Figure 9.2).
There was less difference in ADC values between observers in 'ipsilateral normal'
(mean difference Observer A - Observer B = -9.61 x 10"6 mm2/s; Figure 9.3) and
'contralateral normal' (mean difference Observer A - Observer B = 3.45 x 10"6
mm /s; Figure 9.4) tissue than in 'abnormal' tissue. However, the 95% limits of
agreement for ADC values between Observers A and B are still wide in comparison
to DWI SI values for 'ipsilateral normal' (-69.71 - 50.48 x 10"6 mm2/s; Figure 9.3)
and 'contralateral normal' (-49.83 - 56.73 x 10"6 mm2/s; Figure 9.4) tissue.
PWI and observer differences
When scored according to baseline DWI appearance, PWI values for 'abnormal'
tissue between Observers A and B vary widely compared to DWI SI values: 95%
limits of agreement are widest for CBV values (-227.31 - 128.86 AU; Figure 9.2),
intermediate for CBF values (-205.90 - 99.83 AU; Figure 9.2), and narrowest
(though still wide in comparison to DWI) for MTT values (-103.08 - 159.04 AU;
Figure 9.2).
PWI values for 'ipsilateral normal' tissue between Observers A and B also vary
widely compared to DWI values: the 95% limits of agreement are widest for CBV
values (-92.47 - 92.90 AU; Figure 9.3), intermediate for MTT values (-60.64 -
88.86 AU; Figure 9.3), and narrowest for CBF values (-61.43 - 52.32 AU; Figure
9.3). PWI values for 'contralateral normal' tissue between Observers A and B also
vary widely compared to DWI SI values: the 95% limits of agreement are widest for
CBF values (-76.85 - 106.28 AU; Figure 9.4), intermediate for CBV values (-68.47
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- 79.19 AU; Figure 9.4), and narrowest for MTT values (^48.84 - 43.32 AU; Figure
9.4).
T2WISI and observer differences
Although there does not appear to be a systematic difference in T2WI SI values
between the 'abnormal' tissue as scored by Observers A and B on baseline DWI
(mean difference Observer A - Observer B = -0.43 AU; Figure 9.2), the 95% limits
of agreement are wide compared to DWI SI values (-110.32 - 109.47 AU; Figure
9.2). The 95% limits of agreement for T2WI SI values between Observers A and B
are also wide compared to DWI SI values for 'ipsilateral normal' (-43.30 - 65.94
AU; Figure 9.3) and 'contralateral normal' (-42.52 - 69.90 AU; Figure 9.4) tissue.
Differences between observers as a proportion ofparameter
values
Table 9.3 lists the proportion of DWI SI, T2WI SI, ADC, CBF, CBV, and MTT
values for each tissue classification attributable to differences between Observers A
and B. For all tissue classifications, DWI SI values have the least degree of
difference between observers. For 'abnormal' tissue, ADC values have the greatest
degree of difference between observers (35%), compared to 16% for DWI SI values.
For 'ipsilateral normal' tissue, CBV values have the greatest degree of difference
between observers (15%), compared to 9% for DWI SI values. For 'contralateral
normal' tissue, CBF values have the greatest degree of difference between observers
(16%), compared to 8% for DWI SI values.
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As discussed in Chapter 2, there is currently much interest in developing thresholds
of baseline MR parameter values to predict what tissue is at risk of infarction. A
'good' parameter for development of a threshold would clearly distinguish between
tissue that is already infarcted, tissue that will proceed to infarction, and tissue that
will not proceed to infarction, yet would be also robust to measurement differences
such as observer variation.
Tissue classification volumes
The less experienced observer (Observer A) scored significantly less tissue as
appearing 'abnormal' on baseline DWI compared with the more experienced
observer (Observer B) using the SGAT grid analysis. The tissue scored as 'abnormal'
by Observer A was also more abnormal in terms of DWI SI and ADC values
('brighter' DWI SI and lower ADC values) than tissue scored as 'abnormal' by
Observer B. This agrees with the results of Chapter 5, where, measuring lesions by
manually outlining the visible abnormality on baseline DWI, the less experienced
observer also measured smaller lesion volumes than the more experienced observer.
This reinforces the importance of observer experience on lesion measurement, and
how observer details should be listed in studies reporting lesion measurements.
It is interesting that although the volume of tissue scored as 'abnormal' by Observers
A and B is significantly different, the volume of tissue scored as 'ipsilateral normal'
is not significantly different between observers. However, the volume of tissue
scored as 'abnormal' is much smaller than the volume of tissue scored as 'ipsilateral
normal', so small differences between the observers in the volume of tissue scored as
'abnormal' are more likely to be significant.
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MRI characteristics
When tissue is scored on the appearance of baseline DWI by two observers, the DWI
SI values demonstrate little variability between observers for all tissue
classifications, whereas other measured MR parameters vary widely in comparison,
even for 'contralateral normal' tissue. The 95% limits of agreement for ADC values
between Observers A and B cover a range of 273.22 x 10"6 mm2/s; this range is
extremely wide considering that the difference in ADC values between normal tissue
and tissue that proceeds to infarction has been reported to be between approximately
160 - 350 x 10"6 mm2/s"9'123. Developing an ADC threshold to accurately predict
tissue infarction is thus unlikely, as even small observer differences cause large
degrees of variation in the ADC values measured. Using ADC images to classify
tissue abnormality would not be likely to reduce this observer variability in ADC
values, and would in fact likely introduce more variability as ischaemic lesions on
acute ADC images are harder to distinguish (dark lesions on a dark background) than
on acute DWI ('bright' lesions against a dark background) as discussed in Chapter 2.
PWI values between the two observers for tissue classified as 'abnormal' on baseline
DWI also varied widely in comparison to DWI SI values (Figure 9.2). CBV values
appeared to have the largest, CBF values intermediate, and MTT values the smallest
degree of variance between observers for 'abnormal' tissue. PWI values for
'ipsilateral normal' (Figure 9.3) and 'contralateral normal' (Figure 9.4) tissue also
varied considerably between observers in comparison to DWI SI values, particularly
for CBV values. As discussed in Chapter 6, CBV is not considered a good predictor
of 'tissue at risk' as it exhibits a bimodal behaviour in response to changes in
cerebral perfusion pressure and is insensitive to bolus delay and dispersion37'150,
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possible explanations for why CBV appears to be most prone to small measurement
differences. CBF and MTT values are the most likely PWI measures for predicting
'tissue at risk' as discussed in Chapter 6. However, the wide 95% limits of agreement
of CBF and MTT values between Observer A and B for 'contralateral normal' tissue,
where one would expect little observer variability, suggest that any threshold for
predicting infarction from these parameters would likely be unreliable.
The 95% limits of agreement are much narrower for DWI SI values than any other
measured MR parameters; which may be explained in part by the tissue being
classified according to DWI appearance. However, this would not explain why the
95% limits of agreement for DWI SI values are also much narrower than for other
MR parameters in 'contralateral normal' tissue, where one would expect little
variability between observers, particularly as there was no significant volume
difference between observers, and as most of the 'normal' tissue was automatically
classified using the 'fill' function in the SGAT program. This suggests that even very
small measurement differences cause large degrees of variability in measured T2W
SI, ADC, CBF, CBV, and MTT values; indicating these values are probably
unsuitable for use as thresholds to predict infarction. These differences cannot be
explained by the differences in the mean and range of the parameter values - DWI SI
values have the least degree of difference between observers when expressed as a
proportion of the actual parameter values (i.e. when adjusted for the differences in
mean values for each parameter). DWI SI values appear robust between observers
across tissue classifications, however, this may mean that it is less sensitive to more
subtle degrees of ischaemic abnormality.
176
The analysis of observer variation in tissue classification using the SGAT analysis
program was performed in a large sample of patients with a wide range of severity of
stroke and clinical features, and thus is representative of the general population of
stroke patients for which attempts at designing thresholds for predicting infarction
are aimed. Although only comparing two observers, it is likely that including more
observers in this analysis would only increase the degree of variability of measured
MR parameters. Furthermore, although only one slice through the centre of the
visible lesion on DWI (likely the 'core' of more severely ischaemic tissue) was
analysed for each patient - MR parameters are almost surely more variable
throughout the entire lesion (including peripheral lesion regions that are likely to be
less severely affected).
Use ofgrid-based analysis methods in ischaemic stroke
The 'DWI/PWI mismatch' model discussed in Chapters 2 and 6 purports that the
initial DWI lesion represents the 'core' of irreversibly damaged tissue. However, the
manual grid-based analysis indicated that tissue that appears 'possibly abnormal' on
baseline DWI might have the potential for recovery depending on how quickly blood
flow is restored. Furthermore, the results of the manual grid-based analysis suggests
that the severity of the abnormality ('brightness') on baseline DWI relates to the
underlying severity of tissue damage as assessed by ADC abnormality. The small
sample size limited the ability to generalise these results; analysis of a larger sample
of patients was required. The manual grid-based analysis method is time consuming
and has potential for considerable observer error, so a novel grid analysis program
was developed.
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The SGAT program provides a faster method of grid-based analysis, allowing for
analysis of a larger sample of patients, and is less prone to observer error. The faster
speed of grid-based tissue classification and DWI and PWI parameter extraction
allowed for analysis of a large group of patients with a wide variety of demographic
details and stroke severities. Analysis using the SGAT program in the future could
likely be made even faster, e.g. with the addition of an option to define larger
numbers of grid boxes at one time, and could be used for analysis of different
diseases.
The analysis of the effect of observer differences affirmed the importance of
observer experience, and the great variability in ADC and PWI values suggests that
using these values to predict 'tissue at risk' of infarction accurately is unlikely.
Chapter 10 will discuss the evolution of DWI and PWI parameters in ischaemic
stroke lesions using the SGAT grid analysis program.
178
10. Grid-based analysis of ischaemic
lesion evolution on DWI and PWI
Introduction
This chapter investigates the evolution of DWI and PWI parameters in ischaemic
lesions in a large group of patients, including whether differences in lesion
appearance on baseline DWI are associated with differences in underlying DWI and
PWI parameter values using the grid-based analysis method as developed and tested
in Chapter 9. Differences in DWI and PWI parameter values at baseline and over
time between patients whose lesions grow, stay the same size, or shrink between
baseline and final imaging are also assessed.
Using SGAT to assess lesion evolution and growth
Heterogeneity ofDWI and PWI parameters in ischaemic lesions has not been widely
assessed. Using the manual grid-based analysis in Chapter 8, important differences in
blood flow and ADC values (indicating differences in underlying damage) were
identified between regions of differing degrees of appearance ('brightness') on DWI.
Analysis of a larger sample of patients was required, but was not feasible with the
manual grid analysis method. The development of the SGAT grid analysis program
(Chapter 9) allowed for faster grid-based analysis that is less prone to observer error.
The SGAT program was used to study the evolution ofDWI and PWI parameters in
the lesions of a large group of ischaemic stroke patients. Patients were then classified
as to whether their lesions grew, stayed the same size, or shrank between baseline
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and final imaging, and DWI and PWI parameters were compared to assess if lesion
growth was associated with differences in underlying ADC, CBF, and MTT values.
Lesion evolution analysis methods
Patients with imaging at baseline (< 24 hours after stroke onset) and at 30 and/or 90
days after stroke onset were chosen for analysis from the larger patient cohort as
described in Chapter 4. SGAT grid-scoring (as described in Chapter 9) was
performed by a neuroradiologist (JMW), blind to clinical and other imaging details.
The grid box classifications ('definitely abnormal', 'possibly abnormal', 'ipsilateral
normal', and 'contralateral normal' as defined in Chapter 8) from the baseline scan
were applied to the subsequent coregistered scans, and ADC, CBF, and MTT values
for each grid box and mean values for each tissue classification at each scan time
were extracted. ADC, CBF, and MTT values were also calculated for all 'abnormal'
tissue, calculated as the weighted mean of the 'definitely abnormal' and 'possibly
abnormal' tissue, for comparison with other data. Relative values for each parameter
(ADCr, CBFr, and MTTr) were calculated as previously described.
Statistical analyses
General patient demographic data were obtained and compared as previously
described (Chapter 4).
Mean (± SD) ADCr, CBFr, and MTTr values are reported and compared. Baseline
ADCr, CBFr, and MTTr values were compared to normal (test value = 1, as they are
relative values) using standard t-tests. Baseline ADCr, CBFr, and MTTr in
'definitely abnormal' and 'possibly abnormal' tissues were compared using standard
paired t-tests to determine if differences in baseline DWI appearance were indicative
of the degree of underlying initial ADC, CBF, and MTT abnormalities. ADCr at 30
181
and 90 days after stroke onset in 'definitely abnormal' and 'possibly abnormal'
tissues were also compared using standard paired t-tests to determine if differences in
baseline DWI appearance were indicative of the degree of underlying ADC
abnormality at outcome. Changes in ADCr, CBFr, and MTTr values over time (from
baseline to 30 days after stroke onset) were analysed using GLM repeated measures
regression analysis (dependent variables = ADCr, CBFr, and MTTr values; ADCr
and MTTr fit to a linear model, CBFr fit to a quadratic model). The data from 90
days after stroke onset was not included in the GLM repeated measures regression
analysis as there were small numbers of patients with MRI data at this last MR
scanning time point.
Lesion growth analysis methods
The patients included in the lesion evolution analysis were classified by a
neuroradiologist (JMW) as to whether their lesions appeared to grow, stay the same
size, or shrink between baseline DWI and final (30 or 90 days after stroke onset)
T2WI, blind to clinical and other imaging details. These classifications were made
based on a knowledge of patterns of lesion extent and anatomical boundaries to
account for possible tissue distortion due to tissue swelling that may have biased the
determination of lesion growth205. Differences in mean ADCr, CBFr, and MTTr
values for each tissue classification at each scan time between each lesion type
(grow, stay the same size, or shrink between baseline DWI and final T2WI) were
assessed.
Statistical analyses
Clinical details of the patients whose lesions grew, stayed the same size, or shrank
were compared: age and time from stroke onset to baseline and subsequent MRI with
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a one way analysis of variance (ANOVA); baseline NIHSS with a Kruskal-Wallis
test; and sex, OCSP classifications, and whether the patients were dead or dependent
(mRS = 3 - 6) at 90 days after stroke onset or not with Chi-Square (x2) tests.
Baseline ADCr, CBFr, and MTTr values were compared between patients whose
lesions grew, stayed the same size, or shrank between baseline DWI and final T2WI
with an ANOVA. The evolution of ADCr, CBFr, and MTTr values over time (from
baseline to 30 days after stroke onset) between patients whose lesions grew, stayed
the same size, and shrank were compared with GLM repeated measures regression
analysis (dependent variables = ADCr, CBFr, and MTTr; between subjects factor =
whether the patient's lesion grew, stayed the same size, or shrank between baseline
DWI and final T2WI; ADCr and MTTr fit to a linear model, CBFr fit to a quadratic
model). Peak CBFr and nadir MTTr values and their timing, and areas under the
curves200 of ADCr, CBFr, and MTTr values from baseline to 30 days after stroke
onset for each lesion type were also calculated and compared between patients whose
lesions grew, stayed the same size, or shrank with an ANOVA.
Results oflesion evolution analysis
Patient details
Forty-six patients with visible lesions on baseline DWI and imaging at 30 and/or 90
days after stroke onset were included in the present analysis: 28/46 (61%) were male,
the mean age was 72 years (range: 37 - 94 years), and the mean NIHSS score on
admission was 8 (median 8, range: 0 - 25). OCSP classifications: 12/46 (26%)
patients had a TACI, 29/46 (63%) patients had a PACI, 4/46 (9%) patients had a
LACI, and 1/46 (2%) patients had a POCI. Mean mRS score at 90 days after stroke
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onset was 2 (median 2); 13/46 (28%) patients were dependent (mRS = 3-5) and
2/46 (4%) patients were dead (mRS = 6).
Generalpatient scan characteristics
Mean (± SD) time from stroke onset to baseline imaging was 10 ± 7 hours, with
18/46 (39%) patients imaged within 6 hours, 12/46 (26%) patients between 6 and 12
hours, and 16/46 (35%) patients between 12 and 24 hours after stroke onset. The 5
day scans were performed at a mean of 5 ± 1 days, the 14 day scans at a mean of 12
± 2 days, the 30 day scans at a mean of 31 ±3 days, and the 90 day scans at a mean
of 96 ± 7 days after stroke onset (Table 10.1). The number of patients with scans at
each time point, and whether PWI was performed, are listed in Table 10.1. Note,
2/46 (4%) patients did not have any tissue that was scored as 'definitely abnormal'.
Table 10.1 Mean (± SD) scan times, number of patients (n), and mean (± SD) ADCr,
CBFr, and MTTr values at each scan time for all tissue classifications for all patients
analysed with the SGAT grid analysis program. Tissue classifications were scored
according to baseline DWI appearance, which were applied to subsequent
coregistered scans.












0.776 ± 0.353 1.415 ± 0.502
Possibly abnormal 0.874 ±0.153 0.901 ± 0.257 1.324 ±0.331
Ipsilateral normal 1.006 ±0.048 0.995 ±0.094 1.096 ±0.125





1.143 ±0.460 1.078 ±0.285
Possibly abnormal 0.835 ±0.207 1.079 ±0.307 1.076 ±0.212
Ipsilateral normal 0.968 ± 0.082 0.978 ±0.106 1.057 ±0.132





1.277 ±0.486 1.026 ±0.111
Possibly abnormal 1.007 ±0.204 1.076 ±0.282 1.041 ± 0.114
Ipsilateral normal 1.000 ±0.076 0.962 ± 0.099 1.030 ±0.076





0.873 ±0.233 1.057 ±0.151
Possibly abnormal 1.150 ±0.202 0.896 ± 0.204 1.067 ±0.121
Ipsilateral normal 1.029 ±0.059 0.950 ±0.069 1.036 ±0.073





0.756 ± 0.240 1.087 ±0.180
Possibly abnormal 1.358 ±0.245 0.813 ±0.186 1.066 ± 0.117
Ipsilateral normal 1.092 ±0.107 0.947 ±0.110 1.027 ±0.056
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MR1 characteristics ofSGATgrid analysis
Table 10.1 lists and Figure 10.1 shows graphs of the mean (± SD) ADCr, CBFr, and
MTTr values for each tissue classification (scored according to baseline DWI
appearance and applied to subsequent coregistered scans) from baseline to 90 days
after stroke onset.
The baseline ADC in both 'definitely abnormal' and 'possibly abnormal' tissue was
significantly decreased relative to normal ('definitely abnormal' ADCr = 0.743 ±
0.248, 'possibly abnormal' ADCr = 0.874 ± 0.153, t-tests both p < 0.01; Table 10.1).
ADC was significantly more decreased relative to normal in 'definitely abnormal'
tissue compared to 'possibly abnormal' tissue (paired t-test p < 0.01; Figure 10.1).
The ADC in both 'definitely abnormal' and 'possibly abnormal' tissue significantly
increased over time (GLM regression both p < 0.01), becoming increased relative to
normal at > 14 days after stroke onset after appearing to reach a nadir at baseline for
'definitely abnormal' tissue and at approximately 5 days after stroke onset for
'possibly abnormal' tissue (Figure 10.1). The decrease in ADC in 'possibly
abnormal' tissue between baseline and 5 days after stroke onset indicates that at least
some 'possibly abnormal' tissue became more abnormal in the first 5 days after
stroke onset.
In tissue classified as 'ipsilateral normal', baseline ADC was not significantly
different from normal (t-test p = NS), but did increase significantly over time despite
a slight decrease at 5 days after stroke onset (GLM regression p < 0.01; Figure 10.1).
The decrease in ADC in 'ipsilateral normal' tissue in the first 5 days after stroke
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Figure 10.1 Mean A) ADCr, B) CBFr, and C) MTTr values for all tissue classifications
for all patients analysed with the SGAT grid analysis program. See Table 10.1 for
patient numbers at each scan time. Tissue classifications were scored according to
baseline DWI appearance, which were applied to subsequent coregistered scans.
Error bars represent ± 1 SD of the mean.
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ADC was significantly more increased relative to normal in 'definitely abnormal'
tissue compared with 'possibly abnormal' tissue at both 30 days after stroke onset
('definitely abnormal' ADCr = 1.367 ± 0.371 vs. 'possibly abnormal' ADCr = 1.150
± 0.202, paired t-test p < 0.01; Table 10.1) and 90 days after stroke onset ('definitely
abnormal' ADCr = 1.681 ± 0.416 vs. 'possibly abnormal' ADCr = 1.358 ± 0.245,
paired t-test p < 0.01; Table 10.1), indicating that tissue that is more abnormal
('brighter') on baseline DWI is more severely damaged than tissue that appears less
abnormal on baseline DWI.
CBF was significantly decreased at baseline in both 'definitely abnormal' and
'possibly abnormal' tissue ('definitely abnormal' CBFr = 0.776 ± 0.353, 'possibly
abnormal' CBFr = 0.901 ± 0.257, t-test both p < 0.01; Table 10.1). Baseline CBF
was significantly more decreased relative to normal in 'definitely abnormal' tissue
compared to 'possibly abnormal' tissue (paired t-test p < 0.01; Figure 10.1). CBF
changed significantly over time (GLM regression both p < 0.01); CBF in both
'definitely abnormal' and 'possibly abnormal' tissue increased from a below-normal
to an above-normal level, peaking at approximately 5 days after stroke onset for
'possibly abnormal' tissue and 14 days after stroke onset for 'definitely abnormal'
tissue, and then subsequently decreased to a below-normal level (Figure 10.1).
In tissue classified as 'ipsilateral normal', baseline CBF was not significantly
different from normal (t-test p = NS), but did significantly decrease over time (GLM
regression p < 0.01; Figure 10.1).
MTT in 'definitely abnormal' (MTTr = 1.415 ± 0.502), 'possibly abnormal' (MTTr
= 1.324 ± 0.331), and 'ipsilateral normal' (MTTr = 1.096 ± 0.125) tissue was
significantly prolonged relative to normal at baseline (t-tests all p < 0.01; Table
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10.1). There was no significant difference in MTT at baseline between 'definitely
abnormal' and 'possibly abnormal' tissue (paired t-test p = NS). MTT decreased
significantly over time in all three tissue classifications (GLM regression all p <
0.01; Figure 10.1).
Table 10.2 lists and Figure 10.2 shows graphs of ADCr, CBFr, and MTTr values for
'abnormal' tissue (combined 'definitely abnormal' and 'possibly abnormal' tissue)
from baseline to 90 days after stroke onset.
Table 10.2 Mean (± SD) scan times, number of patients (n), and mean (± SD) ADCr,
CBFr, and MTTr values at each scan time for 'abnormal' tissue for all patients
analysed with the SGAT grid analysis program. Tissue classifications were scored









10 ± 7 h 46 0.825 ±0.153 46 0.867 ±0.283 1.36010.371
5± 1 d 43 0.817 ± 0.201 42 1.093 ±0.347 1.0801 0.235
12 ± 2 d 41 1.013± 0.196 41 1.116 ± 0.315 1.03910.109
31 ± 3 d 43 1.223 ± 0.232 42 0.892 ± 0.205 1.061 1 0.123
96 ± 7 d 40 1.453 ± 0.280 23 0.7891 0.188 1.0741 0.130
ADC was significantly decreased in 'abnormal' tissue at baseline (ADCr = 0.825 ±
0.153, t-test p < 0.01; Table 10.2), appeared to reach a nadir at approximately 5 days
after stroke onset, and significantly increased over time (GLM regression p < 0.01;
Figure 10.2).
CBF was significantly decreased in 'abnormal' tissue at baseline (CBFr = 0.867 ±
0.283, t-test p < 0.01; Table 10.2), and changed significantly over time (GLM
regression p < 0.01), increasing from a below-normal level to an above-normal peak
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Figure 10.2 Mean A) ADCr, B) CBFr, and C) MTTr values for 'abnormal' (combined
'definitely abnormal' and 'possibly abnormal') tissue for all patients analysed with the
SGAT grid analysis program. See Table 10.1 for patient numbers at each scan time.
Tissue classifications were scored according to baseline DWI appearance, which were
applied to subsequent coregistered scans. Error bars represent ± 1 SD of the mean.
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MTT in 'abnormal tissue' was significantly prolonged relative to normal at baseline
(MTTr = 1.360 ± 0.371, t-test p < 0.01; Table 10.2), and decreased significantly over
time (GLM regression p < 0.01), reaching a nadir at approximately 14 days after
stroke onset (Figure 10.2).
Results oflesion growth analysis
Patient details
Overall patient demographics and clinical details are described earlier in the chapter.
There were no significant differences in the baseline NIHSS or OCSP classifications
between patients whose lesions grew, stayed the same size, or shrank between
baseline DWI and final T2WI. However, patients whose lesions grew between
baseline DWI and final T2WI were significantly older than patients whose lesions
shrank between baseline DWI and final T2WI (mean age 77 years vs. 64 years,
ANOVA p = 0.01). There were also significantly more females with lesions that
shrank between baseline DWI and final T2WI than expected (observed 9 vs. expected
5, x2 test p = 0.04). Patients whose lesions grew between baseline DWI and final
T2WI were more likely to be dead or dependent (mRS = 3 - 6) at 90 days after stroke
onset (observed 9 vs. expected 5, f test p = 0.02) than patients whose lesions stayed
the same size or shrank between baseline DWI and final T2WI.
Generalpatient scan characteristics
Overall patient scan characteristics are described earlier in the chapter. Mean (± SD)
times from stroke onset to each scan, and the number of patients with DWI and PWI
data at each scanning time point for each lesion type are listed in Table 10.3. There
were no significant differences in the time from stroke onset to baseline or
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subsequent MRI between patients whose lesions grew, stayed the same size, or
shrank between baseline DWI and final T2WI (ANOVA all p = NS).
Table 10.3 lists and Figure 10.3 shows graphs of the mean (± SD) ADCr, CBFr, and
MTTr values for 'abnormal' and 'ipsilateral normal' tissue (scored according to
baseline DWI appearance and applied to subsequent coregistered scans) for each
lesion type from baseline to 90 days after stroke onset.
MR characteristics of 'abnormal' tissue and lesion growth
Baseline ADCr in 'abnormal' tissue was not significantly different between lesions
that grew, stayed the same size, or shrank between baseline and final scans (ANOVA
p = NS; Table 10.3). There were significant differences in the evolution of ADC in
'abnormal' tissue between the groups: in lesions that either grew or stayed the same
size, ADC decreased to a nadir at approximately 5 days after stroke onset, and then
subsequently increased, whereas in patients whose lesions shrank, ADC was lowest
at baseline and increased more quickly (GLM regression p < 0.02; Figure 10.3).
Although baseline CBFr in 'abnormal' tissue appeared lower relative to normal in
patients whose lesions grew compared with patients whose lesions either stayed the
same size or shrank ('grow' CBFr = 0.739 ± 0.219, 'stay' CBFr = 0.940 ± 0.330,
'shrink' CBFr = 0.929 ± 0.247; Table 10.3), there were no significant differences
between the groups (ANOVA p = NS).
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Figure 10.3 Mean A) ADCr, B) CBFr, and C) MTTr values for 'abnormal' tissue (left,
combined 'definitely abnormal' and 'possibly abnormal' tissue) and 'ipsilateral
normal' tissue (right) by lesion type (grow, stay the same size, or shrink between
baseline and final imaging) for all patients in the SGAT grid analysis. See Table 10.3
for patient numbers at each scan time. Tissue classifications were scored according
to baseline DWI appearance, which were applied to subsequent coregistered scans.
Error bars represent ± 1 SD of the mean.
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There were significant differences in the evolution of CBFr in 'abnormal' tissue
between lesion types: in patients whose lesions grew, CBFr peaked later and at a
lower value than in patients whose lesions stayed the same size or shrank; in patients
whose lesions shrank, CBFr peaked earlier and at a higher value, and remained
higher relative to normal brain for a longer period of time than in patients whose
lesions stayed the same size or grew (GLM regression p < 0.05; Figure 10.3).
Despite baseline MTTr in 'abnormal' tissue appearing more prolonged relative to
normal in patients whose lesions grew compared to patients whose lesions stayed the
same size or shrank ('grow' MTTr = 1.460 ± 0.346, 'stay' MTTr = 1.307 ± 0.335,
'shrink' MTTr = 1.306 ± 0.445; Table 10.3), there were no significant differences
between the groups (ANOVA p = NS). There were no differences in the evolution of
MTTr in 'abnormal' tissue over time between lesion types (GLM regression p = NS),
despite the 'abnormal' tissue MTT of patients whose lesions grew appearing to
remain more prolonged relative to normal for a longer period of time (Figure 10.3).
Comparison of the peak CBFr and nadir MTTr values and their timing in 'abnormal'
tissue revealed no significant differences between patients whose lesions grew,
stayed the same size, or shrank (ANOVA p = NS) despite the apparent differences as
discussed above. Comparison of the area under the curve of ADCr and MTTr values
for 'abnormal' tissue from baseline to 30 days after stroke onset revealed no
significant difference between patients whose lesions grew, stayed the same, or
shrank (ANOVA both p = NS; Figure 10.4). However, the area under the curve of
CBFr values for 'abnormal' tissue from baseline to 30 days after stroke onset
revealed a significant difference between groups: patients whose lesions shrank had
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the largest area under the curve, and patients whose lesions grew the smallest area
under the curve (ANOVA p = 0.03, Figure 10.4).
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Figure 10.4 95% confidence intervals for the area under the curve of CBFr and MTTr
values for 'abnormal' (left) and 'ipsilateral normal' (right) tissue from baseline to 30
days after stroke onset between patients whose lesions grew, stayed the same size,
or shrank between baseline DWI and final T2WI.
MR characteristics of 'ipsilateral normal' tissue and lesion
growth
Baseline ADCr in 'ipsilateral normal' tissue was not significantly different between
lesion types (ANOVA p = NS; Table 10.3). Despite the apparent fall in ADC in
'ipsilateral normal' tissue in patients whose lesions grew, there were no significant
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differences in the evolution of ADCr in 'ipsilateral normal' tissue between lesion
types (GLM regression p = NS; Figure 10.3).
Baseline CBFr in 'ipsilateral normal' tissue was not significantly different between
lesion types (ANOVA p = NS; Table 10.3). There were significant differences in the
evolution of CBFr in 'ipsilateral normal' tissue between lesion types (GLM
regression p < 0.04): in patients whose lesions grew, CBFr was initially reduced and
steadily decreased further over time; in patients whose lesions shrank, CBFr stayed
relatively normal; and in patients whose lesions stayed the same size, CBFr appeared
to increase until approximately 5 days after stroke onset, then decreased rapidly until
approximately 30 days after stroke onset, after which it decreased more slowly
(Figure 10.3).
Despite it appearing that baseline MTT in 'ipsilateral normal' tissue in patients
whose lesions shrank was more normal than in patients whose lesions stayed the
same size or grew, there were no significant differences between the groups
(ANOVA p = NS; Table 10.3). There were no significant differences in the evolution
of MTTr in 'ipsilateral normal' tissue over time between lesion types (GLM
regression p = NS; Figure 10.3). Although not reaching statistical significance (GLM
regression p = NS), it appeared that the MTT in 'ipsilateral normal' tissue in patients
whose lesions shrank was initially more normal and stayed normal over time,
whereas in patients whose lesions stayed the same size or grew, MTT in 'ipsilateral
normal' tissue appeared to be prolonged relative to normal initially and subsequently
decrease, reaching a nadir more quickly in patients whose lesions stayed the same
size than in patients whose lesions grew (approximately 5 days vs. 14 days after
stroke onset; Figure 10.3).
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The peak CBFr of 'ipsilateral normal' tissue was significantly different between
groups (ANOVA p < 0.01): peak CBFr was highest in patients whose lesions stayed
the same size, and lowest in patients whose lesions grew (Figure 10.3). The timing of
the peak CBFr was not significantly different between groups (ANOVA p = NS).
Comparison of the nadir MTTr values for 'ipsilateral normal' tissue and their timing
for each lesion type revealed no significant differences between patients whose
lesions grew, stayed the same size, or shrank (ANOVA p = NS) despite the apparent
differences as discussed above. Comparison of the area under the curve of ADCr,
CBFr, and MTTr values for 'ipsilateral normal' from baseline to 30 days after stroke
onset revealed no significant difference between patients whose lesions grew, stayed
the same, or shrank (ANOVA both p = NS; Figure 10.4).
Discussion
The degree of DWI abnormality indicates the severity of underlying damage -
'definitely abnormal' tissue that appears more abnormal ('brighter') on baseline DWI
has significantly more decreased ADC values compared to normal at baseline, and
significantly more increased ADC values compared to normal at 30 and 90 days after
stroke onset, compared to 'possibly abnormal' tissue that appears only moderately
abnormal on baseline DWI. As discussed in Chapter 3, animal studies have also
found that regions ofmore severe abnormality ('brighter') on acute DWI were in fact
more severely damaged (i.e. higher proportion of dead neurons) compared to regions
of less severe abnormality on acute DWI.
However, there are several studies in humans that do not support the link of the
severity of abnormality on DWI and the severity of underlying tissue damage.
Guadagno et al.125 found no relation between the severity of DWI abnormality and
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permanent tissue damage; however, this was a case study (i.e. n = 1), and DWI
regions were defined using a semiautomated contouring method - both problematic
issues due to lesion heterogeneity as discussed in Chapter 2. Furthermore, Guadagno
125
et al. do not actually compare DWI appearance to an outcome scan, rather they
define 'outcome' tissue damage by applying probabilistic thresholds of acute
positron emission tomography values. Fiehler et al.142 report that even severe acute
ADC decreases in human ischaemic stroke patients did not predict tissue infarction.
However, Fiehler et al.142 measured tissue 'outcome' at 7 days after stroke onset,
when 'fogging' may cause underestimation of lesion extent and lesions are likely still
evolving as discussed in Chapter 2. Thus, it is likely that the severity of abnormality
as seen on acute DWI does indicate something about the underlying severity of tissue
damage.
The severity of abnormality on baseline DWI also relates to the underlying blood
flow to the tissue. Tissue appearing abnormal on baseline DWI had significantly
decreased CBF, and tissue that appears more abnormal ('brighter') on baseline DWI
followed a different pattern of blood flow recovery, seeming to reach a higher peak
CBF at a later time after stroke onset, than tissue that appeared only moderately
abnormal on baseline DWI. The results of the manual grid analysis (Chapter 8) also
indicated that the perfusion changes in the first 5 days after stroke onset might be
important in determining tissue fate - perhaps these differences explain why
'definitely abnormal' tissue is significantly more abnormal than 'possibly abnormal'
tissue in terms ofADC at outcome.
Tissue appearing abnormal on baseline DWI also had significantly prolonged MTT,
however, there did not appear to be any differences between the evolution ofMTT in
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'definitely abnormal' and 'possibly abnormal' tissue. As previously discussed, MTT
abnormalities are generally much larger than DWI and CBF abnormalities (apparent
as significantly prolonged baseline MTT in 'ipsilateral normal' tissue), and thus may
be insensitive to regional differences in the baseline DWI lesion.
The diffusion and perfusion changes in the 'ipsilateral normal' tissue are of interest.
Although not significantly abnormal at baseline, the ADC of 'ipsilateral normal'
tissue increases over time, perhaps indicating recruitment of initially normal tissue
into the lesion. Although CBF in 'ipsilateral normal' tissue was not significantly
abnormal at baseline, there was a significant decrease in CBF in 'ipsilateral normal'
tissue over time; perhaps this is also due to recruitment of initially normal tissue into
the lesion. MTT was significantly prolonged and decreased over time in 'ipsilateral
normal' tissue; baseline MTT lesions have been previously shown to be larger than
baseline DWI lesions, so these changes may be indicative of a large initial region of
oligaemia (as discussed above) that subsequently recovers.
How do lesion DWI and PWI parameters obtained by analysis of the baseline DWI
lesion with the SGAT grid-based program relate to the values obtained by manual
outlining of the baseline DWI lesion as described in Chapter 4? The ADCr values for
tissue classified as 'abnormal' with the SGAT analysis are very similar to the ADCr
values obtained from the manual region of interest analysis in Chapter 4 ('SGAT'
ADCr = 0.825 ± 0.153, 'manual region' ADCr = 0.815 ± 0.162; Table 10.2, Table
4.2). The similarity in ADCr values is to be expected as both analysis methods used
baseline DWI appearance to classify the abnormal tissue. Interestingly, CBFr values
also compare well between the two analysis methods ('SGAT' CBFr = 0.867 ±
0.283, 'manual region' CBFr = 0.865 ± 0.194; Table 10.2, Table 4.2), despite the
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SGAT grid analysis using the visible baseline DWI abnormality, and the manual
region analysis using the visible baseline CBF abnormality to obtain the CBFr
values. There appeared to be a difference in MTTr values between the two methods,
with the MTT of 'abnormal' tissue obtained in the SGAT analysis appearing more
prolonged than the MTT of the manually outlined baseline MTT abnormality
('SGAT' MTTr = 1.360 ±0.371, 'manual region' MTTr = 1.170 ± 0.217; Table 10.2,
Table 4.2). This difference in MTT values is not surprising, as the SGAT analysis
measurements (using the visible baseline DWI abnormality) likely only represent the
more severely hypoperfused tissue, whereas the manual region analysis (using the
visible baseline MTT abnormality) likely includes a much larger amount of tissue
with areas of oligaemia. As discussed in Chapter 6, CBF lesions are generally
smaller than MTT lesions, so it is also unsurprising that the CBF values appear to
correlate better between the two analysis methods than the MTT values.
How do these diffusion and perfusion changes relate to lesion growth between
baseline and final imaging?
Patients whose lesions grew between baseline DWI and final T2WI were older than
patients whose lesions shrank, agreeing with the pilot results of Chapter 8, where age
seemed to relate to whether 'possibly abnormal' tissue behaved more like 'normal'
or 'definitely abnormal' tissue. Lesion growth was also related to clinical outcome;
patients whose lesions grew were more likely to be dead or dependent (mRS = 3-6)
at 90 days after stroke onset than patients whose lesions stayed the same size or
shrank.
There are important differences in early diffusion and perfusion changes that may
influence lesion growth. In patients whose lesions shrank, ADC appeared to have
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already reached a nadir at baseline, whereas in patients whose lesions stayed the
same size or grew, ADC did not reach a nadir until approximately 5 days after stroke
onset. Furthermore, ADC increased more rapidly in patients whose lesions shrank
compared to patients whose lesions stayed the same size or grew. CBF in patients
whose lesions shrank appeared to be less abnormal initially, to increase more rapidly
within the first 5 days after stroke onset, and to remain increased for a longer period
of time ('prolonged hyperaemia') than in patients whose lesions grew. Patients
whose lesion stayed the same size appeared to have rapid increase of CBF within 5
days of stroke onset, but this increase did not seem to last as long as in patients
whose lesions shrank. Significant differences in the area under the curve of CBFr
values from baseline to 30 days also confirmed that there were important differences
in blood flow that were related to lesion growth - patients whose lesions shrank had
much better blood flow to the lesion compared to patients whose lesions grew. There
were no significant differences in MTT between patients, although it appeared that
MTT in both patients whose lesions stayed the same size or shrank between baseline
and final T2WI appeared to be less prolonged initially, and more rapidly returned to
normal within approximately 5 days of stroke onset compared to patients whose
lesions grew. As discussed earlier in the chapter, MTT is likely to be less sensitive to
differences between patients as decreases in MTT tend to be generalised in the
hemisphere ipsilateral to the ischaemic lesion.
When examining patients whose lesions grow or shrink between baseline DWI and
final T2WI, the behaviour of the diffusion and perfusion parameters in the 'ipsilateral
normal' tissue are of interest. Some tissue that is initially 'ipsilateral normal' in
patients whose lesions grow could be expected to become 'abnormal'; indeed it
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appears that the CBF in the 'ipsilateral normal' is initially decreased, and becomes
more decreased relative to normal over time, and that the MTT remains prolonged
relative to normal for a longer period of time in patients whose lesions grow
compared with patients whose lesions stay the same size or shrink. Furthermore,
there are clear significant differences in CBF in the 'ipsilateral normal' tissue - in
patients whose lesions stayed the same size, CBF increases within the first 5-10
days after stroke onset, perhaps indicating the presence of 'tissue at risk' that was
'salvaged' due to this early increase in CBF.
It is important to note that, although one of the largest serial studies ofDWI and PWI
in ischaemic stroke patients, the number of patients whose lesions grew (n = 16),
stayed the same size (n = 17) and shrank (n = 13) between baseline DWI and final
T2WI are small. Furthermore, the commonly used conventional statistical models for
analysis of serial data, such as GLM repeated measures regression analysis, impose
limitations for analysis of DWI and PWI data as the models requires fitting to a
particular line shape. However, the evolution of DWI and PWI parameters are
complex and variable - attempting to find significant differences in these parameters
using the existing analysis methods is not ideal and likely overlooks important
differences between groups of patients. The analysis of 'summary measures' such as
peak CBFr and area under the curve values200 as discussed in Chapter 7 may be more
appropriate, however the comparison of these measures in the current analysis did
not reveal any more differences between the patient groups than the GLM repeated
measures regression analysis.
In the current analysis we analysed changes from baseline until 30 days after stroke
onset although there were data from 90 days after stroke onset. Using 90 days after
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stroke onset as an 'outcome' measure is ideal, however, there were much fewer MRI
data at this late time point, and data from 90 days after stroke onset may be biased -
patients with more severe strokes may have died and patients making a good
recovery may have been unwilling to return for imaging. With use of a larger sample
size, and perhaps the future development of more appropriate statistical models,
further differences in DWI and PWI parameters in this analysis (and other analyses
in this thesis) would likely be found.
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11. Tissue distortion caused by
swelling after ischaemic stroke
Introduction
This chapter investigates both general and localised tissue distortion due to swelling
and tissue cavitation after ischaemic stroke. A novel swelling analysis tool is
developed and tested to quantify tissue distortion at key stages after the onset of
ischaemic stroke.
The effects of swelling in ischaemic stroke
In the acute stages of ischaemic stroke, the failure of cellular ion pumps causes
cytotoxic oedema, or the influx of water from the extracellular space into the
3 9intracellular space ' . In later stages after stroke onset, failure of the cellular
membrane causes vasogenic oedema, or the leakage of plasma constituents into the
extracellular space9. Brain tissue may be distorted by oedema, for instance cytotoxic
oedema can cause swelling, and cell death and loss of tissue can result in tissue
cavitation. As discussed in Chapter 2, swelling may cause overestimation of the
volume of the ischaemic lesion, which might be misconstrued as incorporation of
new tissue into the lesion (i.e. 'lesion growth'), and tissue cavitation could cause
underestimation of lesion extent in the later stages of ischaemic stroke.
During the analyses in this thesis, we noted a considerable number of patients had
visible tissue distortion caused by swelling in the acute phase and subsequent tissue
cavitation in the late phase of ischaemic stroke. Assessment of this tissue distortion is
important because an increase in lesion extent in the acute phase of ischaemic stroke
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could represent either a true increase in lesion extent, or could be due to swelling of
the affected tissue. Any attempt to measure the effectiveness of a new therapy for
ischaemic stroke patients (e.g. measuring the effect of rtPA on lesion growth) that
does not recognise these two distinct possibilities could cause biased estimates of the
effectiveness of the therapy.
There are a handful of non-linear image registration algorithms that may correct for
• 90ft • •
generalised tissue distortion . We explored a number of non-rigid image
registration algorithms said to account for local tissue distortion in the initial
planning stages of this stroke study which led to funding for the study from the Chief
Scientist Office. None of these algorithms were found to be suitable for
distinguishing between a true increase in lesion extent, and an apparent increase in
lesion extent due to swelling. Furthermore, only one infarct coding system has ever
been described that deliberately distinguishes between a true increase in infarct
extent and an increase in lesion extent due to tissue swelling205, something which
simple lesion volume measurement alone can never do. Animal and human studies
have largely failed to recognise this important distinction, let alone address it
(Chapters 2 and 3). Therefore, we aimed to quantify tissue distortion in a small
sample of patients as an exploratory assessment to illustrate the effects of swelling
and subsequent tissue cavitation at key stages after the onset of ischaemic stroke. A
longer term aim was to obtain information to enable development of better image
processing algorithms and lesion measurement methods that could account for local
tissue distortion after ischaemic stroke.
To do this, the grid-based analyses as described in Chapters 8 and 9 were used to
assess the effects of tissue distortion due to lesion swelling. Firstly, we used the
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manual grid-based analysis method to assess the general effect of tissue distortion
due to acute swelling and subsequent tissue cavitation by measuring the total volume
of brain tissue (excluding CSF-containing spaces) in the hemisphere ipsilateral to the
ischaemic lesion from baseline to 30 days after stroke onset. We then investigated
the effect of local tissue distortion within the affected hemisphere by investigating
the movement of 59 anatomical landmarks in and around the ischaemic lesion in one
exemplar between baseline and 4 days after stroke onset.
We then used this information to justify the development of a tool to measure tissue
distortion using the SGAT grid-based analysis method (as described in Chapters 9
and 10). We then tested this faster method of measuring tissue distortion in a group
of 10 representative patients.
Assessing swelling with manual grid analysis
Methods
We assessed the general effects of swelling in the 8 patients analysed with the
manual grid analysis method (Chapter 8), who had a representative range of lesion
morphology and appearance on baseline DWI. For each patient, the axial slice that
passed through the centre of the visible ischaemic lesion on baseline DWI was
chosen for analysis.
Ipsilateral hemisphere volume measurement
The volume of brain tissue of the hemisphere ipsilateral to the ischaemic lesion on
the chosen brain slice was identified by marking each grid box that fell on brain
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tissue (excluding CSF-containing spaces) in the affected hemisphere on the baseline
scan and each subsequent coregistered scan from 5, 14, and 30 days after stroke
onset. The volume of the affected hemisphere for the chosen slice for each patient at
each time point was calculated and compared to assess the effects of tissue distortion
at key stages in the ischaemic process.
Statistical analyses
General patient demographic data were obtained and compared as previously
described (Chapter 4).
The volume of the hemisphere ipsilateral to the ischaemic lesion for the chosen slice
for each patient was calculated by summing the number of grid boxes classified as
brain tissue (i.e. were classified as 'definitely abnormal', 'possibly abnormal', or
'ipsilateral normal' as described in Chapter 8) at each time point and multiplying by
the volume of each grid box (109.86 mm3). The volumes were normally-distributed
(Kolmogorov-Smirnov test p = NS) so mean (± SD) volumes are reported and
compared. GLM repeated measures regression analysis was performed to assess the
change in the volume of brain tissue of the hemisphere ipsilateral to the ischaemic
lesion over time (from baseline to 30 days after stroke onset, dependent variable =
volume of hemisphere ipsilateral to ischaemic lesion; fit to a linear model).
Results
Patient details
General patient demographic data, scanning details, and MR characteristics for the
patients in the current analysis have been reported previously in Chapter 8 (Table
8.1, Table 8.2, Figure 8.3, Figure 8.4).
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Changes in ipsilateral hemisphere volume
Table 11.1 lists, and Figure 11.1 shows a graph of the volume of the hemisphere
ipsilateral to the lesion, from baseline to 30 days after stroke onset. Mean (± SD)
baseline ipsilateral hemisphere volume was 661926.3 ± 114220.5 mm3 (Table 11.1).
The volume of the ipsilateral hemisphere significantly increased over time (GLM
regression, p < 0.01; Figure 11.1). Only 1/8 (12.5%) patient (Patient F) did not have
an increase in the volume of the hemisphere ipsilateral to their ischaemic lesion
(Table 11.1). The only apparent significant difference between Patient F and the rest
of the patient group is that Patient F is the only female in the group (Table 8.1).
Table 11.1 Volume (mm3) of the hemisphere ipsilateral to the ischaemic lesion (and %
of baseline volume) at each scan time (mean ± SD) for the patients analysed with the
manual grid-based analysis method (n = 8).
Patient
Scan time















A 585022.0 903625.5 154% 782775.9 134% 700378.4 120%
B 664672.9 694885.3 105% 681152.3 102% 711364.7 107%
C 832214.4 892639.2 107% 876159.7 105% 851440.4 102%
D 475158.7 639953.6 135% 560302.7 118% 585022.0 123%
E 637207.0 758056.6 119% 705871.6 111% 722351.1 113%
F 793762.2 780029.3 98% 763549.8 96% 766296.4 97%
G 694885.3 766296.4 110% 785522.5 113% 771789.6 111%
H 612487.8 648193.4 106% 661926.3 108%
Mean 661926.3 760459.9 117% 727157.6 111% 729806.1 110%
SD 114220.5 99868.6 96133.2 81765.1
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Figure 11.1 Volume (mm3) of the hemisphere ipsilateral to the ischaemic lesion from
baseline to 30 days after stroke onset for the patients analysed with the manual grid-
based analysis method (n = 8). Note the x-axis crosses the y-axis at the mean baseline
volume. Error bars represent ± 1 SD of the mean.
One patient (Patient A) from the manual grid analysis with evidence of lesion
swelling (Figure 11.2) was chosen to perform a more detailed analysis of localised
tissue distortion due to acute lesion swelling using the manual grid-based analysis
method.
Methods
A neuroradiologist (JMW), blind to clinical and other imaging details, examined a
printout of the axial slice passing through the centre of the visible lesion on DWI at
baseline and 4 days after stroke onset and marked 59 standard anatomical landmarks
In depth case study of tissue distortion
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appropriate to the stroke lesion and location in the brain. These landmarks included
the anterior and posterior horns of the lateral ventricles, the genu and splenium of the
corpus callosum, the lateral and medial aspects of the Sylvian fissure, and the
anteriomedial aspect of the thalamus. The 59 landmarks were then marked on a
printout of the patient's scan from 4 days after stroke onset (Figure 11.2).
Differences in the location of the landmarks between the baseline and 4 day scans














































































































4 h 4 d
Figure 11.2 DWI at 4 hours and 4 days after stroke onset (in Patient A, with a left
hemisphere ischaemic lesion) with overlaid grid as used to score the movement of the
59 anatomical landmarks. Note the swelling at 4 days with the pronounced midline
shift and compression of the left lateral ventricle.
Statistical analyses
Movement was quantified by the direction of movement and the number of grid
boxes moved, using the centre of the grid boxes as a reference point (grid box = 4.69
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mm x 4.69 mm). For example, if the landmark moved one square vertically or
laterally, the point was recorded as having moved by 4.69 mm, and a landmark
moving both one grid box vertically and one grid box laterally was recorded as
having moved by 6.63 mm (= hypotenuse of a right angle triangle where both of the
other sides = 4.69 mm), etc. The landmark movements were not normally-distributed
(Kolmogorov-Smirnov test p < 0.01) so median (and range) landmark movements
are reported, however, overall mean (± SD) landmark movements are also reported
for comparison with other data.
Results
Patient A's clinical details are listed in Table 8.1. Figure 11.2 shows Patient A's
DWI from baseline and 4 days after stroke onset as used for landmark scoring.
Out of the 59 landmarks scored, 53/59 (90%) moved between the baseline and 4 day
scan (Table 11.2). The median movement of the 59 landmarks was 9.38 mm (mean ±
SD = 8.07 ± 3.95 mm), and the range of landmark movement was 0 - 14.82 mm
(Table 11.2).
Table 11.2 Number and % of landmarks by amount of movement (mm) of the 59
landmarks analysed between 4 hours and 4 days after stroke onset in the in-depth



















In Figure 11.2, there is clear evidence of tissue swelling at 4 days after stroke onset,
including effacement of the left lateral ventricle and a mild midline shift. Lesion
volume measured from this scan could thus misleadingly imply a large increase in
lesion extent - the true extent of the lesion in relation to anatomical boundaries does
not appear to have greatly increased, rather the apparent increase in lesion extent is
likely mostly attributable to tissue swelling (Figure 11.2).
Discussion
The assessment of swelling in ischaemic stroke patients using the manual grid
analysis revealed significant tissue distortion between acute and subacute times after
stroke onset, and persistence of tissue distortion even in the late stages of ischaemic
stroke. Analysis of tissue distortion in a larger group of patients would help to
elucidate the effect of swelling and subsequent cavitation on lesion measurement in
ischaemic stroke patients at different key stages after stroke onset. However, as
discussed in Chapter 8, the manual grid analysis method is time-consuming and
prone to observer error, making it impractical for analysis of larger sample sizes. By
modifying the SGAT analysis program as discussed in Chapter 9, we developed a
'swell tool' to allow for more efficient analysis of tissue distortion.
Assessing swelling with SGAT 'swell tool'
Methods
A swelling analysis tool ('swell tool') was developed by Dr. P. Armitage as a
modification of the SGAT grid analysis program to provide a more efficient method
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of measuring the effect of tissue distortion over time caused by swelling and
subsequent cavitation after ischaemic stroke. The 'swell tool' (Figure 11.3) allows
the user to select and record the location of an anatomical landmark by clicking on it
with the mouse. Landmarks can be chosen as appropriate to the individual analysed,
i.e. they are not predetermined by the program.
Landmark scoring
Of the 25 patients from the larger cohort of stroke patients as described in Chapter 4
who had MRI data at all five MR scanning time points from baseline to 90 days after
stroke onset (and who had not already been analysed with the manual grid-based
analysis of tissue distortion), 10 patients were randomly selected for analysis with
'swell tool'.
The axial slice that passed through the centre of each patient's visible lesion on
baseline DWI was selected for analysis. Landmarks were scored on the coregistered
T2WI slice on each coregistered scan by a neuroscientist, blind to the clinical and
other imaging details. Landmark scoring was performed on T2WI as it provides
better anatomical detail than DWI (Figure 11.3). For each patient, 10 standard
anatomical landmarks (midline or ipsilateral to the lesion) were chosen for scoring.
These landmarks were distributed throughout the affected hemisphere in order to
measure distortion independent of lesion location and extent, and were standard
between patients, unless a landmark was not visible on the slice chosen for analysis,
in which case another appropriate landmark was chosen. Landmarks included the
anterior and posterior horns of the lateral ventricles, the genu and splenium of the
corpus callosum, the lateral and medial aspects of the Sylvian fissure, and the
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Statistical analyses
General patient demographic data were obtained and compared as previously
described (Chapter 4).
Landmark movement (in mm, as automatically calculated and recorded by the SGAT
'swell tool') was assessed between each subsequent scan and between baseline and
90 days after stroke onset. The landmark movements were not normally-distributed
(Kolmogorov-Smirnov test p < 0.01) so median (and range) landmark movements
are reported, however, overall mean (± SD) landmark movements are also reported
for comparison with other data.
Clinical details were compared between the five patients with the least and greatest
degree of landmark movement: age and time from stroke onset to baseline and
subsequent MRI with standard t-tests; baseline NIHSS with a Mann-Whitney U-test;
and sex, OCSP classifications, and whether the patients were dead or dependent
(mRS = 3 - 6) at 90 days after stroke onset or not with Chi-Square (x2) tests.
Results
Patient details
Of the 10 patients analysed with 'swell tool': 4/10 (40%) were male, the mean age
was 72 years (range: 36-91 years), and the mean NIHSS score on admission was 12
(median 10, range: 5 - 23). OCSP classifications: 6/10 (60%) patients had a TACI,
and 4/10 (%) patients had a PACI. Mean mRS score at 90 days after stroke onset was
3 (median 3); 6/10 (60%) patients were dependent (mRS = 3-5) and 0/10 (0%)
patients were dead (mRS = 6). Individual patient details are listed in Table 11.3.
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There were no significant demographic or clinical differences between the patients
with the least (Patients I, K, N, O and Q) and greatest (Patients J, L, M, P, and R)
degree of landmark movement.
Table 11.3 Demographics, clinical details, baseline DWI lesion volume, and MR scan












Time from onset to MRI
1 (h) 2(d) 3(d) 4(d) 5(d)
1 F 91 10 TACI 11118.2 4 11 7 15 30 92
J F 73 10 TACI 154489.8 3 23 4 14 30 95
K F 76 11 PACI 13548.3 3 15 4 10 31 90
L M 64 5 PACI 44701.2 0 21 5 12 33 97
M F 75 7 PACI 11496.1 0 6 6 13 30 98
N F 76 12 TACI 27000.0 2 23 5 12 35 91
O M 83 9 TACI 87077.6 4 7 5 12 35 105
P M 79 20 TACI 44213.4 5 26 6 10 28 92
Q F 36 9 PACI 8125.5 2 9 5 12 28 90
R M 66 23 TACI 86941.4 4 13 6 13 32 94
Mean 72 12 48871.1 3 15 h 5 d 12 d 31 d 94 d
Median 10 35606.7 3
Generalpatient scan characteristics
Mean (± SD) time from stroke onset to baseline imaging was 15 ± 7 hours, with 1/10
(10%) patients imaged within 6 hours, 3/10 (30%) patients between 6 and 12 hours,
and 6/10 (60%) patients between 12 and 24 hours after stroke onset. The 5 day scans
were performed at a mean of 5 ± 1 days, the 14 day scans at a mean of 12 ± 2 days,
the 30 day scans at a mean of 31 ±3 days after stroke onset, and the 90 day scans at a
mean of 94 ± 5 days after stroke onset.
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There were no significant differences in the times from stroke onset to baseline or
subsequent MRI between the patients with the least and greatest degree of landmark
movement (t-tests all p = NS).
Landmark movement
The median movement of all landmarks in all 10 patients between each of the
sequential scan times was 1.88 mm (range: 0 - 22.50 mm; Table 11.4). The maximal
median landmark movement between scan times for all 10 patients was 1.88 mm and
occurred between three of the analysed time periods; between baseline and 5 days
(range: 0 - 10.31 mm), 5 and 14 days (range: 0 - 10.31 mm), and baseline and 90
days after stroke onset (range: 0 - 15.94 mm; Table 11.4). Individual landmark
movement was maximal in 3/10 (30%) patients between baseline and 5 days, in 3/10
(30%) patients between 5 and 14 days, and in 1/10 patients between 30 and 90 days
after stroke onset (Table 11.4). Note, in 3/10 (30%) patients (Patients I, N, and O),
there was an equivalent maximal landmark movement between multiple time points
(Table 11.4). The median landmark movement between just baseline and 90 days
after stroke onset was 1.88 mm (range: 0 - 15.94 mm; Table 11.4). Although the
median movements of landmarks are small, some landmarks move by large degrees
(e.g. 22.50 mm), as shown by the range of landmark movements (Table 11.4). As
landmarks were specifically not chosen in relation to each lesion to avoid biasing
measurement of the effects of tissue distortion, some landmarks were inevitably
remote from the individual lesions and thus would experience minimal, if any,
degree ofmovement.
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Figure 11.4 shows DWI and T2WI for a patient with mild degrees of landmark
movement (Patient N) and a patient with more severe degrees of landmark
movement (Patient R). Note the obvious swelling and midline shift of the left lateral
ventricle in Patient R at 6 days after stroke onset, and subsequent cavitation at 94
days after stroke onset.
23 h 5 d 12 d 35 d 91 d
13 h 6 d 13 d 32 d 94 d
Figure 11.4 DWI and T2WI from baseline to 90 days after stroke onset for two patients
analysed with the SGAT 'swell tool' program. A) Patient N (with left hemisphere
ischaemic lesion), with minimal tissue distortion due to swelling; B) Patient R (with
left hemisphere ischaemic lesion), with more extensive tissue distortion due to




Swelling and subsequent cavitation after ischaemic stroke cause tissue distortion that
persists well beyond the acute stages of stroke. This tissue distortion could cause
error in lesion volume measurements; swelling could lead to the false conclusion that
a lesion had 'grown' (i.e. new tissue had been incorporated into the lesion), and
subsequent cavitation could lead to the false conclusion that the lesion had 'shrunk'.
This aim of this analysis was not to determine the time course of swelling and tissue
distortion following ischaemic stroke, but rather to highlight the effect of swelling
and subsequent tissue cavitation at various key stages after stroke onset when MR
data are often collected and lesion volumes are often measured. Tissue distortion was
observed between all investigated time points, indicating that the effects of distortion
should be considered at all stages of ischaemic stroke.
Although the analyses in this chapter only investigated the effects of tissue distortion
on one slice of the brain in each patient, the amount of tissue distortion would likely
be greater if assessed on all brain slices and in three dimensions. The SGAT 'swell
tool' provided a more efficient method of analysing the movement of landmarks, and
could be used in the future to assess the effects of swelling in a larger sample of
patients, and could be used to investigate the effects of tissue distortion in other
diseases.
What can be done to avoid overestimating lesion extent due to swelling or
underestimating lesion extent due tissue cavitation after ischaemic stroke when
trying to measure lesion volume? There is one coding system that allows distinction
between a true increase in lesion extent and an increase in lesion extent due to
swelling205, however, while this coding system allows an estimation of lesion size, it
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does not allow for precise quantification of lesion volume. Measuring lesion extent
serially by scoring the presence of ischaemic tissue within a range of pre-defined
regions based on anatomical landmarks, as suggested by Yang et al.78, might
minimise the effects of tissue distortion on lesion measurement, however this method
is not truly quantitative, has not been validated, is time consuming, and is difficult to
implement for smaller lesions and with certain MR sequences. Further modification
of the SGAT 'swell tool' might provide a more efficient method of measuring lesions
serially with respect to anatomical boundaries that would help to avoid lesion
overestimation caused by tissue swelling or underestimation caused by tissue
cavitation.
Although it was beyond the scope of this thesis to develop an image processing
algorithm that would solve the problem of distinguishing between changes in lesion
size due to true changes in lesion extent and changes due to tissue distortion, we have
obtained important information about the effects of tissue distortion after ischaemic
stroke. This information may help in the future challenge of development of effective
image registration algorithms and lesion measurement methods that account for
tissue distortion after ischaemic stroke.
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12. Summary and conclusions
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Summary and final conclusions
The aim of this thesis was to explore the evolution, and issues affecting the analysis
of, ischaemic lesions on DWI and PWI from acute to late times after stroke onset,
using a large cohort of patients with serial DWI and PWI scanning data. In Chapter
2, we asked:
• what does appearance on DWI mean in terms of underlying tissue state?
• what are the problems with measuring lesions on DWI?
• how do we identify 'tissue at risk' of infarction with MRI?
• are 'thresholds' to predict infarction possible?
What are the strengths and limitations of the analyses in this thesis, what were the
results of the analyses of this large patient cohort, and what questions still remain to
be answered?
Methodology - strengths and limitations
Patient cohort
This study is one of the largest of serial DWI and PWI in the same patients within
discreet MR scanning time points. Despite this, the number of patients available for
subgroup analyses in this thesis are lower (e.g. n = 13 - 17 in the analysis of patients
whose lesions grew, stayed the same size, or shrank in Chapter 10), reducing the
power of the analyses. Patients with all severities of stroke were included, providing
a representation of the population of hospital-admitted stroke patients. The patients
were recruited prospectively according to standardised criteria and consent was
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obtained whenever possible. No patients included in the analyses in this thesis were
treated with thrombolysis or any experimental neuroprotective drugs that may have
biased the relationship between baseline MR parameters and final infarct extent.
Imaging
The patient cohort were imaged serially, within discreet time points, allowing a more
accurate assessment of the temporal evolution ofMR parameters in ischaemic stroke
patients than past composites of 'snapshot' images from single scans at widely
varying times after stroke onset. We also used a measure of outcome (>30 days after
stroke onset) that is adequate in terms of lesion evolution, and avoids the problem of
'fogging' as discussed in Chapter 2. Although we aimed to image patients at 90 days
after stroke onset, an ideal outcome time, fewer patients were imaged at this late time
point. Furthermore, data from 90 days after stroke onset is likely biased by the loss of
patients both with more severe strokes who may have died, and patients with less
severe strokes who may have made a full recovery and been unwilling to return for
this final MR scan. These issues reflect fundamental aspects of the disease of
ischaemic stroke - it is simply not possible to image all patients at all time points.
Lesion measurement
We employed a manual method of lesion measurement based on visual estimation of
the lesion edge, which most closely represents what is practical in the clinical setting,
rather than using a MR parameter (e.g. ADC value) threshold which might reduce
observer error. Lesion measurement with thresholds would still require some degree
of observer input as discussed in Chapter 2 and as demonstrated for two commonly
quoted ADC thresholds in Chapter 5. The heterogeneity of ischaemic lesions is
problematic, and the analyses in this thesis suggest that identification of accurate
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threshold values to predict lesion infarction would not be possible - ADC, CBF, and
MTT values vary too widely to reliably discriminate ischaemic from normal tissue
(Chapter 9).
The differentiation of 'definitely abnormal' and 'possibly abnormal' tissue was
subjective, however this classification method successfully differentiated tissue with
significantly different degrees of underlying damage as identified by ADC and PWI
values (Chapters 8 and 10).
The 'index' measures of PWI parameters used in this thesis are not quantitative,
however current 'quantitative' measures of PWI parameters are still only estimates
that have not been proven superior to 'index' measures.
'Relative' values of DWI and PWI parameters were calculated and compared,
making each patient their own 'control' to correct for individual differences and
allow for comparison between patients, and between imaging time points.
Analysis of repeated measures data is complex. The statistics used for analysis of the
serial data in this thesis are conventional for the analysis of repeated measures data,
and despite their drawbacks these methods identified important differences in DWI
and PWI parameters between different lesion regions and patient groups; we consider
the these findings to be robust.
Development ofa novel grid-based lesion analysis method
We developed a novel grid-based lesion analysis method in order to analyse
subregions of heterogeneity within ischaemic lesions. The grid-based analysis
program allowed rapid and accurate differentiation of regions of heterogeneity on
DWI, and underlying differences in ADC, CBF, and MTT values. From these
analyses, the DWI signal intensity, the most obvious visible MRI feature in the
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clinical setting, closely related to different degrees of pathology, and was least
susceptible to observer variation.
What does appearance on DWI mean in terms of
underlying tissue state?
The results of the systematic review of DWI and PWI in animal models of ischaemic
stroke (Chapter 3) indicated that DWI appearance is linked to underlying tissue state;
tissue that is more abnormal ('brighter') on DWI has a greater proportion of dead
neurons on histological analysis than tissue that appears less abnormal on DWI.
However, the review also highlighted that changes on DWI, for example 'secondary
decline', may be caused by glial cells changes rather than being indicative of
worsening or resolution of neuronal damage.
The various analyses of the large patient cohort in this thesis also demonstrated that
appearance on DWI is indicative of underlying tissue state. The manual grid-based
analysis in Chapter 8 and SGAT grid-based analysis in Chapter 10 showed that tissue
that appears more abnormal ('brighter') on baseline DWI ('definitely abnormal'
tissue) was more abnormal in terms of underlying baseline ADC and PWI values
than tissue that appeared less abnormal on baseline DWI ('possibly abnormal'
tissue). Furthermore, the degree of abnormality on baseline DWI was related to the
degree of late tissue damage as indicated by ADC values from 30 and 90 days after
stroke onset. As discussed in Chapter 8, the fate of ischaemic tissue is related to
tissue haemodynamics within the first 5 days after stroke onset. Patient age might
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also be important; 'possibly abnormal' tissue may be more likely to become more
abnormal in older patients, although this may be an artefact of the case mix and small
sample size.
What are the problems with measuring lesions on
DWI?
Manual lesion measurement has been the most common method of lesion
measurement in studies of MRI in ischaemic stroke, and, as discussed in Chapter 2,
avoids the problems of lesion heterogeneity and unproven assumptions that are
inherent in other less common methods of lesion measurement such as using
thresholds ofMR parameter values.
Manual lesion measurement
In Chapter 5 we evaluated factors that may affect lesion volume measurement on
DWI. Lesion morphology, lesion volume, and observer experience were important
• • 3 •factors in lesion measurement: lesions that were ill-defined and > 5000 mm in
volume had the greatest degree of volume difference between the two observers. The
less experienced observer was more conservative in outlining baseline DWI
abnormality, obtaining lesion volumes that were significantly smaller than the more
experienced observer.
T2 'shine through'
Hyperintensity on DWI late after stroke onset has in the past been dismissed as T2
'shine through'. However, in Chapter 7, we demonstrated that tissue that remains
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hyperintense on late DWI was more abnormal in terms of underlying ADC values at
> 30 days after stroke onset compared to tissue that is isointense or hypointense,
invalidating the common assumption that hyperintensity on late DWI is merely T2
'shine through' without any underlying pathological basis. The ADC of tissue
remaining hyperintense on late DWI was also significantly more decreased relative
to normal at baseline, and increased more slowly over time compared to tissue that
did not remain hyperintense. There also appeared to be differences in blood flow
within the first 5 days after stroke onset between regions that did and did not remain
hyperintense on late DWI - peak CBF and nadir MTT values seemed to occur later
in regions remaining hyperintense. These differences in ADC, CBF, and MTT values
suggest that tissue that remains hyperintense on late DWI experiences a delayed,
slower progression through the 'ischaemic cascade'; perhaps this tissue remains
viable for longer periods of time, or experiences progressive tissue damage,
providing the opportunity to intervene at later stages after stroke onset. Until
intervention is attempted, it is difficult to know whether these late differences
represent reversible changes or not.
Tissue composition
Tissue that remained hyperintense on late DWI was almost exclusively white matter.
As discussed in Chapter 2, there is evidence that grey and white matter may be
different in terms of vulnerability to ischaemia, appearance on DWI, and evolution
after stroke onset. The results of Chapter 7 imply that there are important differences
in the evolution of tissue damage in grey and white matter, and that white matter may
be more vulnerable to ischaemia than previously thought.
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Lesion swelling
Using the grid-based analysis method, we quantified the effect of tissue distortion
caused by swelling and tissue cavitation after ischaemic stroke (Chapter 11). There
was significant tissue distortion at key stages in the ischaemic process, from acute to
late stages after stroke onset. Swelling may cause lesion overestimation, which may
erroneously suggest 'lesion growth', and tissue cavitation may erroneously suggest
lesion resolution.
How do we identify 'tissue at risk' of infarction with
MRI?
Identifying the 'ischaemic penumbra', or 'tissue at risk' of infarction may provide a
target of salvageable tissue in the acute stages of stroke. The 'DWI/PWI mismatch'
model is generally considered to represent the 'ischaemic penumbra', and is in fact
being used as a selection criterion for trials of thrombolysis. However it is unclear
what PWI parameter, if any, best identifies 'tissue at risk' of infarction.
'DWI/PWImismatch'
In Chapter 6 we demonstrated that neither an acute DWI/CBF or DWI/MTT
'mismatch' correlated with 'lesion growth'. Approximately half of the patients that
had 'lesion growth' did not have a 'DWI/PWI mismatch', meaning that patients with
potentially salvageable tissue may have been excluded from trials of therapies from
which they might have benefited. The presence and timing of reperfusion is more
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likely to be correlated with 'lesion growth', however, this has been largely ignored in
the focus on the 'DWI/PWI mismatch' in the past few years.
Can we develop thresholds to predict tissue
infarction?
Developing thresholds of baseline MR parameter values that predict tissue infarction
could reduce observer variation and allow for rapid estimation of the extent of
permanently damaged or potentially salvageable ischaemic tissue. However, the
underlying heterogeneity of ischaemic lesions means regions of different degrees of
tissue damage or vulnerability to ischaemia may be overlooked.
ADC thresholds
Although thresholds of baseline ADC values are frequently used to measure
ischaemic lesions, the results of several analyses in this thesis suggest that baseline
ADC values are poor discriminators of infarcted tissue, 'tissue at risk' of infarction,
and normal tissue. Firstly, animal studies from the systematic review in Chapter 3
demonstrated that initial decreases in ADC are not significantly different between
areas of tissue that have almost no neuronal damage and areas that have almost
complete neuronal death. Secondly, analysis of interobserver variability of MR
parameters in the SGAT grid-based analysis of Chapter 9 showed that ADC values
are widely variable - even in the 'contralateral normal' hemisphere where there was
little, if any, observer input. Lastly, the results of Chapter 10 demonstrated that
baseline ADC values were not significantly different between lesions that grew,
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stayed the same size, or shrank between baseline and final imaging. Thus it appears
likely that baseline ADC values are too variable and overlap too much between
infarcted tissue, 'tissue at risk' of infarction, and normal tissue to provide a clinically
useful threshold.
PWI thresholds
Several studies suggest PWI thresholds that might identify tissue infarction and
'tissue at risk' of infarction. Which, if any, PWI parameter best identifies 'tissue at
risk' of infarction?
CBF information appears to be most useful in the analysis of ischaemic lesions: the
visible baseline CBF abnormality appeared to identify the final lesion (Chapter 6);
there were significant differences in baseline CBF values and in the evolution of
CBF values over time in tissue with different degrees of tissue damage indicated by
underlying ADC values (Chapter 8); and, despite no difference in baseline CBF
values, there were significant differences in the subsequent evolution of CBF values
between patients whose lesions grew, stayed the same size, or shrank between
baseline to final imaging (Chapter 10). In other words, no baseline CBF value
identifies whether the lesion will grow or not, but early and pronounced
improvement in CBF after baseline is associated with tissue salvage. Furthermore,
the analysis of interobserver variation in the SGAT grid-based analysis (Chapter 9)
demonstrated that CBF values are widely variable, even in normal tissue.
It is unlikely that MTT values can identify 'tissue at risk' of infarction: visible
baseline MTT lesions significantly overestimated the final lesion (Chapter 6);
there were no significant differences in MTT values between regions of different
degrees of tissue damage on DWI, or indeed between abnormal and normal tissue
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(Chapter 8); there were no significant differences in MTT values between patients
whose lesions grew, stayed the same size, or shrank between baseline and final
imaging (Chapter 10); and MTT values are widely variable, even in normal tissue
(Chapter 9).
The analyses in this thesis suggest that a single threshold of any PWI parameter
value would not be able to distinguish between tissue that is infarcted tissue, 'tissue
at risk' of infarction, and normal tissue. Outcome is highly dependent on the timing
and presence of reperfusion: thresholds of PWI values would be highly time
dependent, and would also likely be highly patient dependent.
The future of DWI and PWI in the study of ischaemic
stroke
Future studies of MRI in ischaemic stroke, or indeed any imaging study in any
disease, should both consider and report observer details, such as observer
experience, that might effect lesion measurement. Studies should also use
appropriate final time points, allowing for completion of lesion evolution before
making 'outcome' measurements.
The conventional statistics for analysis of repeated measures data are not ideal,
particularly for MR parameters that exhibit complex and variable evolution over time
after stroke onset. Development of more complex statistical models for these serial
data could elucidate further important differences between lesion regions and
patients.
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Although PWI parameters are being used as selection criteria in large clinical trials,
there is no consensus on what method of obtaining PWI information and what PWI
parameter is best, indeed there are few study groups using similar methods so it will
be hard to validate the results of any one group. Discussion of the problems with
current PWI methods and development of a standardised approach would clarify the
complex changes in PWI parameters after ischaemic stroke.
Future analysis of a larger patient cohort with the grid-based analysis method
developed in this thesis would clarify the evolution of DWI and PWI parameters
after ischaemic stroke onset, and would elucidate any differences in MR parameters
between patients whose lesions grow and do not grow between baseline and final
imaging, as well as relationships to other factors such as stroke severity, reperfusion,
and other demographic and clinical data. A multiparametric model for identifying
'tissue at risk' could be developed and tested in a large patient cohort. The grid-based
analysis method developed in this thesis could also be implemented in the study of
other diseases.
The effect of tissue distortion after ischaemic stroke on lesion measurement needs to
be addressed, perhaps with use of an automated non-rigid image registration method
if one could be developed with the necessary reliability. A method of lesion
measurement that avoids lesion overestimation due to swelling and lesion
underestimation due to tissue cavitation needs to be developed, perhaps with the use
of the grid-based analysis method.
Late hyperintensity on DWI may indicate delayed lesion evolution, meaning there is
potentially the opportunity for intervention at later times after stroke onset - this
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should be examined further in a larger patient cohort to elucidate underlying
pathology and perhaps point to suitable interventions.
The use of the 'DWI/PWI mismatch' as a selection criterion in clinical trials of
thrombolysis means about half of patients with potentially salvageable tissue are





1. The New Shorter Oxford English Dictionary on Historical Principles. 1993.
Clarendon Press, Oxford, U.K.
2. Hankey GJ. Stroke. Your Questions Answered. 2002. Churchill Livingstone,
Edinburgh, U.K.
3. Warlow CP, Dennis MS, van Gijn J, Hankey GJ, Sandercock PAG, Bamford JM,
Wardlaw JM. Stroke. A practical guide to management. 2nd edition. 2001. Blackwell
Science Ltd., Oxford, U.K.
4. Schiller F. Concepts of stroke before and after Virchow. Medical History. 1970;
14(2): 115-131.
5. Fields WS, Lemak NA. A History of Stroke. Its Recognition and Treatment.
1989. Oxford University Press, New York, U.S.A.
6. Mackay J, Mensah GA. The Atlas of Heart Disease and Stroke. 2004. World
Health Organization, Geneva, Switzerland.
7. Astrup J, Symon L, Branston NM, Lassen NA. Cortical evoked potential and
extracellular K+ and H+ at critical levels of brain ischemia. Stroke. 1977; 8(1 ):51 -57.
8. Hatano S. Experience from a multicentre stroke register: a preliminary report.
Bulletin ofthe World Health Organisation. 1976; 54(5):541 -553.
9. Hacke W, Hennerici M, Gelmers HJ, Kramer G. Cerebral Ischemia. 1991.
Springer-Verlag, Berlin, Germany.
10. WHO MONICA Project. Part IV. Event Registration. MONICA Manual. 1990.
World Health Organization, Geneva, Switzerland.
11. Bamford J, Sandercock P, Dennis M, Warlow C, Jones L, McPherson K. A
prospective study of acute cerebrovascular disease in the community: the
Oxfordshire Community Stroke Project 1981-86. 1. Methodology, demography and
incident cases of first-ever stroke. Journal of Neurology, Neurosurgery, and
Psychiatry. 1988; 51(11): 1373-1380.
12. Sudlow CLM, Warlow CP. Comparable studies of the incidence of stroke and its
pathological types. Results from an international collaboration. Stroke. 1997;
28(3):491-499.
13. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and
natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;
337(8756): 1521-1526.
237
14. Hossman KA. Pathophysiology of cerebral infarction. 107-139. In: Vinken PJ,
Bruyn GW, Klawans HL, Toole JF, editors. Vascular Diseases Part 1. 1988. Elsevier
Science Publishers, Amsterdam, Netherlands.
15. Fieschi C, Di Piero V, Lenzi GL, Pantano P, Giubilei F, Buttinelli C, Carolei A.
Pathophysiology of ischemic brain disease. Stroke. 1990; 21(Suppl IV):IV-9-IV-l 1.
16. Neumann-Haefelin T, Kastrup A, de Crespigny A, Yenari MA, Ringer T, Sun
GH, Moseley ME. Serial MRI after transient focal cerebral ischemia in rats:
dynamics of tissue injury, blood-brain barrier damage, and edema formation. Stroke.
2000; 31 (8): 1965-1972.
17. Li F, Liu KF, Silva MD, Meng X, Gerriets T, Helmer KG, Fenstermacher JD,
Sotak CH, Fisher M. Acute postischemic renormalization of the apparent diffusion
coefficient of water is not associated with reversal of astrocytic swelling and
neuronal shrinkage in rats. American Journal of Neuroradiology. 2002; 23(2): 180-
188.
18. Li F, Silva MD, Liu KF, Helmer KG, Omae T, Fenstermacher JD, Sotak CH,
Fisher M. Secondary decline in apparent diffusion coefficient and neurological
outcomes after a short period of focal brain ischemia in rats. Annals ofNeurology.
2000; 48(2):236-244.
19. Li F, Liu KF, Silva MD, Omae T, Sotak CH, Fenstermacher JD, Fisher M, Hsu
CY, Lin W. Transient and permanent resolution of ischemic lesions on diffusion-
weighted imaging after brief periods of focal ischemia in rats: correlation with
histopathology. Stroke. 2000; 31(4):946-954.
20. Pulsinelli W. Pathophysiology of acute ischaemic stroke. Lancet. 1992;
339(8792):533-536.
21. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia - the ischemic
penumbra. Stroke. 1981; 12(6):723-725.
22. Sandercock P, Willems H. Medical treatment of acute ischaemic stroke. Lancet.
1992; 339(8792):537-539.
23. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute
ischaemic stroke. The Cochrane Database of Systematic Reviews. 2003;
3:CD000213.
24. Ribo M, Molina CA, Rovira A, Quintana M, Delgado P, Montaner J, Grive E,
Arenillas JF, Alvarez-Sabin J. Safety and Efficacy of Intravenous Tissue
Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using
238
Multimodal Transcranial Doppler/MRI Selection Protocol. Stroke. 2005; 36(3):602-
606.
25. Liberatore GT, Samson A, Bladin C, Schleuning WD, MedcalfRL. Vampire bat
salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that
does not promote neurodegeneration. Stroke. 2003; 34(2):537-543.
26. Kertesz A, Black SE, Nicholson L, Carr T. The sensitivity and specificity of
MRI in stroke. Neurology. 1987; 37(10): 1580-1585.
27. Fisher M, Sotak CH. Diffusion-weighted MR imaging and ischemic stroke.
American Journal ofNeuroradiology. 1992; 13(4): 1103-1105.
28. Moseley ME, Cohen Y, Mintorovitch J, Chileuitt L, Shimizu H, Kucharczyk J,
Wendland MF, Weinstein PR. Early detection of regional cerebral ischemia in cats:
comparison of diffusion- and T2-weighted MRI and spectroscopy. Magnetic
Resonance in Medicine. 1990; 14(2):330-346.
29. Gadian DG. NMR and its applications to living systems. 2nd edition. 1995.
Oxford University Press, Oxford, U.K.
30. Elster AD, Burdette JH. Questions & Answers in Magnetic Resonance Imaging.
2nd edition. 2001. Mosby, St. Louis, U.S.A.
31. Stejskal EO, Tanner JE. Spin Diffusion Measurements: Spin Echoes in the
Presence of a Time-Dependent Field Gradient. The Journal of Chemical Physics.
1965; 42(l):288-292.
32. Ulug AM, Beauchamp N, Jr., Bryan RN, van Zijl PC. Absolute quantitation of
diffusion constants in human stroke. Stroke. 1997; 28(3):483-490.
33. Calamante F, Thomas DL, Pell GS, Wiersma J, Turner R. Measuring cerebral
blood flow using magnetic resonance imaging techniques. Journal ofCerebral Blood
Flow & Metabolism. 1999; 19(7):701-735.
34. Meier P, Zierler KL. On the theory of the indicator-diluted method for
measurement of blood flow and volume. Journal of Applied Physiology. 1954;
6(12):731-744.
35. Zierler KL. Equations for measuring blood flow by external monitoring of
radioisotopes. Circulation Research. 1965; 16(4):309-321.
36. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High
resolution measurement of cerebral blood flow using intravascular tracer bolus
239
passages. Part I: Mathematical approach and statistical analysis. Magnetic Resonance
in Medicine. 1996; 36(5):715-725.
37. Calamante F, Gadian DG, Connelly A. Quantification of perfusion using bolus
tracking magnetic resonance imaging in stroke: assumptions, limitations, and
potential implications for clinical use. Stroke. 2002; 33(4): 1146-1151.
38. Singer OC, Sitzer M, du Mesnil de Rochemont R, Neumann-Haefelin T.
Practical limitations of acute stroke MRI due to patient-related problems. Neurology.
2004; 62(10): 1848-1849.
39. Hand PJ, Wardlaw JM, Rowat AM, Haisma JA, Lindley RI, Dennis MS. MR
brain imaging in patients with acute stroke - feasibility and patient-related
difficulties. Journal of Neurology, Neurosurgery, and Psychiatry. 2005;
76(11):1525-1527.
40. Fiebach JB, Schellinger PD, Gass A, Kucinski T, Siebler M, Villringer A, Olkers
P, Hirsch JG, Heiland S, Wilde P, Jansen O, Rother J, Hacke W, Sartor K (for the
Kompetenznetzwerk Schlaganfall B5). Stroke magnetic resonance imaging is
accurate in hyperacute intracerebral hemorrhage. A multicenter study on the validity
of stroke imaging. Stroke. 2004; 35(2):502-507.
41. von Kummer R. MRI: the new gold standard for detecting brain hemorrhage?
Stroke. 2002; 33(7): 1748-1749.
42. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V,
Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P.
Randomised double-blind placebo-controlled trial of thrombolytic therapy with
intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-
Australasian Acute Stroke Study Investigators. Lancet. 1998; 352(9136): 1245-1251.
43. The National Institute ofNeurological Disorders and Stroke rt-PA Stroke Study
Group. Tissue plasminogen activator for acute ischemic stroke. New England
Journal ofMedicine. 1995; 333(24): 1581-1587.
44. Arnould MC, Grandin CB, Peeters A, Cosnard G, Duprez TP. Comparison of
CT and three MR sequences for detecting and categorizing early (48 hours)
hemorrhagic transformation in hyperacute ischemic stroke. American Journal of
Neuroradiology. 2004; 25(6):939-944.
45. Bradley WG, Jr. MR appearance of hemorrhage in the brain. Radiology. 1993;
189(1): 15-26.
46. Kidwell CS, Chalela JA, Saver JL, Starkman S, Hill MD, Demchuk AM,
Butman JA, Patronas N, Alger JR, Latour LL, Luby ML, Baird AE, Leary MC,
240
Tremwel M, Ovbiagele B, Fredieu A, Suzuki S, Villablanca JP, Davis S, Dunn B,
Todd JW, Ezzeddine MA, Haymore J, Lynch JK, Davis L, Warach S. Comparison of
MRI and CT for detection of acute intracerebral hemorrhage. Journal of the
American Medical Association. 2004; 292(15): 1823-1830.
47. Patel MR, Edelman RR, Warach S. Detection of hyperacute primary
intraparenchymal hemorrhage by magnetic resonance imaging. Stroke. 1996;
27(12):2321-2324.
48. Schellinger PD, Jansen O, Fiebach JB, Hacke W, Sartor K. A standardized MRI
stroke protocol: comparison with CT in hyperacute intracerebral hemorrhage. Stroke.
1999; 30(4):765-768.
49. Yuh WTC, Crain MR, Loes DJ, Greene GM, Ryals TJ, Sato Y. MR imaging of
cerebral ischaemia: findings in the first 24 hours. American Journal of
Neuroradiology. 1991; 12(4):621-629.
50. Bryan RN, Willcott MR, Schneiders NJ. Nuclear magnetic resonance evaluation
of stroke. A preliminary report. Radiology. 1983; 149(1): 189-192.
51. Bryan RN, Levy LM, Whitlow WD, Killian JM, Preziosi TJ, Rosario JA.
Diagnosis of acute cerebral infarction: comparison of CT and MR imaging.
American Journal ofNeuroradiology. 1991; 12(4):611-620.
52. Gonzalez RG, Schaefer PW, Buonanno FS, Schwamm LH, Budzik RF, Rordorf
G, Wang B, Sorensen AG, Koroshetz WJ. Diffusion-weighted MR imaging:
diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset.
Radiology. 1999; 210(1): 155-162.
53. Le Bihan D, Breton D, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M.
MR imaging of intravoxel incoherent motions: application to diffusion and perfusion
in neurological disorders. Radiology. 1986; 161 (2):401-407.
54. Chien D, Buxton RB, Kwong KK, Brady TJ, Rosen BR. MR diffusion imaging
of the human brain. Journal of Computer Assisted Tomography. 1990; 14(4):514-
520.
55. Mintorovitch J, Moseley ME, Chileuitt L, Shimizu Ff, Cohen Y, Weinstein PR.
Comparison of diffusion- and T2-weighted MRI for the early detection of cerebral
ischemia and reperfusion in rats. Magnetic Resonance in Medicine. 1991; 18(1):39-
50.
56. Minematsu K, Li L, Fisher M, Sotak CH, Davis MA, Fiandaca MS. Diffusion-
weighted magnetic resonance imaging: rapid and quantitative detection of focal brain
ischemia. Neurology. 1992; 42(l):235-240.
241
57. Moseley ME, Kucharczyk J, Mintorovitch J, Cohen Y, Kurhanewicz J, Derugin
N, Asgari H, Norman D. Diffusion-weighted MR imaging of acute stroke:
correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in
cats. American Journal ofNeuroradiology. 1990; 11(3):423-429.
58. Moseley ME, Butts K, Yenari MA, Marks M, de Crespigny A. Clinical aspects
ofDWI. NMR in Biomedicine. 1995; 8(7-8):387-396.
59. Warach S, Chien D, Li W, Ronthal M, Edelman RR. Fast magnetic resonance
diffusion-weighted imaging of acute human stroke. Neurology. 1992; 42(9): 1717-
1723.
60. Lutsep HL, Albers GW, DeCrespigny A, Kamat GN, Marks MP, Moseley ME.
Clinical utility of diffusion-weighted magnetic resonance imaging in the assessment
of ischemic stroke. Annals ofNeurology. 1997; 41(5):574-580.
61. Warach S, Gaa J, Siewert B, Wielopolski P, Edelman RR. Acute human stroke
studied by whole brain echo planar diffusion-weighted magnetic resonance imaging.
Annals ofNeurology. 1995; 37(2):231-241.
62. Marks MP, de Crespigny A, Lentz D, Enzmann DR, Albers GW, Moseley ME.
Acute and chronic stroke: navigated spin-echo diffusion-weighted MR imaging.
Radiology. 1996; 199(2):403-408.
63. Albers GW, Lansberg MG, Norbash AM, Tong DC, O'Brien MW, Woolfenden
AR, Marks MP, Moseley ME. Yield of diffusion-weighted MRI for detection of
potentially relevant findings in stroke patients. Neurology. 2000; 54(8): 1562-1567.
64. Lansberg MG, Albers GW, Beaulieu C, Marks MP. Comparison of diffusion-
weighted MRI and CT in acute stroke. Neurology. 2000; 54(8): 1557-1561.
65. Fiebach JB, Schellinger PD, Jansen O, Meyer M, Wilde P, Bender J, Schramm
P, Juttler E, Oehler J, Hartmann M, Hahnel S, Knauth M, Hacke W, Sartor K. CT
and diffusion-weighted MR imaging in randomized order: diffusion- weighted
imaging results in higher accuracy and lower interrater variability in the diagnosis of
hyperacute ischemic stroke. Stroke. 2002; 33(9):2206-2210.
66. Barber PA, Darby DG, Desmond PM, Gerraty RP, Yang Q, Li T, Jolley D,
Donnan GA, Tress BM, Davis SM. Identification of major ischemic change:
Diffusion-weighted imaging versus computed tomography. Stroke. 1999;
30(10):2059-2065.
67. Saur D, Kucinski T, Grzyska U, Eckert B, Eggers C, Niesen W, Schoder V,
Zeumer H, Weiller C, Rother J. Sensitivity and interrater agreement of CT and
242
diffusion-weighted MR imaging in hyperacute stroke. American Journal of
Neuroradiology. 2003; 24(5):878-885.
68. Welch KM, Windham J, Knight RA, Nagesh V, Hugg JW, Jacobs M, Peck D,
Booker P, Dereski MO, Levine SR. A model to predict the histopathology of human
stroke using diffusion and T2-weighted magnetic resonance imaging. Stroke. 1995;
26(11): 1983-1989.
69. Chien D, Kwong KK, Gress DR, Buonanno FS, Buxton RB, Rosen BR. MR
diffusion imaging of cerebral infarction in humans. American Journal of
Neuroradiology. 1992; 13(4): 1097-1102.
70. Schlaug G, Siewert B, Benfield A, Edelman RR, Warach S. Time course of the
apparent diffusion coefficient (ADC) abnormality in human stroke. Neurology. 1997;
49(1): 113-119.
71. Burdette JH, Ricci PE, Petitti N, Elster AD. Cerebral infarction: time course of
signal intensity changes on diffusion-weighted MR images. American Journal of
Roentgenology. 1998; 171(3):791-795.
72. Ahlhelm F, Schneider G, Backens M, Reith W, Hagen T. Time course of the
apparent diffusion coefficient after cerebral infarction. European Radiology. 2002;
12(9):2322-2329.
73. Copen WA, Schwamm LH, Gonzalez RG, Wu O, Harmath CB, Schaefer PW,
Koroshetz WJ, Sorensen AG. Ischemic stroke: Effects of etiology and patient age on
the time course of the core apparent diffusion coefficient. Radiology. 2001;
221(l):27-34.
74. Eastwood JD, Engelter ST, MacFall JF, DeLong DM, Provenzale JM.
Quantitative assessment of the time course of infarct signal intensity on diffusion-
weighted images. American Journal ofNeuroradiology. 2003; 24(4):680-687.
75. Helenius J, Soinne L, Salonen O, Kaste M, Tatlisumak T. Leukoaraiosis,
ischemic stroke, and normal white matter on diffusion- weighted MRI. Stroke. 2002;
33(l):45-50.
76. Lansberg MG, Thijs VN, O'Brien MW, Ali JO, de Crespigny AJ, Tong DC,
Moseley ME, Albers GW. Evolution of apparent diffusion coefficient diffusion-
weighted, and T2-weighted signal intensity of acute stroke. American Journal of
Neuroradiology. 2001; 22(4):637-644.
77. Schwamm LEI, Koroshetz WJ, Sorensen G, Wang B, Copen WA. Time course
of lesion development in patients with acute stroke. Serial diffusion- and
243
hemodynamic-weighted magnetic resonance imaging. Stroke. 1998; 29(11 ):2268-
2276.
78. Yang Q, Tress BM, Barber PA, Desmond PM, Darby DG, Gerraty RP, Li T,
Davis SM. Serial study of apparent diffusion coefficient and anisotropy in patients
with acute stroke. Stroke. 1999; 30(11):2382-2390.
79. Burdette JH, Elster AD, Ricci PE. Acute cerebral infarction: Quantification of
spin-density and T2 shine-through phenomena on diffusion-weighted MR images.
Radiology. 1999; 212(2):333-339.
80. Fiehler J, Knab R, Reichenbach JR, Fitzek C, Weiller C, Rother J. Apparent
diffusion coefficient decreases and magnetic resonance imaging perfusion
parameters are associated in ischemic tissue of acute stroke patients. Journal of
Cerebral Blood Flow & Metabolism. 2004; 21(5):577-584.
81. Grandin CB, Duprez TP, Smith AM, Mataigne F, Peeters A, Oppenheim C,
Cosnard G. Usefulness of magnetic resonance-derived quantitative measurements of
cerebral blood flow and volume in prediction of infarct growth in hyperacute stroke.
Stroke. 2001; 32(5): 1147-1
82. Heiss WD, Sobesky J, Hesselmann V. Identifying thresholds for penumbra and
irreversible tissue damage. Stroke. 2004; 35(11 Suppl l):2671-2674.
83. Karonen JO, Vanninen RL, Liu Y, Ostergaard L, Kuikka JT. Combined
diffusion and perfusion MRI with correlation to single-photon emission CT in acute
ischaemic stroke. Stroke. 1999; 30(8): 1583-1590.
84. Liu Y, Karonen JO, Vanninen RL, Ostergaard L, Roivainen R, Nuutinen J,
Perkio J, Kononen M, Hamalainen A, Vanninen EJ, Soimakallio S, Kuikka JT,
Aronen HJ. Cerebral hemodynamics in human acute ischemic stroke: a study with
diffusion- and perfusion-weighted magnetic resonance imaging and SPECT. Journal
ofCerebral Blood Flow & Metabolism. 2000; 20(6):910-920.
85. Neumann-Haefelin T, Wittsack H-J, Wenserski F, Siebler M, Seitz RJ.
Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute
stroke. Stroke. 1999; 30(8): 1591-1597.
86. Perkio J, Soinne L, Ostergaard L, Helenius J, Kangasmaki A, Martinkauppi S,
Salonen O, Savolainen S, Kaste M, Tatlisumak T, Aronen HJ. Abnormal Intravoxel
Cerebral Blood Flow Heterogeneity in Human Ischemic Stroke Determined by
Dynamic Susceptibility Contrast Magnetic Resonance Imaging. Stroke. 2004;
36(l):44-49.
244
87. Rordorf G, Koroshetz WJ, Copen WA, Cramer SC, Schaefer PW, Budzik RF.
Regional ischaemia and ischemic injury in patients with acute middle cerebral artery
stroke as defined by early diffusion-weighted and perfusion-weighted imaging.
Stroke. 1998; 29(5):939-943.
88. Schaefer PW, Ozsunar Y, He J, Hamberg LM, Hunter GJ, Sorensen AG,
Koroshetz WJ, Gonzalez RG. Assessing Tissue Viability with MR Diffusion and
Perfusion Imaging. American Journal ofNeuroradiology. 2003; 24(3):436-443.
89. Schlaug G, Benfield A, Baird AE, Siewert B, Lovblad KO, Parker RA, Edelman
RR, Warach S. The ischemic penumbra: operationally defined by diffusion and
perfusion MRI. Neurology. 1999; 53(7): 1528-1537.
90. Lovblad KO, Baird AE, Schlaug G, Benfield A, Siewert B, Voetsch B, Connor
A, Burzynski C, Edelman RR, Warach S. Ischemic lesion volumes in acute stroke by
diffusion-weighted magnetic resonance imaging correlate with clinical outcome.
Annals ofNeurology. 1997; 42(2): 164-170.
91. Baird AE, Lovblad KO, Dashe JF, Connor A, Burzynski C, Schlaug GS,
Staroselskaya I, Edelman RR, Warach S. Clinical correlations of diffusion and
perfusion lesion volumes in acute ischemic stroke. Cerebrovascular Diseases. 2000;
10(6):441-448.
92. Pereira AC, Doyle VL, Clifton A, Howe FA, Griffiths JR, Brown MM. The
transient disappearance of cerebral infarction on T2 weighted MRI. Clinical
Radiology. 2000; 55(9):725-727.
93. O'Brien P, Sellar RJ, Wardlaw JM. Fogging on T2-weighted MR after acute
ischaemic stroke: how often might this occur and what are the implications?
Neuroradiology. 2004; 46(8):635-641.
94. Kelly PJ, Hedley-Whyte ET, Primavera J, He J, Gonzalez RG. Diffusion MRI in
ischemic stroke compared to pathologically verified infarction. Neurology. 2001;
56(7):914-920.
95. Knight RA, Dereski MO, Helpern JA, Ordidge RJ, Chopp M. Magnetic
resonance imaging assessment of evolving focal cerebral ischemia. Comparison with
histopathology in rats. Stroke. 1994; 25(6): 1252-1261.
96. Baird AE, Dambrosia J, Janket S, Eichbaum Q, Chaves C, Silver B, Barber PA,
Parsons M, Darby D, Davis S, Caplan LR, Edelman RE, Warach S. A three-item
scale for the early prediction of stroke recovery. Lancet. 2001; 357(9274):2095-2099.
245
97. van Everdingen KJ, van der Grond J, Kappelle LJ, Ramos LM, Mali WP.
Diffusion-weighted magnetic resonance imaging in acute stroke. Stroke. 1998;
29(9): 1783-1790.
98. Warach S. Use of diffusion and perfusion magnetic resonance imaging as a tool
in acute stroke clinical trials. Current Controlled Trials in Cardiovascular Medicine.
2001; 2(l):38-44.
99. Barber PA, Darby DG, Desmond PM, Yang Q, Gerraty RP, Jolley D. Prediction
of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI.
Neurology. 1998; 51(2):418-426.
100. Baird AE, Benfield A, Schlaug G, Siewert B, Lovblad KO, Edelman RR.
Enlargement of human cerebral ischemic lesion volumes measured by diffusion-
weighted magnetic resonance imaging. Annals ofNeurology. 1997; 41(5):581-589.
101. Beaulieu C, de Crespigny A, Tong DC, Moseley ME, Albers GW, Marks MP.
Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke:
Evolution of lesion volume and correlation with clinical outcome. Annals of
Neurology. 1999; 46(4):568-578.
102. Kluytmans M, van Everdingen KJ, Kappelle LJ, Ramos LM, Viergever MA,
van der Grond J. Prognostic value of perfusion- and diffusion-weighted MR imaging
in first 3 days of stroke. European Radiology. 2000; 10(9): 1434-1441.
103. Wintermark M, Reichhart M, Cuisenaire O, Maeder P, Thiran JP, Schnyder P,
Bogousslavsky J, Meuli R. Comparison of admission perfusion computed
tomography and qualitative diffusion- and perfusion-weighted magnetic resonance
imaging in acute stroke patients. Stroke. 2002; 33(8):2025-2031.
104. Thijs VN, Adami A, Neumann-Haefelin T, Moseley ME, Marks MP, Albers
GW. Relationship between severity of MR perfusion deficit and DWI lesion
evolution. Neurology. 2001; 57(7): 1205-1211.
105. Ueda T, Yuh WT, Maley JE, Quets JP, Hahn PY, Magnotta VA. Outcome of
acute ischemic lesions evaluated by diffusion and perfusion MR imaging. American
Journal ofNeuroradiology. 1999; 20(6):983-989.
106. Rose SE, Janke AL, Griffin M, Finnigan S, Chalk JB. Improved prediction of
final infarct volume using bolus delay-corrected perfusion-weighted MRI:
implications for the ischemic penumbra. Stroke. 2004; 35(11):2466-2471.
107. Rana AK, Wardlaw JM, Armitage PA, Bastin ME. Apparent diffusion
coefficient (ADC) measurements may be more reliable and reproducible than lesion
246
volume on diffusion-weighted images from patients with acute ischaemic stroke -
implications for study design. Magnetic Resonance Imaging. 2003; 21(6):617-624.
108. Girot M, Leclerc X, Gauvrit JY, Verdelho A, Pruvo JP, Leys D. Cerebral
magnetic resonance imaging within 6 hours of stroke onset: inter- and intra-observer
reproducibility. Cerebrovascular Diseases. 2003; 16(2): 122-127.
109. Sorensen AG, Buonanno FS, Gonzalez RG, Schwamm LH, Lev MH, Huang-
Hellinger FR. Hyperacute stroke: evaluation with combined multisection diffusion-
weighted and hemodynamically weighted echo-planar MR imaging. Radiology.
1996; 199(2):391 -401.
110. Neumann-Haefelin T, Wittsack HJ, Fink GR, Wenserski F, Li TQ, Seitz RJ,
Siebler RJ, Modder U, Freund HJ. Diffusion- and perfusion-weighted MRI: influence
of severe carotid artery stenosis on the DWI/PWI mismatch in acute stroke. Stroke.
2000; 31 (6): 1311-1317.
111. Wittsack HJ, Ritzl A, Fink GR, Wenserski F, Siebler M, Seitz RJ, Modder U,
Freund HJ. MR imaging in acute stroke: diffusion-weighted and perfusion imaging
parameters for predicting infarct size. Radiology. 2002; 222(2):397-403.
112. Tong DC, Yenari MA, Albers GW, O'Brien M, Marks MP, Moseley ME.
Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute
(<6.5 hour) ischemic stroke. Neurology. 1998; 50(4):864-870.
113. Guadagno JV, Warburton EA, Jones PS, Fryer TD, Day DJ, Gillard JH,
Carpenter TA, Aigbirhio FI, Price CJ, Baron JC. The Diffusion-Weighted Lesion in
Acute Stroke: Heterogeneous Patterns of Flow/Metabolism Uncoupling as Assessed
by Quantitative Positron Emission Tomography. Cerebrovascular Diseases. 2005;
19(4):239-246.
114. Perkins CJ, Kahya E, Roque CT, Roche PE, Newman GC. Fluid-attenuated
inversion recovery and diffusion- and perfusion-weighted MRI abnormalities in 117
consecutive patients with stroke symptoms. Stroke. 2001; 32(12):2774-2781.
115. Sorensen AG, Copen WA, Ostergaard L, Buonanno FS, Gonzalez RG, Rordorf
G, Rosen BR, Schwamm LH, Weisskoff RM, Koroshetz WJ. Hyperacute stroke:
simultaneous measurement of relative cerebral blood volume, relative cerebral blood
flow, and mean tissue transit time. Radiology. 1999; 210(2):519-527.
116. Wu O, Koroshetz WJ, Ostergaard L, Buonanno FS, Copen WA, Gonzalez RG,
Rordorf G, Rosen BR, Schwamm LH, Weisskoff RM, Sorensen AG. Predicting
tissue outcome in acute human cerebral ischemia using combined diffusion- and
perfusion-weighted MR imaging. Stroke. 2001; 32(4):933-942.
247
117. Jacobs MA, Mitsias P, Soltanian-Zadeh H, Santhakumar S, Ghanei A,
Hammond R, Peck DJ, Chopp M, Patel S. Multiparametric MRI tissue
characterization in clinical stroke with correlation to clinical outcome: part 2. Stroke.
2001; 32(4):950-957.
118. Mitsias PD, Jacobs MA, Hammoud R, Pasnoor M, Santhakumar S,
Papamitsakis NIH, Soltanian-Zadeh H, Lu M, Chopp M, Patel SC. Multiparametric
MRI ISODATA ischemic lesion analysis. Correlation with the clinical neurological
deficit and single-parameter MRI techniques. Stroke. 2002; 33(12):2839-2844.
119. Bykowski JL, Latour LL, Warach S. More accurate identification of reversible
ischemic injury in human stroke by cerebrospinal fluid suppressed diffusion-
weighted imaging. Stroke. 2004; 35(5): 1100-1106.
120. Nagesh V, Welch KM, Windham JP, Patel S, Levine SR, Hearshen D, Peck D,
Robbins K, D'Olhaberriague L, Soltanian-Zadeh H, Boska MD. Time course of
ADCw changes in ischemic stroke: beyond the human eye! Stroke. 1998;
29(9): 1778-1782.
121. Marks MP, Tong DC, Beaulieu C, Albers GW, de Crespigny A, Moseley ME.
Evaluation of early reperfusion and IV tPA therapy using diffusion- and perfusion-
weighted MRI. Neurology. 1999; 52(9): 1792-1798.
122. Bilgili Y, Unal B. Effect of region of interest on interobserver variance in
apparent diffusion coefficient measures. American Journal ofNeuroradiology. 2004;
25(1): 108-111.
123. Desmond PM, Lovell AC, Rawlinson AA, Parsons MW, Barber PA, Yang Q,
Li T, Darby DG, Gerraty RP, Davis SM, Tress BM. The value of apparent diffusion
coefficient maps in early cerebral ischemia. American Journal ofNeuroradiology.
2001; 22(7): 1260-1267.
124. Koroshetz WJ, Gonzales RG. Imaging stroke in progress: magnetic resonance
advances but computed tomography is poised for counterattack. Annals of
Neurology. 1999; 46(4):556-558.
125. Guadagno JV, Warburton EA, Aigbirhio FI, Smielewski P, Fryer TD, Harding
S, Price CJ, Gillard JH, Carpenter TA, Baron JC. Does the acute diffusion-weighted
imaging lesion represent penumbra as well as core? A combined quantitative
PET/MRI voxel-based study. Journal ofCerebral Blood Flow & Metabolism. 2004;
24(11): 1249-1254.
126. Coutts SB, Simon JE, Tomanek AI, Barber PA, Chan J, Hudon ME, Mitchell
R, Frayne R, Eliasziw M, Buchan AM, Demchuk AM. Reliability of assessing
percentage of diffusion-perfusion mismatch. Stroke. 2003; 34(7): 1681-1685.
248
127. O'Brien MD. Ischemic cerebral edema. A review. Stroke. 1979; 10(6):623-628.
128. Loubinoux I, Volk A, Borredon J, Guirimand S, Tiffon B, Seylaz J, Meric P.
Spreading of vasogenic edema and cytotoxic edema assessed by quantitative
diffusion and T2 magnetic resonance imaging. Stroke. 1997; 28(2):419-426.
129. Wardlaw JM, Dennis MS, Lindley RI, Warlow CP, Sandercock PAG, Sellar R.
Does early reperfusion of a cerebral infarct influence cerebral infarct swelling in the
acute stage or the final clinical outcome? Cerebrovascular Diseases. 1993; 3(2):86-
93.
130. Engelter ST, Provenzale JM, Petrella JR, DeLong DM, MacFall JR. The effect
of aging on the apparent diffusion coefficient of normal-appearing white matter.
American Journal ofRoentgenology. 2000; 175(2):425-430.
131. Gideon P, Thomsen C, Henriksen O. Increased self-diffusion of brain water in
normal aging. Journal ofMagnetic Resonance Imaging. 1994; 4(2): 185-188.
132. Mukherjee P, Bahn MM, McKinstry RC, Shimony JS, Cull TS, Akbudak E,
Snyder AZ, Conturo TE. Differences between gray matter and white matter water
diffusion in stroke: Diffusion-tensor MR imaging in 12 patients. Radiology. 2000;
215(1):211-220.
133. Munoz-Maniega S, Bastin ME, Armitage PA, Farrall AJ, Hand PJ, Rivers CS,
Wardlaw JM. Temporal evolution of water diffusion parameters is different in grey
and white matter in human ischaemic stroke. Journal ofNeurology, Neurosurgery,
and Psychiatry. 2004; 75(12): 1714-1718.
134. Warach S, Dashe JF, Edelman RR. Clinical outcome in ischaemic stroke
predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a
preliminary analysis. Journal of Cerebral Blood Flow & Metabolism. 1996;
16(1 ):53-59.
135. Schellinger PD, Fiebach JB, Jansen O, Ringleb PA, Mohr A, Steiner T, Heiland
S, Schwab S, Pohlers O, Ryssel H, Orakcioglu B, Sartor K, Hacke W. Stroke
magnetic resonance imaging within 6 hours after onset of hyperacute cerebral
ischemia. Annals ofNeurology. 2001; 49(4):460-469.
136. Wardlaw JM, Keir SL, Bastin ME, Armitage PA, Rana AK. Is diffusion
imaging appearance an independent predictor of outcome after ischaemic stroke?
Neurology. 2002; 59(9): 1381-1387.
137. Zivin JA. Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch
on MRI Can Now Be Used to Select Patients for Recombinant Tissue Plasminogen
Activator Beyond 3 Hours. Con. Stroke. 2005; 36(5): 1099-1100.
249
138. Rohl L, Geday J, Ostergaard L, Simonsen CZ, Vestergaard-Poulsen P,
Andersen G, Le Bihan D, Gyldensted C. Correlation between diffusion- and
perfusion-weighted MRI and neurological deficit measured by the Scandinavian
Stroke Scale and Barthel Index in hyperacute subcortical stroke (< or = 6 hours).
Cerebrovascular Diseases. 2001; 12(3):203-213.
139. Weber J, Mattle HP, Heid O, Remonda L, Schroth G. Diffusion-weighted
imaging in ischaemic stroke: a follow-up study. Neuroradiology. 2000; 42(3): 184-
191.
140. Mancuso A, Nimura T, Weinstein PR. Prediction of delayed ischemic injury
with diffusion-weighted MRI following temporary middle cerebral artery occlusion
in rats. Brain Research. 1997; 760(1-2):42-51.
141. Dijkhuizen RM, Knollema S, van der Worp HB, Ter Horst GJ, De Wildt DJ,
Berkelbach van der Sprenkel JW, Tulleken KA, Nicolay K. Dynamics of cerebral
tissue injury and perfusion after temporary hypoxia-ischemia in the rat: evidence for
region-specific sensitivity and delayed damage. Stroke. 1998; 29(3):695-704.
142. Fiehler J, Foth M, Kucinski T, Knab R, von Bezold M, Weiller C, Zeumer H,
Rother J. Severe ADC decreases do not predict irreversible tissue damage in humans.
Stroke. 2002; 33(l):79-86.
143. Barber PA, Parsons MW, Desmond PM, Bennett DA, Donnan GA, Tress BM,
Davis SM. The use of PWI and DWI measures in the design of "proof-of-concept"
stroke trials. Journal ofNeuroimaging. 2004; 14(2): 123-132.
144. Rose SE, Chalk JB, Griffin MP, Janke AL, Chen F, McLachan GJ, Peel D,
Zelaya FO, Markus HS, Jones DK, Simmons A, O'Sullivan M, Jarosz JM, Strugnell
W, Doddrell DM, Semple J. MRI based diffusion and perfusion predictive model to
estimate stroke evolution. Magnetic Resonance Imaging. 2001; 19(8): 1043-1053.
145. Davis SM, Donnan GA. Using Mismatch on MRI to Select Thrombolytic
Responders. An Attractive Hypothesis Awaiting Confirmation. Stroke. 2005;
36(5):1100-1101.
146. Sobesky J, Zaro WO, Lehnhardt FG, Hesselmann V, Neveling M, Jacobs A,
Heiss WD. Does the Mismatch Match the Penumbra? Magnetic Resonance Imaging
and Positron Emission Tomography in Early Ischemic Stroke. Stroke. 2005;
36(5):980-985.
147. Parsons MW, Yang Q, Barber PA, Darby DG, Desmond PM, Gerraty RP, Tress
BM, Davis SM. Perfusion magnetic resonance imaging maps in hyperacute stroke:
relative cerebral blood flow most accurately identifies tissue destined to infarct.
Stroke. 2001; 32(7): 1581-1587.
250
148. Schellinger PD, Fiebach JB. Perfusion-Weighted Imaging/Diffusion-Weighted
Imaging Mismatch on MRI Can Now Be Used to Select Patients for Recombinant
Tissue Plasminogen Activator Beyond 3 Hours. Pro. Stroke. 2005; 36(5): 1098-1101.
149. Butcher K, Parsons M, Baird T, Barber A, Donnan G, Desmond P, Tress B,
Davis S. Perfusion thresholds in acute stroke thrombolysis. Stroke. 2003;
34(9):2159-2164.
150. Rohl L, Ostergaard L, Simonsen CZ, Vestergaard-Poulsen P, Andersen G,
Sakoh M, Le Bihan D, Gyldensted C. Viability thresholds of ischemic penumbra of
hyperacute stroke defined by perfusion-weighted MRI and apparent diffusion
coefficient. Stroke. 2001; 32(5):1140-1146.
151. Barber PA, Davis SM, Darby DG, Desmond PM, Gerraty RP, Yang Q, Jolley,
D, Donnan GA, Tress BM. Absent middle cerebral artery flow predicts the presence
and evolution of the ischemic penumbra. Neurology. 1999; 52(6): 1125-1132.
152. Barnett HJM, Mohr JP, Stein BM, Yatsu FM. Stroke. Pathophysiology,
Diagnosis, and Management. 3rd edition. 1998. Churchill Livingstone, Philadelphia,
U.S.A.
153. Miiller TB, Haraldseth O, Jones RA, Sebastiani G, Godtliebsen F, Lindboe CF,
Unsgard G. Combined perfusion and diffusion-weighted magnetic resonance
imaging in a rat model of reversible middle cerebral artery occlusion. Stroke. 1995;
26(3):451-457.
154. Hasegawa Y, Fisher M, Latour LL, Dardzinski BJ, Sotak CH. MRI diffusion
mapping of reversible and irreversible ischemic injury in focal brain ischemia.
Neurology. 1994; 44(8):1484-1490.
155. Rivers CS, Wardlaw JM. What has diffusion imaging in animals told us about
diffusion imaging in patients with ischaemic stroke? Cerebrovascular Diseases.
2005; 19(5):328-336.
156. Sandercock PAG, Algra A, Anderson C, Bath P, Bereczki D, Berge E, Bowen
A, Candelise L, Forster A, Fraser HW, Hankey G, Langhorne P, Lewis S, Mclnnes
A, Prasad K, Thomas B. Stroke Group. About the Cochrane Collaboration
(Collaborative Review Groups (CRGs)). The Cochrane Library. 2005; 2:STROKE.
157. Paul R, Zhang ZG, Eliceiri BP, Jiang Q, Boccia AD, Zhang RL, Chopp M,
Cheresh DA. Src deficiency or blockade of Src activity in mice provides cerebral
protection following stroke. Nature Medicine. 2001; 7(2):222-227.
251
158. Xue R, Sawada M, Goto S, Hurn PD, Traystman RJ, van Zijl PC, Mori S.
Rapid three-dimensional diffusion MRI facilitates the study of acute stroke in mice.
Magnetic Resonance in Medicine. 2001; 46(1): 183-188.
159. Shi J, Bui JD, Yang SH, He Z, Lucas TH, Buckley DL, Blackband SJ, King
MA, Day AL, Simpkins JW. Estrogens decrease reperfusion-associated cortical
ischemic damage: an MRI analysis in a transient focal ischemia model. Stroke. 2001;
32(4):987-992.
160. Bebarta V, Luyten D, Heard K. Emergency medicine animal research: Does use
of randomization and blinding affect the results? Academic Emergency Medicine.
2003; 10(6):684-687.
161. Jacobs MA, Knight RA, Soltanian-Zadeh H, Zheng ZG, Goussev AV, Peck DJ,
Windham JP, Chopp M. Unsupervised segmentation of multiparameter MRI in
experimental cerebral ischemia with comparison to T2, diffusion, and ADC MRI
parameters and histopathological validation. Journal of Magnetic Resonance
Imaging. 2000; 11(4):425-437.
162. Ringer TM, Neumann-Haefelin T, Sobel RA, Moseley ME, Yenari MA.
Reversal of early diffusion-weighted magnetic resonance imaging abnormalities does
not necessarily reflect tissue salvage in experimental cerebral ischemia. Stroke. 2001;
32(10):2362-2369.
163. Detre JA, Zager EL, Alsop DC, Harris VA, Welsh FA. Correlation of diffusion
MRI and heat shock protein in a rat embolic stroke model. Journal of the
Neurological Sciences. 1997; 148(2): 163-169.
164. Grohn OH, Lukkarinen JA, Silvennoinen MJ, Pitkanen A, van Zijl PC,
Kauppinen RA. Quantitative magnetic resonance imaging assessment of cerebral
ischemia in rat using on-resonance T(l) in the rotating frame. Magnetic Resonance in
Medicine. 1999; 42(2):268-276.
165. Kokubo Y, Matson GB, Liu J, Mancuso A, Kayama T, Sharp FR, Weinstein
PR. Correlation between changes in apparent diffusion coefficient and induction of
heat shock protein, cell-specific injury marker expression, and protein synthesis
reduction on diffusion-weighted magnetic resonance images after temporary focal
cerebral ischemia in rats. Journal ofNeurosurgery. 2002; 96(6): 1084-1093.
166. Liu KF, Li F, Tatlisumak T, Garcia JH, Sotak CH, Fisher M, Fenstermacher
JD. Regional variations in the apparent diffusion coefficient and the intracellular
distribution of water in rat brain during acute focal ischemia. Stroke. 2001;
32(8): 1897-1905.
252
167. Miiller TB, Haraldseth O, Jones RA, Sebastiani G, Lindboe CF, Unsgard G,
Oksendal AN. Perfusion and diffusion-weighted MR imaging for in vivo evaluation
of treatment with U74389G in a rat stroke model. Stroke. 1995; 26(8): 1453-1458.
168. Sutherland GR, Perron JT, Kozlowski P, McCarthy DJ. AR-R15896AR
reduces cerebral infarction volumes after focal ischemia in cats. Neurosurgery. 2000;
46(3):710-719.
169. Keir SL, Wardlaw JM. Systematic review of diffusion and perfusion imaging in
acute ischaemic stroke. Stroke. 2000; 31(11):2723-2731.
170. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations
for standards regarding preclinical neuroprotective and restorative drug development.
Stroke. 1999; 30(12):2752-2758.
171. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG. Measurements of
acute cerebral infarction: a clinical examination scale. Stroke. 1989; 20(7):864-870.
172. Rankin J. Cerebral vascular accidents in patients over the age of 60. II.
Prognosis. Scottish Medical Journal. 1957; 2(5):200-215.
173. Bonita R, Beaglehole R. Recovery ofmotor function after stroke. Stroke. 1988;
19(12): 1497-1500.
174. Basser PJ, Pierpaoli C. A simplified method to measure the diffusion tensor
from seven MR images. Magnetic Resonance in Medicine. 1998; 39(6):928-934.
175. Jenkinson M, Smith S. A global optimisation method for robust affine
registration of brain images. Medical Image Analysis. 2001; 5(2): 143-156.
176. Basser PJ, Mattiello J, LeBihan D. Estimation of the effective self-diffusion
tensor from the NMR spin echo. Journal ofMagnetic Resonance Series B. 1994;
103(3):247-254.
177. Ostergaard L, Sorensen AG, Kwong KK, WeisskoffRM, Gyldensted C, Rosen
BR. High resolution measurement of cerebral blood flow using intravascular tracer
bolus passages. Part II: Experimental comparison and preliminary results. Magnetic
Resonance in Medicine. 1996; 36(5):726-736.
178. Oppenheim C, Grandin C, Samson Y, Smith A, Duprez T, Marsault C, Cosnard
G. Is there an apparent diffusion coefficient threshold in predicting tissue viability in
hyperacute stroke? Stroke. 2001; 32(11):2486-2491.
179. Smith AM, Grandin CB, Duprez T, Mataigne F, Cosnard G. Whole brain
quantitative CBF, CBV, and MTT measurements using MRI bolus tracking:
253
implementation and application to data acquired from hyperacute stroke patients.
Journal ofMagnetic Resonance Imaging. 2000; 12(3):400-410.
180. Hacke W, Warach S. Diffusion-weighted MRI as an evolving standard of care
in acute stroke. Neurology. 2000; 54(8): 1548-1549.
181. Bastin ME, Rana AK, Wardlaw JM, Armitage PA, Keir SL. A study of
apparent diffusion coefficient of grey and white matter in human ischaemic stroke.
Neuroreport. 2000; 11(13):2867-2874.
182. Baird AE, Warach S. Magnetic resonance imaging of acute stroke. Journal of
Cerebral Blood Flow & Metabolism. 1998; 18(6):583-609.
183. Kidwell CS, Alger JR, Saver JL. Beyond mismatch: evolving paradigms in
imaging the ischemic penumbra with multimodal magnetic resonance imaging.
Stroke. 2003; 34(11):2729-2735.
184. Lovblad KO, Wetzel SG, Somon T, Wilhelm K, Mehdizade A, Kelekis A, El
Koussy M, El Tatawy S, Bishof M, Schroth G, Perrig S, Lazeyras F, Sztajzel R,
Terrier F, Rufenacht D, Delavelle J. Diffusion-weighted MRI in cortical ischaemia.
Neuroradiology. 2004; 46(3): 175-182.
185. Sorensen AG, Wu O, Copen WA, Davis TL, Koroshetz WJ, Reese T, Rosen
BR. Human acute cerebral ischaemia: detection of changes in water diffusion
anisotropy by using MR imaging. Radiology. 1999; 212(3):785-792.
186. Bland JM, Altman DG. Statistical methods for assessing agreement between
two methods of clinical measurement. Lancet. 1986; 1 (8476):307-310.
187. Perkins DO, Wyatt RJ, Bartko JJ. Penny-Wise and Pound-Foolish: The Impact
of Measurement Error on Sample Size Requirements in Clinical Trials. Biological
Psychiatry. 2000; 47(8):762-766.
188. Zivin JA, Holloway RG. Weighing the evidence on DWI: caveat emptor.
Neurology. 2000; 54(8): 1552.
189. Shenkin SD, Bastin ME, MacGillivray TJ, Deary IJ, Starr JM, Wardlaw JM.
Childhood and current cognitive function in healthy 80-year-olds: a DT-MRI study.
Neuroreport. 2003; 14(3):345-349.
190. Davis SM, Donnan GA. Advances in penumbra imaging with MR.
Cerebrovascular Diseases. 2004; 17(Suppl 3):23-27.
191. Karonen JO, Liu Y, Vanninen RL, Ostergaard L, Kaarina Partanen PL, Vainio
PA, Vanninen EJ, Nuutinen J, Roivainen R, Soimakallio S, Kuikka JT, Aronen HJ.
254
Combined perfusion- and diffusion-weighted MR imaging in acute ischemic stroke
during the 1st week: a longitudinal study. Radiology. 2000; 217(3):886-894.
192. Teng MM, Cheng HC, Kao YH, Hsu LC, Yeh TC, Hung CS, Wong WJ, Hu
HH, Chiang JH, Chang CY. MR perfusion studies of brain for patients with
unilateral carotid stenosis or occlusion: evaluation of maps of "time to peak" and
"percentage of baseline at peak". Journal of Computer Assisted Tomography. 2001;
25(1): 121-125.
193. Parsons MW, Barber PA, Chalk J, Darby DG, Rose S, Desmond PM, Gerraty
RP, Tress BM, Wright PM, Donnan GA, Davis SM. Diffusion- and perfusion-
weighted MRI response to thrombolysis in stroke. Annals of Neurology. 2002;
51(l):28-37.
194. Simonsen CZ, Rohl L, Vestergaard-Poulsen P, Gyldensted C, Andersen G,
Ostergaard L. Final infarct size after acute stroke: prediction with flow heterogeneity.
Radiology. 2002; 225(l):269-275.
195. Butcher KS, Parsons M, Macgregor L, Barber PA, Chalk J, Bladin C, Levi C,
Kimber T, Schultz D, Fink J, Tress B, Donnan G, Davis S. Refining the Perfusion-
Diffusion Mismatch Hypothesis. Stroke. 2005; 36(6): 1153-1159.
196. Hacke W, Albers G, A1 Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M,
Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S. The Desmoteplase
in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute
stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005; 36(1 ):66-73.
197. Barber PA, Davis SM, Infeld B, Baird AE, Donnan GA, Jolley D, Lichtenstein
M. Spontaneous reperfusion after ischemic stroke is associated with improved
outcome. Stroke. 1998; 29(12):2522-2528.
198. Vang C, Dunbabin D, Kilpatrick D. Effects of spontaneous recanalization on
functional and electrophysiological recovery in acute ischemic stroke. Stroke. 1999;
30(10):2119-2125.
199. Jansen O, Schellinger PD, Fiebach JB, Hacke W, Sartor K. Early recanalisation
in acute ischaemic stroke saves tissue at risk defined by MRI. Lancet. 1999;
353(9169):2036-2037.
200. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial
measurements in medical research. British Medical Journal. 1990; 300(6719):230-
235.
255
201. Geijer B, Lindgren A, Brockstedt S, Stahlberg F, Holtas S. Persistent high
signal on diffusion-weighted MRI in the late stages of small cortical and lacunar
ischaemic lesions. Neuroradiology. 2001; 43(2): 115-122.
202. Schulz UGR, Briley D, Meagher T, Molyneux A, Rothwell PM. Abnormalities
on diffusion weighted magnetic resonance imaging performed several weeks after a
minor stroke or transient ischaemic attack. Journal ofNeurology, Neurosurgery, &
Psychiatry. 2003; 74(6):734-738.
203. Smith SM. Fast robust automated brain extraction. Human Brain Mapping.
2002; 17(3):143-155.
204. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a
hidden Markov random field model and the expectation-maximization algorithm.
IEEE Transactions on Medical Imaging. 2001; 20(l):45-57.
205. Wardlaw JM, Sellar RJ. A simple practical classification of cerebral infarcts on
CT and its interobserver reliability. American Journal of Neuroradiology. 1994;
15(10): 1933-1939.
206. Rueckert D, Frangi AF, Schnabel JA. Automatic construction of 3-D statistical
deformation models of the brain using nonrigid registration. IEEE Transactions on





ADC Apparent diffusion coefficient
ADCr 'Relative' ADC
AIF Arterial input function
ANOVA Analysis of variance
ASL Arterial spin labelling
ATP Adenosine triphosphate
AU arbitrary units
b Diffusion weighting value (s/mm2)
B0 Magnetic field
BBB Blood brain barrier
CBF Cerebral blood flow
CBFa 'Absolute' cerebral blood flow
CBFj 'Index' cerebral blood flow
CBFr 'Relative' cerebral blood flow
CBV Cerebral blood volume
CBVa 'Absolute' cerebral blood volume
CBVi 'Index' cerebral blood volume
CBVr 'Relative' cerebral blood volume
CCAO Common carotid artery occlusion
CSF Cerebrospinal fluid
CT Computed tomography
D Apparent diffusion tensor of water
d days
DSC Dynamic susceptibility contrast
DT Diffusion tensor
DW Diffusion-weighted
DWI Diffusion-weighted magnetic resonance imaging
e Base of natural logarithm (Euler's constant)
EP Echo planar
FID Free induction decay
FOV Field-of-view
GFAP Glial fibrillary acidic protein
GLM General linear model
h hours
H&E Haematoxylin and eosin
hsp72 Fleat shock protein 72
ICAO Internal carotid artery occlusion
LACI Lacunar infarct
MAP-2 Microtubule associated protein 2
MCA Middle cerebral artery
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Abbreviation Definition
MCAO Middle cerebral artery occlusion
min minutes
MR Magnetic resonance
MRI Magnetic resonance imaging
mRS Modified Rankin score
MTT Mean transit time
mtta 'Absolute' mean transit time
mttj 'Index' mean transit time
MTTr 'Relative' mean transit time
n Number of subjects
NIHSS National Institutes of Health Stroke Scale
NS Not significant (p > 0.05)
OCSP Oxfordshire Community Stroke Project
P Observed significance level
PACI Partial anterior circulation infarct
POCI Posterior circulation infarct
PWI Perfusion-weighted magnetic resonance imaging
r Pearson's product moment correlation coefficient
RF Radiofrequency
rtPA Recombinant tissue plasminogen activator
S Signal
So Signal without diffusion effects
SBIRCS SHEFC Brain Imaging Research Centre for Scotland
SD Standard deviation
SE Spin echo
SGAT SBIRCS grid analysis tool





taci Total anterior circulation infarct
TE Time to echo





P Spearman's rank correlation coefficient
X2 Chi-square test
00 Larmor frequency
K Cohen's reliability coefficient
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Abstract
Background and Purpose: In acute ischaemic stroke, the
amount (and type) of cellular damage underlying diffu¬
sion-weighted imaging (DWI) lesion appearances is un¬
clear. We summarized all information from experimental
studies of DWI in focal ischaemia models. Methods: We
systematically reviewed all published studies of DWI in
focal ischaemic stroke models. We extracted key experi¬
mental details to determine correlations between histo¬
logical features and DWI lesion characteristics. Results:
Of 141 potentially eligible papers (including more than
2,817 animals, mostly rats), details of key experimental
methods were unfortunately often omitted. Consistent
findings amongst high-quality studies with blinded anal¬
ysis included: neuronal damage persists or progresses
despite early DWI lesion 'normalisation'; the apparent
diffusion coefficient is not very sensitive to the amount
of neuronal damage; the 'brighter' the DWI lesion, the
greater the neuronal damage; and the DWI lesion may
reflect glial more than neuronal changes. Anaesthesia
and fixation techniques may inadvertently affect these
findings. Conclusions:The relationship between cellular
damage and DWI lesion appearance, particularly recov¬
ery patterns in reperfusion experiments, remains impre¬
cise. Key experimental details could be reported more
completely and consistently. Potontial problemsfrom re¬
peated anaesthetics need to be addressed. Early DWI le¬
sion 'recovery' in acute stroke patients may largely re¬
flect glial rather than neuronal 'recovery'.
Copyright © 2005 S. Karger AG, Basel
Introduction
Magnetic resonance (MR) diffusion-weighted (DWI)
and perfusion-weighted (PWI) imaging are very sensitive
to early ischaemic changes and may distinguish perma¬
nently from transiently damaged brain. MR lesion ap¬
pearance might be a surrogate marker for the effective¬
ness ofnew treatments [ 1 ]. Although DWI has been avail¬
able for a decade, the relationship between DWI lesion
characteristics and tissue viability remains unclear.
The 'ischaemic cascade' (stages of neuronal damage
occurring as cerebral blood flow falls) includes disruption
ofenergy metabolism, ion pump failure, accumulation of
intracellular water (cytotoxic oedema [2]), and neuronal
and other cell death. DWI is extremely sensitive to water
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molecule movement, showing cytotoxic oedema, and
thus very early ischaemic changes [3], within minutes of
injury [4], However the precise point in the ischaemic
cascade where lesions become visible on DWI, and the
point of no recoverability, is not known. PWI uses the
magnetic properties of flowing blood, or the injection of
a contrast agent, to visualize where, and to what degree,
cerebral blood flow has been compromised [5], Combin¬
ing DWI and PWI demonstrates the 'mismatch' which
may be potentially salvageable tissue [6]. If correct, the
'mismatch' might help determine the use of potentially
dangerous therapies like thrombolysis.
Animal studies of focal ischaemia as amodel ofhuman
ischaemic stroke provide an opportunity to investigate
the pathological cellular changes behind lesion appear¬
ance on MR imaging [7], We aimed to identify informa¬
tion available about the histology underlying DWI and/or
PWI lesion appearances in experimental studies, to in¬
form the interpretation of DWI/PWI lesion appearance
and tissue salvageability in stroke patients. We therefore
performed a systematic review ofall experimental studies
of DWI and PWI in animal models of focal ischaemic
stroke to put together all the information available on the
histological correlates of DWI/PWI lesion appearances,
and the likelihood of permanent tissue damage or recov¬
ery in the presence of particular DWI and/or PWI lesion
appearances.
Methods
The methodology of this systematic review was adapted from
that used in the Cochrane Database ofSystematic Reviews [8]. Al¬
though developed for systematic reviews of randomized controlled
trials, the same principles apply to, and have been successful in,
several systematic reviews of observational and diagnostic stud¬
ies.
Search Strategy
We searched for published articles ofDWI. PWI, or a combina¬
tion of the two in animal models of ischaemic stroke in the English
and non-English language literature on MEDLINE and EMBASE
from 1966 to December 31,2002 (for a complete list ofsearch terms
see Appendix 1). To validate the search strategy (in accordance with
established systematic review methodology [8]), we also hand-
searched the last 5 years (January 1998 to December 2002) of the
three journals that contributed the most papers from the literature
search (Brain Research, Journal of Cerebral Blood Flow and Me¬
tabolism, and Stroke), and reference lists in all included articles.
Inclusion Criteria
We included studies published in full of DWI, PWI, or a com¬
bination of the two, in mammalian models of focal ischaemic
stroke, with histology performed within a maximum of 24 h of the
last MR imaging. One reviewer identified the abstracts and exclud¬
ed articles not relevant to this review. Papers were reviewed by the
second reviewer and final decisions made by discussion.
Exclusion Criteria
Studies without DWI or PWI, non-mammalian animal models,
non-focal models of stroke, global models of ischaemic insult, non-
ischaemic models of brain injury, no histology performed, and his¬
tology performed more than 24 h after the last MR imaging were
excluded as the dynamic nature of ischaemic stroke would prevent
histological results being related to imaging appearance after a long
time lapse between imaging and histology. Reviews, conference
papers, studies only appearing as an abstract and publication of
duplicate data were excluded. Where the inclusion of a paper was
in question, a consensus was reached between the two reviewers.
Methodological Quality Scoring
Amethodological score system was devised to reflect key aspects
of the experimental methods used (table 1). Aspects of the animal
model, imaging and histology methods, blinding, and method of
comparison of histology with imaging were assessed for all papers.
These criteria were drawn up in advance of evaluating the identi¬
fied papers, as part of the primary methodology of the review and
in accordance with Cochrane methods [8].
Data Extraction
One reviewer extracted information on the study year, number
and type of animals (species, strain, and sex), ischaemia model
(method and duration of occlusion, whether permanent or tran¬
sient), MR imaging (make, model, strength of scanner, scanning
protocol), anaesthetic and animal life support in scanner, time from
imaging to sacrifice, histological protocol (details of fixation and
analysis of histological slices, including how the histological slices
were matched to the MR slices for analysis), MR image analysis
[lesion volume, apparent diffusion coefficient (ADC) values], blind¬
ing of image and histological analysis, and what MR imaging ap¬
pearance corresponded to what macroscopic or histological state.
Data extraction was verified by the second reviewer.
Studies explicitly stating that the analysis of the histological le¬
sion was blind to the DWI lesion and vice versa, and/or studies
achieving a quality score of 6 or more were examined further to
extract specific information about the relationship between DWI
appearance and histological damage. We aimed to undertake anal
yses of the odds of DWI/PWI appearances being associated with
histological features, if such information was available.
Results
The search yielded 1,420 articles on MEDLINE and
1,243 articles on EMBASE, between 1966 and December
2002, totalling 2,663 papers, 943 of which were repeats,
leaving an initial database of 1,720 articles. Of these,
1,579 papers were excluded (reasons given in table 2),
mostly because the injury model was not appropriate (e.g.
global not focal).
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Table 1. Methodological quality scoring system
Question Issue 1/2 mark 1 mark (in addition to 1/2 mark require¬
ments)
1 Animal ischaemia model reproducible? method (e.g. MCAO) with
reference to original procedure
anaesthetic type/dose, surgical procedure,
sham/experimental groups described
2 Animal subjects reproducible? species, strain, sex source, average weight, housing and feeding
details
3 MR imaging reproducible? make, model and strength of
MR scanner, B value
DWI performed in 3 orthogonal directions,
method of analysis reproducibly described
4 Histological procedure reproducible? fixatives and stains listed
without specific values and
concentrations
concentration of fixatives and stains, size/
location brain slices, method of analysis
reproducibly described
5 Histological time <24 h from last imaging session <6 h from last imaging session
6 Blinding of image analysis to histology implied (e.g. user independent) specifically mentioned blinding in text
7 Blinding of histology analysis to imag¬
ing
implied (e.g. user independent) specifically mentioned blinding in text
8 Imaging/histology comparison 'correlated well' on visual exam in-depth investigation with reproducible
methods listed
9 Sub-region analysis done on either imaging or
histology
if performed on hoth imaging and
histological results
10 Aim clear hypothesis with discussion of how
results relate
Table 2. Reasons for excluding papers
Reason for exclusion Papers %
Not stroke model 649 41.1
Not animal model 99 6.3
Global ischaemia 162 10.2
Inappropriate injury models
(e.g., head trauma, aneurysm) 136 8.6
Reviews, letters, conference papers 153 9.7
No DWI 297 18.8
No histology1 83 5.3
Total 1,579 100.0
1 Including 11 papers with histology >24 h from MR imaging.
The remaining 141 studies, concerning the use of
DWI, PWI, or the combination of the two, were included.
The total number of animals in these papers was over
2,817 (two studies did not report animal numbers [9,10]),
giving a mean of 21 animals per paper (median 18).
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General Details ofIncluded Studies
Of the 141 papers, 108 papers (76.7%, n = 2,255,
80.2% ofanimals) used rats, 19 used cats (13.5%, n = 315,
11.1% of animals), 8 used mice (5.7%, n = 178, 6.3% of
animals), 3 used pigs (2.1%, n = 31, 1.1% of animals), 2
used rabbits (1.4%, n = 36, 1.3% of animals), and 1 used
non-human primates (0.7%, n = 2, 0.1% of animals)
(fig. 1).
A middle cerebral artery occlusion model (MCAO)
was used in 130 (92%, n = 2,641) studies, an internal ca¬
rotid artery occlusion model (ICAO) in 4 (3%, n = 63)
studies, a common carotid artery occlusion model
(CCAO) in 3 (2%, n = 48) studies, the Rose-Bengal cortex
lesion model in 3 (2%, n = 52) studies, and a middle ce¬
rebral artery and common carotid artery occlusion mod¬
el (CCA & MCAO) in 1 (1%, n = 33) study (fig. 2). Some
studies sacrificed animals immediately after a period of
artery occlusion and therefore were non-reperfusion mod¬
els; others allowed the animals to survive for some time
(from several hours up to 1 week) after a period of occlu¬
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Fig. 1. Percentage of total animals by species in the studies consid¬
ered in the review. Mean n = 21, median n = 18, total n >2,500.
Table 3. Average scores on the methodological quality scoring sys¬
tem
Quality score Average score No. of papers (/141) Percent
question scoring 1/1 scoring 1/1
1 0.920 119 84.4
2 0.468 13 9.2
3 0,614 34 24.1
4 0.850 102 72.3
5 0.850 98 69.5
6 0.250 y 6.4
7 0.093 9 6.4
8 0 511 31 22.0
9 0.168 18 12.8
10 0.879 124 87.9
Overall (/10) 5.777 0' O1
1 No papers scored 10/10.
Methodological Quality Scores
In general, methods were not reported in detail. The
total average score was 5.7 out of 10 (table 3). Only 13
(9.2%) papers adequately described their animal subjects.
Basic differences in animal strain and sex can make a
large difference in results (e.g. the apparently neuropro¬
tective effects of oestrogen in an MCAO model of isch
aemia in female rats [11]). Only 34 (24%) papers ade¬
quately described the MR procedures well enough that
they might be reproduced. Many papers did not mention
measurement ofDWI in three orthogonal directions (nec-
Systematic Review of Animal Imaging
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Fig. 2. Percentage of lesion models in the studies in the review.
MCAO = Middle cerebral artery occlusion; ICAO = internal ca¬
rotid artery occlusion; R-B = Rose-Bengal cortex lesion; CCAO =
common carotid artery occlusion; CCA & MCAO = common ca¬
rotid and middle cerebral artery occlusion.
essary to obtain reliable and reproducible quantitation of
diffusion and ADC values [12]). Few studies mentioned
blinding of the image and histological analysis to each
other. Failure to employ blinding and randomization in
animal studies of drug effects is known to increase the
likelihood ofa positive result [ 13], Over half (n = 71,51%)
of the studies did not mention blinding ofany of the anal
yses at all. Only 3 studies (n = 51 animals, 2% of total
animals), explicitly stated that histological analysis was
blind to DWI analysis and vice versa [14-16], so we can
only be sure that data from 2% of the animals were ana
lyzed completely free of bias. The way in which the MR
images and analyses were compared to histological data
generally lacked detail, with only 31 (22%) studies com¬
paring DWI and histological slices any further than sim¬
ply saying they 'correlated well'. However, the precise
meaning of a 'good correlation' was not given, and ex¬
plicit mention ofhow the histological sliceswere matched
to MR slices for analysis was either lacking or described
only as being 'eyeballed' for a best lit. Only 18(13%) stud¬
ies examined any sub-regions of the DWI lesion or histo¬
logical abnormality.
Perfusion values were obtained and reported in some
papers, but in such different ways that it was not possible
to extract the information as to the relationship between
perfusion parameters, DWI and histology in ways that
allowed data synthesis. Wc have therefore concentrated
on the DWI and histology correlations.
Cerebrovasc Dis 2005;19:328-336 331
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Imaging results Histological feature
studied
Histological results
Detre e( al. [17] 6 4.7 120 min No reperfusion1 'center' ADCr 35% < and 'edge'
ADCr 77% < of initial ADC
hsp70 expression hsp70 +ve in 'penumbra' indicating permanent
damage
Crohn et al. [18] 12 4.7 90 min 24 h DWJ normalizes but DWI
abnormality recurs at 24 h
scoring % of neuronal
damage
tissue dead despite DWI renormalisation
Jacobs el al. [14] 22 2.0 4-8 h
16-24h
48-168h
No reperfusion1 DWI 14%, ADC 14% lesion volume
difference to histology
DWI 17%, ADC 14% lesion volume
difference to histology






DWI lesion < histological lesion, ADC not
significantly different
ADC and DWI lesions significantly correlated
with histology but which was larger (ADC/DW1
or histology- volume) not specified
Kokubo et al. [19] 6 7.0 60 min 23 h 'caudate' ADCr 65% < initial ADC
'cortex' ADCr 80% < initial ADC
hsp70 expression hsp70 -ve in caudate - 'irreversible damage'
hsp70 +ve in cortex - 'reversible damage*
Li et al. [20] 14 2.0 30 min 12 h 'caudate'ADC 45 x 10"5 mm2/s
'cortex' ADC 46-47 x I0"5 mnr/s
scoring % of neuronal
damage
'caudate' >50% neuronal necrosis
'cortex' <10% neuronal necrosis




ADC initial decrease, then complete
recovery
ADC decrease, recovery, secondary
decrease at 12 h
pseudo-normalisation at 24-48 h
scoring % of neuronal
damage
scoring % of neuronal
damage
17% neuronal necrosis in lesion despite ADC
renormalisation
95% neuronal necrosis in lesion despite ADC
renormalisation
Li et al. [22] 18 2.0 30 min 12 h ADC 25% < normal at 0-1 h
ADC normalizes at 1.5 h
ADC 25% < normal at 12 h
scoring % of neuronal
damage
92% neuronal necrosis, most astrocytes swollen
at 12 h
94% neuronal necrosis, astrocyte disintegration
at >12 h
Liu el al. [23] 10 2.0 90 min No reperfusion1 ADC contralateral cortex normal
ADC ipsilateral frontoparietal cortex
25% < initial ADC
ADC ipsilateral caudoputamen
45% < initial ADC
scoring % of neuronal
damage
contralateral cortex - no neuronal damage
ipsilateral frontoparietal cortex - 62% of
neurons shrunken
ipsilateral caudoputamen - 46% of
neurons shrunken




DWI lesion 9.9% of hemispheric area
DWI lesion 29.1 % of hemispheric
area
size unstained I I&E
lesion
histological lesion < DWI lesion
histological lesion < DWI lesion
Mfiller et al. [24] 9 2.35 120 min 2 h 15% increase of DWI hyperintensity
in 19% of hem isphere area
size unstained H&E
lesion
histological lesion (25% of hemisphere) > DWI
lesion (19% of hemisphere)
Neumann-Haefelin
el al. [15]




DWI lesion disappeared, but recurred
at 24 h
DWI lesion disappeared, but recurred
at 24 h




damage present with 110 significant difference
between groups at 7 days despite different
patterns of DWI changes
Ringer et al. [16] 10 2.0 30 min 4.5 h or 7 days DWI abnormalities reversed at 3-5 h,
recurred al 1 day
MAP-2, hsp72, GFAP
expression
30% loss MAP-2 reactivity, extensive hsp72
reactivity, 'astrocytes normal' on GFAP
Sutherland
et al. [25]
10 7.0 90 min 6.5 h DWI lesion area > T2 lesion area size of unstained H&E
lesion
histological lesion < T: lesion < DWI lesion
ADC = Apparent diffusion co efficient; ADCr = ratio of stroke lesion ADC to contralateral normal brain ADC; H&E - haematoxylin and eosin; n - number of animal subjects in
study.
1 No reperfusion = animals were sacrificed at end of occlusion period.
Data Extracted on DWI and Histopathological
Lesion Appearances
Although all 141 papers were examined, papers with a
quality score of less than 6 consistently did not provide
data on the relationship between DWI appearance and
histological findings. We therefore focused on papers
332 Cerebrovasc Dis 2005;19:328-336
scoring >: 6, and papers with explicit mention ofblinding
of histological and imaging analyses. Fifty-one papers
achieved a quality score of > 6, yet only 13 contained in¬
formation on the relationship of DWI lesion appearance
to histology (table 4), including the 3 that explicitly men¬
tioned blinding of image to histological analysis [14-16].
Rivers/Wardlaw
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Only I of the 13 papers explicitly described the method
of aligning histological slices to MR slices for analysis
[ 14]; the other 12 papers either did not mention how his¬
tological slices were matched to MR slices or simply used
'eyeballing' to match up the DWI and histology slices.
Three Papers with Explicit Blinding ofHistology to
DWl and vice versa
As these 3 papers provide the least biased comparison
ofDWI to histology, we examined their results in detail.
Jacobs et al. [14] used a permanent occlusion model in
rats, with unsupervised, automated tissue segmentation
technique (ISODATA) to outline the lesion from a com¬
posite ofT2 and ADC data. The ISODATA regions were
co-registered and compared to manually outlined hae-
matoxylin and eosin (H&E)-stained histological slices at
acute (4-8 h), sub-acute (16-24 h) and chronic (48-
168 h) times after initiating arterial occlusion. Histo¬
logical damage, including swollen and shrunken neu¬
rons, was seen beyond the edges of the 'bright' DWI
lesion at 4 h, showing that at acute stages DWI under¬
estimated cortical ischaemia. The ADC image was poor¬
er than the DWI image at assessing tissue damage extent
as seen histologically in the acute stage of ischaemia, but
better at the sub-acute and chronic stages.
Neumann-Haefelin et al. [15] compared 30 min, 1 h,
or 2.5 h of transient ischacmia in rats with histology at
7 days (table 4). DWI and ADC abnormalities reversed
after 30 min and 1 h (but not after 2.5 h) of vessel oc¬
clusion followed by reperfusion, but reappeared at 24 h
in all groups. At 24 h. the DWI lesion in the 30 min and
1-hour occlusion groups was not as extensive as in the
2.5-hour occlusion group. However, an infarct was seen
histologically at 7 days with all 3 durations of occlusion,
and was not significantly different in area between the
groups, even in those with complete initial DWI lesion
disappearance after reperfusion.
Ringer et al. [16] used a transient 30-min MCAO
model with DWI during, at 3 5 h, 1 day, and 7 days,
and neuronal [microtubule associated protein 2 (MAP
2)], astrocytic [glial fibrillary acidic protein (GFAP)],
heat shock protein 72 (hsp72), and cresyl violet stained
histology at 5 h and 7 days. The DWI abnormalities vis¬
ible at 30 min reversed at 3-5 h after reperfusion but
recurred at 24 h. When the DWI was normal at 5 h, there
was a significant decrease in MAP-2 immunoreactivity
in 30% of the initial DWI lesion, GFAP was normal,
hsp72 staining was extensive and, together with cresyl
violet staining extent, corresponded to the initial DWI
lesion extent. Hence, the 'normalisation' of the DWI
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abnormality did not mean that the underlying tissue was
normal, as the neurons (MAP-2) showed signs of struc¬
tural damage and stress. The normal GFAP staining sug¬
gested that non neuronal cell components may be cu
pable ofmore recovery, thereby partially compensating
for altered fluid balances and contributing to the appar¬
ently 'normal' DWI appearance early after rcperfu-
sion.
Remaining Ten Papers Achieving a Quality Score of
6 orMore
Although blinding was not explicitly mentioned in
these papers, they did achieve high quality scores reflect¬
ing good methodological descriptions in other domains.
Of these 10 papers, all except 1 ([25], which used cats)
used rats. The intraluminal suture method ofMCAO was
used in all papers except by Detre et al. [17], who used
fibrin-rich emboli in the MCA, and Sutherland et al. [25],
who used a microaneurysm clip on the MCA. All studies
sacrificed the animals immediately after the final MR im
aging except 1 ([25], in which the animals weie killed 2 h
after the start of the final imaging session).
These 13 papers (table 4) also indicated that histologi¬
cal neuronal damage persisted or progressed despite the
apparent waxing and waning of the DWI lesion [15, 16,
18]. They further support the observation that the resolu¬
tion of the early DWI lesion after rcpcrfusion, and its re
appearance after 24 h of rcpcrfusion, may be more due to
changes in astrocytes and glial cells than a decrease in
neuronal damage. A consistent comment in several papers
was that it was the astrocytes that swelled (so presumably
restricted the extracellular space and water movement to
produce the hyperintense DWI/rcduccd ADC images),
while the neurons shrank. Neuronal damage appeared to
persist once initiated, while astrocytes swelled or deflated,
which may explain the apparent 'normalisation' of the
DWI lesion [16, 22,23], This suggests that DWI recovery
and 'secondary DWI decline' are perhaps not caused by
'secondary injury' to neurons but occur due to the progres
sion of primary damage as astrocytic swelling changes
over time [16, 20, 22, 23], The DWI lesion signal inten¬
sity ('brightness') seemed to reflect the amount of ncuro
nal damage - after 90 min of occlusion and 24 h of reper¬
fusion, within the DWI lesion, the more intense the DWI
signal, the greater the proportion of dead neurons [18],
Acute ADC values may not be a good determinant for re-
coverability, as, despite great variability in acute ADC
values in 30, 60, and 150 min ischemia groups, in one
study all groups showed a similai degree of histological
tissue damage at 7 days [15], Also, in one group, the re-
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duction in ADC after 30 min of occlusion was similar in
areas with 10% of neurons dead and areas with 50% of
neurons dead [20]. However, in another study, the ADC
value at the end of vessel occlusion did correspond to the
amount of neuronal damage, as larger decreases in the
ADC occurring after 90 min occlusion correlated with in¬
creasing levels of neuronal damage after 24 h of rcperfu-
sion [18], It was also clear that even short periods (30 min)
of transient ischaemia in rats caused permanent damage
to neurons [15,20-22], Differing degrees of damage were
also seen in different parts of the brain for a given dura¬
tion ofocclusion; damage to the striatum (particularly the
caudoputamen) was worse than damage to the cortex on
both DWI and histological slices [19-22],
Discussion
MR DWI and PWI are popular in ischaemic stroke,
and are generally thought ofas displaying 'neuronal' dam¬
age. However, the exact degree of ischaemic damage at
the cellular level demonstrated by DWI and PWI, and the
likelihood of recovery, has yet to be determined [26], Al¬
though the proportion of studies that we were able to ex¬
amine in detail was disappointing (due to missing infor¬
mation or potential bias of results), a consistent message
did emerge, suggesting that glial cell ischacmic changes
are a major contributor to the initial appearance and sub¬
sequent evolution of the DWI lesion, Thus 'neuroprotec¬
tion' strategies may not be best monitored with DWI,
unless it is likely that the drug in question has actions on
other cell types. If glial cells are responsible for much of
the DWI lesion evolution, then new approaches to avoid
adverse events (such as massive infarct swelling) should
consider interventions in the glial cell 'ischaemic cas¬
cade'.
This review has identified several important correla¬
tions between DWI and histology, but many papers were
not informative. Possibly some studies were not set up
specifically to examine the relationship between DWI and
histology; however, the limited description of the animals
used, MR imaging, and histological analysis, combined
with absence of blinding of image and histological analy¬
ses, uncertainties about how the image data were com¬
pared to the histology, and little sub-regional analyses,
means that there arc still many unanswered questions
about the relationship of DWI/PWI lesion appearance,
the pathophysiological state of the brain, and the chances
of tissue recovery. Blinding of image and histology inter¬
pretation is vital if biases are to be avoided [13].
We examined all papers but found that papers scoring
less than 6 on the quality score did not inform the relation¬
ship between DWI and histological appearance. In fact,
frustratinglyonly 13 of51 (25.5%) ofpapers scoring >6/10
had information on the DWI/histology relationship.
Amongst the studies achieving a higher methodologi¬
cal score (table 4), several potentially important method¬
ological points became apparent which might explain
some of the differing results. Firstly, several of the studies
used repeated anaesthesia with isoflurane [20, 21] or very
prolonged periods of anaesthesia - either might contrib¬
ute to cerebral damage in areas of vulnerable ischemic
brain, tipping potentially vulnerable tissue towards per¬
manent damage and making cell damage appear worse
for a given ischaemic insult than would actually have
been the case without the anaesthetic. Secondly, only one
study mentioned taking carc to perfuse and fix the tissue
for histological analysis in a way that should eliminate
artefactual 'dark, shrunken' neurons [23], How much of
the neuronal damage seen on histological examination in
other studies could be due, even in part, to fixation ef¬
fects? Perhaps damage inflicted by tissue fixation could
account for some of the inconsistency of results, as for
example seen in Miiller et al. [6, 24], where the lesion on
DWI was larger than the histological lesion in the former,
and smaller than the histological lesion in the latter. When
comparing histological slices to MR slices, it is important
to ensure that the same areas of the brain arc being com¬
pared. It was not clear in themajority of the papers wheth
er, and how, this histology/MR lesion 'matching' was per¬
formed, although 'eycballing' seemed to be a commonly
used method. Thus it is difficult to be sure that the histo¬
logical slice was the same tissue as that of the 'matched'
MR image.
Despite this, several consistent patterns emerged (ta¬
ble 4) with implications for studies in patients. The his¬
tological damage persists and progresses despite the DWI
lesion waxing and waning, i.e. referring to reappearance
of the DWI lesion after a period of normalisation as 'sec¬
ondary neuronal injury' in human studies is probably not
correct in pathophysiological terms. The initial ADC val¬
ue is not a good index of likely recovery as similar values
were obtained from tissue that subsequently mostly re¬
covered as from other areas which were permanently
damaged. However, the intensity of the DWI signal
('brightness') docs seem to relate to the proportion of
damaged neurons - the more abnormal ('brighter') the
DWI signal, the greater the proportion of damaged neu¬
rons. Also, the DWI hyperintensity more closely identi
fied the extent ofabnormal tissue than did the hypointen-
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sity on ADC. This is helpful as the intensity of the DWI
signal is the most rapidly and easily interpreted informa¬
tion from DWI in the clinical situation - the observer can
assess the lesion 'brightness' immediately, so this is prob¬
ably one of the more clinically useful outputs of this work.
Changes in astrocytes, rather than neurons, probably ac¬
count for much of the DWI lesion waxing and waning -
the neurons are said to shrink, while the astrocytes are
reported to swell. IfDWI signal change is at least in part
the result of restricted water movement in the extracel¬
lular space, then swollen astrocytes rather than shrunken
neurons (assuming the 'shrinkage' is not a fixation arte¬
fact) could be the major contributor to DWI hyperinten-
sity/ADC reduction. In rats, even 30 nrin of ischaemia is
lethal to some neurons, and damage (both on DWI and
histologically) was worse for a given degree of ischaemia
in the caudoputamen than in the cortex.
Where next? Experimental methodology could be
more clearly and consistently described; occlusion meth¬
ods, animals, and MR imaging should be described in a
reproducible way, and blinded methods of image and his¬
tological analyses are essential to reduce bias. More infor¬
mation is required on how DWI abnormalities relate to
cellular changes - at what degree of'brightness' on DWI
does the tissue pass the point of no recovery, and how
does this change with increasing time after stroke onset?
The Stroke Therapy Academic Industry Roundtablc [27]
discussion concluded that little animal research done to
date 'has translated into effective treatment modalities
for stroke in humans'. Perhaps the focus on neurons, both
experimentally and in imaging studies, has deflected at¬
tention from the contribution of other important cell
types to the total burden of damage, and likelihood of re¬
covery, in ischaemic lesions as a whole. Experimental
studies may help with translational research to clarify and
determine mechanisms for important histopathological
imaging relationships found in clinical studies. However,
the methodology should be clearly described, use a mod¬
el relevant to stroke patients, and take account of impor¬
tant differences in proportions of cerebral cells, and their
contributions to the ischaemic process, between animals
and humans.
Acknowledgements
C.S.R. is funded by a Royal Society of Edinburgh/Lloyds TSB
Foundation studentship. The work was conducted at the SHEFC
Brain Imaging Research Centre for Scotland (www.dcn.ed.ac.uk/
bic).
Appendix 1: Search Terms
Medline Search Terms:
(1) exp Magnetic Resonance Imaging/
(2) Tomography, X-Ray Computed/
(3) (mri or magnetic resonance or ct scanS or cat scanS or comptS
tomographyj.tw.
(4) l or 2 or 3
(5) Disease Models, Animal/
(6) Models, Animal/
(7) ((animal or stroke or experimental) adj5 model$).tw.
(8) experimental stroke.tw.
(9) exp rats/ or exp mice/ or rabbits/ or exp primates/
(10) animal/
(11) exp animals, laboratory/




(15) exp Brain ischemia
(16) Carotid artery diseases/ or Carotid artery thrombosis/
(17) exp Cerebrovascular accident/
(18) exp Hypoxia-ischemia, brain/
(19) Cerebral artery diseases/ or Intracranial arterial diseases/
(20) exp 'Intracranial embolism and thrombosis'/
(21) (strokeS or apoplexS or cerebral vascS or cerebrovascS or cva
or transient isch?emic attacks or tia).tw.
(22) ((brain or cerebrS or cerebellS or vertebrobasilS or hemi-
spherS or intracranS or intracerebral or infratcntorial or su
pratentorial or middle cerebrS or mca$ or anterior circula¬
tion) adj5 (isch?emi$ or infarcts or thromboS or emboliS or
occlusS or hypoxi$)).tw.
(23) 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
(24) 4 and 13 and 23
Embase Search Terms:
(1) Nuclear magnetic resonance imaging/
(2) exp computer assisted tomography/
(3) (mri or ct scan or cat scan or magnetic resonance or computS
tomography).tw.
(4) 1 or 2 or 3
(5) exp Cerebrovascular disease/
(6) (strokeS or cerebrovascS or cerebral vascS or cva or poststrokc
or apoplexy or transient ischS or tia$).tw.
(7) ((brain or cerebrS or cerebellS or vertebrobasilar or henti-
spherS or intracranS or intracerebral or infratentorial or su-
pratentorial or mca$ or anterior circulation) adj5 (isch'.'cmiS
or infarcts or thromboS or emboliS or occlusS or hypoxiS)).
tw.
(8) 5 or 6 or 7
(9) 4 and 8
(10) animal model/ or disease model/
(11) animal/ or animal experiment/ or exp experimental animal/
(12) ((animal or stroke or experimental) adj5 model$).tw.
(13) experimental stroke.tw.
(14) ((rat or mouse or mice or rabbit or cat) adj5 model$).tw.
(15) exp rat/ or exp mouse/ or rabbits/ or exp cat/
(16) or/10-15
(17) 9 and 16
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